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Recently, new discoveries in the field of cancer immunology have been able to 
increase the strength of immune responses against tumors. For example, 
monoclonal antibodies such as Ipilimumab and Nivolumab are able to drastically 
reduce the suppressive capabilities of cancer cells and regulatory T cells leading to 
complete or partial responses in a substantial portion of patients with non-small-
cell lung cancer, melanoma and renal-cell cancer. Other immuno-therapeutic 
approaches are aimed at stimulating an immune response against specific molecular 
targets expressed by tumor cells. This could be achieved by the administration of 
modified immune cells derived from the patient or by inducing an immune response 
against tumor cells with cancer vaccines. In the case of cancer vaccines, the therapy 
involves the delivery of an antigen (in the form of protein or peptide) that is 
expressed by cancer cells to antigen presenting cells (APCs). To further modulate 
the activity of target APCs, the delivery system could be designed to enhance the 
function of APCs as an adjuvant therapy in order to stimulate a stronger and 
prolonged immune response. 
Recent data suggest that the function and survival of APCs can be modulated by 
targeting genes involved in immune suppression/regulation with small interfering 
RNAs (siRNAs). siRNAs are a class of double stranded RNA molecules designed 
to interfere with the expression of specific genes with complementary nucleotide 
sequences. siRNAs are incorporated into the RNA interference specificity complex 
(RISC) leading to the cleavage and degradation of the target mRNA.  
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Since siRNAs are prone to ribonucleases and lysosomal degradation, they require 
a delivery system designed to rapidly target an appropriate cell population and to 
avoid degradation. This research work addresses whether implementation of a 
molecular release mechanism associated with an APC targeting vector would be 
advantageous to avoid the degradation of siRNAs and peptide antigens. A bacteria 
derived microparticle called MIS416 designed to target APCs was used as a 
delivery system to test this hypothesis. 
MIS416 is an intact minimal cell wall skeleton derived from Proprionibacterium 
acnes and comprises NOD-2 (nucleotide-binding oligomerization domain 
containing 2) and TLR-9 (toll-like receptor-9) ligands, both of which have well-
described adjuvant activity. Given its inherent adjuvant properties, MIS416 
microparticles could provide an ideal vehicle for co-delivery of cargo such as 
peptide antigens, as well as immunomodulatory siRNAs to APCs.  
In this work, MIS416 microparticles were used as a vehicle for the delivery of the 
peptide antigen SIINFEKL and siRNAs to target Dendritic cells (DCs) in order to 
modulate the immune response against tumors. These conjugates were designed to 
facilitate the release of the attached molecular cargo by the inclusion of a 
glutathione sensitive cleavable bond (disulfide). The release strategy takes 
advantage of the different concentration of glutathione between the extracellular 
environment and the cytoplasm of target cells. This approach was hypothesized to 
facilitate the release of siRNAs and peptides from MIS416 after internalization of 
MIS416 conjugates in target cells to avoid lysosomal degradation. A conjugation 
strategy based on a streptavidin bridge was developed to link biotinylated 
peptide/siRNA to biotinylated MIS416. The conjugation strategy was validated by 
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delivery of fluorophores and the model peptide antigen, SIINFEKL to DCs. 
MIS416/siRNA conjugates were also developed to investigate whether they could 
negatively regulate the expression of target proteins on DCs.  
The results showed that conjugates containing a disulfide linker were able to more 
rapidily release SIINFEKL in the cytoplasm of DCs than conjugates not containing 
a disulfide. However, the inclusion of a cleavable bond in these conjugates did not 
improve the presentation of the antigen on MHC (major histocompatibility 
complex) molecules on DCs. Furthermore, DCs treated with MIS416/SIINFEKL 
conjugates were able to induce activation and expansion of specific CD8 T cells, in 
addition to a cytotoxic response against the peptide antigen SIINFEKL in treated 
mice. However, the cytotoxic response was greater in mice vaccinated with 
MIS416/SIINFEKL conjugates that did not possess a disulfide bond in the linker. 
Furthemore, following treatment of DCs with MIS416/siRNA conjugates target 
protein levels were significantly downregulated, leading to the conclusion that 
MIS416/siRNA conjugates should be investigated for in vivo use.  
To conclude, the results suggest that a disulfide-based release strategy could be used 
for the delivery of siRNAs to DCs. However, the release mechanism does not 
improve the immune response generated by MIS416/SIINFEKL conjugates 
indicating that a more rapid release is not advantageous for peptide delivery. In a 
future extension of this research MIS416 microparticles could potentially be used 
in vivo for the co-delivery of peptide antigens and siRNAs, to modulate APC 
activity and to induce a specific immune response against molecular targets 
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1. Introduction  
 
Cancer is increasingly recognised as a disease in which microenvironment and 
immunity play an important role. Although genetic and epigenetic alterations drive 
genomic plasticity, cellular transformation and evolution, it is evident that multiple 
signals derived from the tumor microenvironment are critical factors in determining 
the progression or eradication of a cancer lesion, and also whether metastasis may 
occur. Thus, cancer is thought to be a multifactorial process facilitated by 
cumulative genetic and epigenetic alterations in addition to environmental and 
microenvironmental factors, which also play very important roles in tumor 
initiation and progression. There are several factors, both endogenous and 
exogenous, which are known to affect cancer risk in the population such as lifestyle, 
hormonal status, genetic predisposition, diet and radiation exposure (Langevin, 
Kratzke et al. 2014). Furthermore, there is considerable international concern that 
potentially synthetic chemicals in our environment today may be directly linked to 
a large percentage of cancer cases (Poirier 2012), although there are few 
epidemiological studies to determine this with accuracy. 
However, it is known that some specific physio/pathological events such as hypoxia 
or a prolonged inflammation state, could lead to the development of an unhealthy 
microenvironment prone to cancer development. Anomalies of the immune system 
have also been linked with cancer risk (Shimanovsky, Jethava et al. 2013). When 
immunosuppression is present, sensor cells such as dendritic cells (DCs) and 




macrophages might not be able to fulfil their role leaving space for unregulated 
growth of preneoplastic lesions that are not efficiently neutralized by specialized 
cells such as cytotoxic T lymphocytes. The crosstalk between antigen presenting 
cells and lymphocytes is crucial for the development of a strong and sustained 
immune response able to eradicate tumor lesions in an early stage of development. 
When the primary tumor is established, even an ongoing immune response is 
usually unable to limit tumor growth. Immunosuppressive mechanisms previously 
established in the microenvironment by tumor cells, stroma cells or immune cells 
such as regulatory T cells are able to block the activity of cytotoxic T cells leading 
to tumor growth. The accumulation of subsequent driving mutations in the primary 
tumor will eventually lead to metastasis that may be very difficult to treat with 
conventional therapies (Vogelstein, Papadopoulos et al. 2013). 
 
1.1. Gene Therapy: an overview 
Gene therapy is an approach involving the delivery of genetic material to host cells 
to treat disease. This can be achieved by either the introduction of DNA or RNA in 
order to express a gene, or the introduction of interfering RNA to reduce the 
expression of a specific gene. Various different gene therapy technologies have 
been developed to enhance the delivery of nucleic acids into cells since negatively 
charged nucleic acids cannot easily pass through the plasma membrane and are 
quickly degraded by nucleases in vivo. Several challenges such as limited transgene 
expression, toxicity, inflammatory responses and random gene integration are still 
yet to be completely solved. A more detailed description of such challenges can be 
found in this review (Brenner, Gottschalk et al. 2013). Despite these existing 




challenges, the gene therapy field is rapidly expanding. Different vectors for nucleic 
acid delivery have been developed and each has varied advantages and 
disadvantages. Viruses such as Lentivirus and Adenovirus have been widely used 
for gene therapy since they have the ability to infect target cells and integrate their 
genome into the host cell genome (Chira, Jackson et al. 2015). However, the 
potential harm caused by viral infection has to be taken into consideration. The 
amount of genetic material that can be carried by viruses is also limited by their 
capsid size and is not suitable for the delivery of long nucleic acid sequences. 
Various non-viral methods of delivering gene therapy have been developed with 
different ways of protecting the carried nucleic acid and gaining entry to the cell. 
One way of delivering DNA to cells is by forming a complex between DNA 
(negatively charged) and a cationic lipid/polymer able to deliver the attached cargo 
inside target cells (Merdan, Kopecek et al. 2002). Another way of delivering DNA 
relies on the use of nanovescicles such as liposomes (Xiong, Mi et al. 2011) or 
polymersome (Lomas, Johnston et al. 2011). These are self assembled vesicles with 
a diameter that can vary between 60nm and 400nm.  
An important factor to take into consideration during gene therapy is the 
transfection efficiency since to achieve a high efficiency vectors must overcome 
various biological barriers such as degradation by serum nucleases, endosomal 
entrapment and nuclear localization as reviewed in (Roth and Sundaram 2004). In 
fact many non-viral approaches that have been developed in vitro, fail to deliver 
nucleic acids in vivo. One of the issues encountered is the degradation of the 
delivery vector before the arrival at the target tissue with the nucleic acid cargo 
intact. Target cells also have specific defences that are able to degrade foreign 




nucleic acids before they can be translated into proteins or inserted into the genome. 
This molecular mechanism is able to protect cells from pathogens such as viruses 
and bacteria, limiting their ability to exploit the DNA replication machinery in the 
nuclei and the translation capabilities of the ribosomes in the cytoplasm. 
Understanding the protein complexes involved in this self-defense mechanism has 
allowed the development of a new methodology that uses this defence strategy to 
advantage: antisense technology. 
 
1.1.1. Antisense Therapy  
The initial research focus on antisense strategies involved the use of DNA based 
oligonucleotides. This class of antisense molecules were delivered inside a cell and 
the mechanism of action was based on the binding to target complementary mRNA, 
producing DNA/mRNA complexes. The translation of DNA/mRNA complexes 
was blocked since the protein complex involved in the translation of these 
sequences into protein was not able to bind to the target sequence leading to 
degradation of the target mRNA (Kalota, Shetzline et al. 2004). Further studies on 
antisense strategies used modified DNA molecules for the silencing of a specific 
mRNA target. These classes of molecules (such as morpholinos, locked nucleic 
acids (LNAs) and peptide nucleic acids (PNAs)) are called synthetic DNA mimics. 
These and other similar compounds differ from standard DNA since they are not 
composed of deoxyribose as a molecular backbone (Geller 2005). The main 
advantage of the use of modified DNA oligos is due to the increased resistance to 
degradation caused by endonucleases compared to standard DNA oligos. On the 




other hand, some of these chemical modifications could induce cytotoxicity in 
eucaryotic cells (Llovera, Berthold et al. 2012).  
The discovery of RNA interference (RNAi) in 1998 by Fire et al., has laid the 
foundation for the development of a new antisense methodology based on RNA 
oligonucleotides instead of DNA. RNAi is a post-transcriptional process that results 
in sequence-specific gene silencing. This antisense strategy is based on the use of 
double-stranded RNA (dsRNA) molecules that are introduced into target cells using 
a delivery vector (see next chapter for details). Dicer, an RNAse III family member, 
then cleaves the dsRNA molecules into 19-23 nucleotide fragments (siRNAs) that 
contain a 5’ phosphorylated end and an unphosphorylated 3’ end with two unpaired 
nucleotide overhangs (Ameres, Martinez et al. 2007). These small dsRNAs are 
called small interfering RNAs (siRNAs). The “unwindase” activity of Argonaute 
(Ago)-2 unwinds the siRNA duplex into two single strands: the guide and passenger 
strands. Once unwound, the guide strand is incorporated into the RNA Interference 
Specificity Complex (RISC), while the passenger strand is degraded. The RISC 
complex then finds endogenous RNA complementary to the guide strand and 
cleaves the target RNA through the separate endonuclease activity of Ago-2 (Figure 
1)(Fuchs, Damm-Welk et al. 2004).  RNAi is a powerful tool to regulate gene 
expression and it is emerging as a form of treatment for many human diseases 
including cancer (Aigner 2007, Deng, Wang et al. 2014). For instance, antisense 
molecules combined with conventional chemotherapy can be used to induce 
apoptosis in tumor cells (Rytelewski, Ferguson et al. 2013). Clinical studies have 
revealed the safety of RNAi silencing. However these studies are still pioneering 
and do not show a great degree of efficacy in Phase I clinical trials (Tabernero, 




Shapiro et al. 2013). Furthermore very few clinicals trials have been completed 
using vector based siRNA therapies for the treatment of cancer. There are only 28 
ongoing/completed clinical trial regarding siRNAs based therapies at the moment 
(September 2015) and only 7 are related to cancer treatment as revied by Jenny Lam 
(Lam, Chow et al. 2015). The delivery systems used in these clinical trials are 
Liposome/lipoplexes, polimer based nanoparticles or lipid based nanoparticles. All 
these system encapsulate and protect the siRNAs into a vescicle-based structure or 
biodegradable polymers (Lam, Chow et al. 2015). There are no clinical phase II 
trial completed and clinical phase I trials showed some degree of toxicity related to 
the triggering of immune responses versus the vectors, or hepatotoxicity 
(Landesman-Milo and Peer 2014). No clinical trials have been done so far with 
siRNA therapy aimed at targeting APCs/DCs for immunotherapic purposes. 
Multiple critical characteristics of tumor cells in vivo (including tumor growth, 
metastasis, chemoresistance, and angiogenesis) could potentially be targeted by 
specific antisense therapies. Studies in animals showed good success in inhibiting 
tumor growth and function (Brummelkamp, Bernards et al. 2002, Li, Lin et al. 2003, 
Verma, Surabhi et al. 2003, Aharinejad, Paulus et al. 2004). 
However, while the delivery of siRNA to specific target cells in vivo remains a 
challenge, compared to classic gene therapy where the nucleic acids have to reach 
the nuclei and integrate into the genome of target cells, siRNAs have only to be 
released in the cytoplasm. Another advantage of antisense therapy is the limited 
duration of the effect induced by siRNA compared to a long lasting effect induced 
by successful gene therapy that could lead to side effects difficult to control (Xu, Li 
et al. 2014). Taking everything into consideration, the efficacy of antisense therapy 




relies on the delivery system used and on the ability to deliver siRNA to target cells 
avoiding degradation (Deng, Wang et al. 2014). 
 
 
Figure 1: Antisense therapy: molecular pathway involved in siRNA processing. 
Long dsRNA and synthetic siRNA are processed by the protein complex RISC in the cytoplasm. 
Silencing sequences could be complementary to the target sequence leading to mRNA degradation. 
If a mismatch is present between the sequences, translation is repressed. Permission to publish was 
granted by Nature Reviews (Mittal 2004). 
 
1.1.2. Delivery systems in antisense therapy 
The choice of delivery system depends on the type of RNAi strategy used, which 
includes shRNAs, long dsRNAs and siRNAs. A small hairpin RNA or short hairpin 




RNA (shRNA) is a sequence of RNA that makes a tight hairpin turn that can be 
used to silence target gene expression via RNAi. shRNA products mimic the effects 
of pri-microRNAs (pri-miRNA) and are processed by the RNAse Drosha. The 
resulting pre-shRNAs are exported from the nucleus to the cytoplasm by Exportin 
5. This product is then processed by Dicer and loaded into RISC. shRNAs are 
usually expressed from virus based expression vectors or plasmids. Pioneer studies 
relied on the use of DNA plasmids for in vivo shRNA therapy as reviewed in (Meyer 
and Wagner 2006). However, subsequent studies have focused on the use of viral 
vectors (Perrimon, Ni et al. 2010). The choice of viral delivery system usually depends 
on the cell type targeted and on the need for short- or long term shRNA expression. 
Most shRNA-based studies have employed the standard viral vector expression 
systems used in traditional gene therapy (Burnett, Rossi et al. 2011).  
Long dsRNAs (200-500 nucleotides) can be delivered into cultured cells by 
transfection using standard physico-chemical methods. Long dsRNAs are usually not 
used in mammalian systems since they can trigger an unwanted interferon response that 
interferes with the activity of the transfected dsRNA (Perrimon, Ni et al. 2010).   
siRNAs in contrast to shRNAs do not have to be integrated into the genome of target 
cells to achieve their purpose (Zou, Scarfo et al. 2010). In vitro, siRNAs are usually 
transfected into cultured mammalian cells by various different methodologies such as 
cationic lipids, cationic polymers or electroporation and standard transfection reagents 
such as Lipofectamine. Different cell systems require different transfection methods 
depending on the cell type due to variation in transfection efficiency between cell types 
(Shegokar, Al Shaal et al. 2011). 
In vivo delivery of siRNA has many challenges. First of all, naked siRNAs are not 
stable in serum since they are easily degraded by RNAses. They are also easily removed 




by renal clearance, which results in a short half-life in blood (Brenner, Gottschalk et al. 
2013). Multiple strategies that involve the chemical modifications of the backbone or 
the bases of oligoribonucleotides have been used in order to stabilize the siRNA 
molecule without impairing the capacity to knock down the target (Czauderna, 
Fechtner et al. 2003, Soutschek, Akinc et al. 2004). Nanoparticle carriers have the 
ability to prevent siRNAs from intravascular degradation and to deliver them into cells 
limiting the risk of degradation and/or interaction with non-target molecules (Xu, Li et 
al. 2014). However, in the bloodstream delivery systems will encounter sensor cells 
including leukocytes, platelets, monocytes, and DCs and nanoparticles will be 
phagocytosed by these cell types. This uptake by immune cells can lead to subsequent 
immune responses against the nanoparticle structure with the production of reactive 
antibodies against the delivery system. These antibodies will be able to bind further 
injected nanoparticles of the same type, reducing the effectiveness of the delivery 
(Sroda, Rydlewski et al. 2005). Moreover, the involvement of the immune system may 
also lead to thrombogenicity and complement activation, resulting in altered 
biodistribution of the nanoparticle system and potential toxicity (Dobrovolskaia, 
Aggarwal et al. 2008). 
Secondly, the delivery system has to overcome barriers to entry into tissues and 
subsequently deliver the cargo into the cytoplasm of targeted cells. Nanoparticles for 
siRNA delivery may range from 1 nm to 1000 nm in diameter. However,  nanoparticles 
>100 nm in diameter are likely to be trapped by scavenger cells such as macrophages 
in the liver, spleen, lung, and bone marrow when intravenously injected in vivo, leading 
to ineffective delivery and potentially negative consequences due to activated 
monocytes and macrophages (Dobrovolskaia, Aggarwal et al. 2008). Larger 
particles (around 100 nm) may enter the lymphatic capillaries and lymph nodes 




where they may be trapped for a long time (Prokop and Davidson 2008). 
Furthermore, the surface chemistry of >100nm nanoparticles could activate 
the complement cascade, generating a danger signal in situ and potently activating 
DCs (Reddy, van der Vlies et al. 2007). The non-specific activation of these cell types 
could lead to the secretion of cytokines that could interfere with the correct function of 
other immune cells. Nanoparticle delivery systems of around 100 nm in diameter are 
ideally optimal for avoiding non-specific uptake by immune cells (Pecot, Calin et al. 
2011).  
Thirdly, even if the delivery system is able to be taken up by target cells, it will most 
likely be trapped inside an endosome usually leading to degradation of the nanoparticle. 
Endosomes are a group of vescicles important for the correct delivery of cellular 
components and nutrients towards a specific part of the cell. Usually, nanoparticles 
enter cells by endocytosis (Decuzzi and Ferrari 2008). As soon as the nanoparticle is 
endocytosed by cells, it begins travelling in early endosomal vesicles. The early 
endosome will then fuse with sorting endosomes equipped with a particular set of 
receptors designed to recognize pathogens and trap them before they can cause any 
damage (He, Jia et al. 2013). Unfortunately some pathogens have evolved to avoid 
this trap and are able to create pores using specific enzymes allowing them to 
escape. Eventually sorting endosomes will transfer their contents to late endosomes 
that are able to maintain a low pH through the activity of proton pumps (ATP 
dependant). Late endosomes will then fuse with lysosomes, which have an even 
more acidic environment (~pH4.5-5.5 (Sorkin and Von Zastrow 2002)) and are able 
to degrade nucleic acids very efficiently due to the presence of specific DNAses 
and RNAses (Dominska and Dykxhoorn 2010). Thus, siRNAs will not be released 
into the cell cytoplasm and function as RNAi effectors if the nanoparticle is unable 




to deliver the attached siRNA cargo outside the endosomal compartments. Multiple 
strategies can be used to promote endosome escape such as the use of fusogenic 
lipids (Vanic, Barnert et al. 2012), fusogenic peptides (Sakurai, Hatakeyama et al. 
2011), pH-sensitive lipoplexes (Li, Cheng et al. 2014), and pH-sensitive polyplexes 
(Sanjoh, Hiki et al. 2010). Fusogenic lipids are able to make liposomes fuse with 
the endosome membrane in order to release their contents inside the cytoplasm. pH-
sensitive materials use a proton sponge effect based on the release of material inside 
the endosome that is able to induce an influx of chloride ions and subsequent 
osmosis. This effect results in the destruction of the endosome and subsequent 
release of its contents to the cytoplasm (Dominska and Dykxhoorn 2010). 
Another important point regarding the delivery of siRNAs to solid tumors is the 
fact that research efforts have been focused mainly on strategies involving the 
optimization of delivery inside the cells and subsequent endosomal escape. 
Unfortunately the tumor microenvironment can interfere with the delivery before 
reaching target cells and strategies to overcome this issue have not been studied 
intensively. For example, nanoparticles must extravasate and move through the 
extracellular matrix (ECM) to reach the cancer cells. This complex tumor 
microenvironment barrier poses a challenge for the  accumulation of therapeutic 
drugs at high concentrations in target cells (Kleeff, Beckhove et al. 2007). ECM 
components (laminin, collagen IV, entactin and heparan sulfate proteoglycans) 
could interfere with nanoparticles leading to unpackaging and release of their 
contents prior to delivery to target cells (Burke and Pun 2008). Also, nanoparticles 
perform Brownian random walks through the spaces between network structures in 
ther ECM and are influenced by components of the matrix in several ways. For 




example, they collide with matrix fibers (steric interactions) and, as they diffuse 
near fibers, restricted thermal motion of water molecules due to proximity to the 
fibers slows their diffusion (hydrodynamic interactions) (Stylianopoulos, Poh et al. 
2010). Furthermore, neutrally charged nanoparticles diffuse through the ECM more 
rapidly compared to positively and negatively charged nanoparticles 
(Stylianopoulos, Poh et al. 2010). These findings suggest that in vitro studies of 
nanoparticle uptake could not predict the effectiveness in vivo since they do not take 
into consideration multiple barriers that the delivery system has to overcome before 
reaching target cells. Furthermore, the immune system is also an important 
extracellular barrier. Nanoparticles with charge (i.e. cationic or anionic) are more 
easily phagocytosed by macrophages (such as Kupffer cells in liver), DCs in lymph 
nodes (Dobrovolskaia, Aggarwal et al. 2008) and neutrophils (Brinkmann, 
Reichard et al. 2004, Bartneck, Keul et al. 2010). 
 
 
1.2. Dendritic cells (DCs) and Macrophages  
1.2.1. Characteristics of the innate immune system 
The innate immune system mediates the initial protection and defence against 
pathogens and removal of necrotic cells. Phagocytic cells such as DCs and 
macrophages not only provide a first barrier against microbes but also instruct cells 
of the adaptive immune system how to effectively combat (Bieber and Autenrieth 
2014). One of the main roles of DCs and macrophages is to act as sensor cells in 
order to rapidly identify intruders and aberrant cells that could potentially develop 




into malignant tumors if not removed promptly (Chanmee, Ontong et al. 2014). 
There are also important non-cellular components which are part of the innate 
immune system. Biomolecules such as natural antibiotics, plasma proteins 
(including the complement system) and some cytokines can be produced as a 
consequence of danger signals or be constantly present in the blood stream to 
prevent and extinguish any possible source of infection and initiate important 
physiological defence mechanisms such as fever, platelet accumulation, lysis of the 
microbe, chemotaxis and wound healing (Rozman and Bolta 2007). Danger signals 
as reviewed in (Gallucci and Matzinger 2001), can be defined as molecules released 
or produced by cells undergoing abnormal cell death or stress, that are recognized 
by resting antigen-presenting cells (APCs). These molecules can induce APCs 
activation with consequent upregulation of co-stimulatory signals and immune 
responses initiations. Epithelial barriers are constantly patrolled by immune cells 
since mucosae are the main route of entrance for pathogens (Ganesan, Comstock et 
al. 2013). The innate immune system is crucial in order to limit the initial threat and 
to initiate the crosstalk between the innate immune response and the more specific 
adaptive immune response that is essential for an effective and long-lasting immune 
protection (Ito, Connett et al. 2012). 
 
1.2.2. Classification and subsets of DCs 
DCs are heterogeneous and their classification relies on the expression of specific 
surface markers on the plasma membrane. In mice, CD11c is used to identify DCs, 
however the level of expression may vary between DCs subsets (Alvarez, Vollmann 




et al. 2008). Although DCs populations are many, conventional DCs, also called 
classical DCs (cDCs), and plasmacytoid DCs (pDCs) are the two main groups. 
pDCs express intermediate levels of B220 (CD45R, a B cell marker) and lower 
levels of CD11c and MHC-II compared to cDCs.  
1.2.3. The role of Dendritic cells (DCs) 
DCs are the ‘professional’ APCs of the immune system, which are able to prime T 
cells. Because of their central role in the initiation of immune responses, DCs are 
an important tool for antigen-specific immunotherapy of cancer. Immature DCs are 
present in peripheral tissues, where they possess the capacity to acquire and process 
antigens into small peptides. In the absence of inflammation, DCs remain in an 
immature state. Tissue inflammation induces the maturation of DCs and their 
migration to draining lymph nodes in order to present antigens to naive 
lymphocytes (Teijeira, Russo et al. 2014). Mature DCs express high levels of cell-
surface major histocompatibility complex (MHC) and co-stimulatory molecules 
such as CD40, CD80 and CD86 (Dilioglou, Cruse et al. 2003). This allows the 
priming of CD4 T helper cells through MHC class II and CD8 cytotoxic T 
lymphocytes (CTLs) through MHC class I. It is now known that activated CD4 T 
helper cells up-regulate CD40 ligand, and that signaling through CD40 fully license 
CD4 T cells (Hostager and Bishop 2013). Conversely, T cells may 
undergo apoptosis or become altered if antigen presentation is not followed by 
proper costimulatory signals (Stein 2015). Furthermore, without initial 
costimulatory signals T cells may not be able to activate properly even after 
receiving costimulatory signals at later stages. For example, this is one mechanism 




by which a T cell can become tolerant to self antigens or be induced to became a 
regulatory T cell (Gaudreau, Guindi et al. 2007). 
 
1.2.4. Activation of DCs: the role of Toll-like receptors and Nod-like 
receptors 
Immune sensor cells are able to recognize pathogens through different classes of 
receptors. Some of these receptors specifically bind components and proteins 
expressed on a pathogen’s membrane while others are able to recognize specific 
types of DNA and RNA that are different between eukaryotes and prokaryotes. 
These include Toll-like receptors (TLRs), C-type lectin receptors (CLRs), 
nucleotide-binding and oligomerisation domain, leucine-rich repeat (Nod)-like 
receptors (NLRs) and retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) 
(see Table 1). Their activation induces recruitment of adapter proteins and kinases 
that are able to activate the signalling cascade leading to the activation of 
transcription factors that cause wide ranging gene expression changes (Jenner and 
Young 2005, Akira 2006).  
TLRs are the best characterised group of pattern recognition receptors (PRRs). 
They are transmembrane molecules with an intracellular C-terminal domain that is 
known as the Toll/IL-1 receptor (TIR). It is homologous to the IL-1 receptor 
intracellular region and it is responsible for the binding of adaptor molecules that 
will activate the signalling cascade (Brown, Wang et al. 2011). Stimulation of all 
TLRs recruits a protein called myeloid differentiation primary response gene 
(MyD88) (Brown, Wang et al. 2011). The only exception is TLR3 that recruits the 




adaptor molecule TIR-domain-containing adapter-inducing interferon-beta (TRIF), 
which can also associate with the TIR domain of TLR4 through the TRIF-related 
adaptor molecule (TRAM) (Brown, Wang et al. 2011). Therefore, TLR4 is the only 
TLR able to induce both the MyD88-dependent and TRIF-dependent signalling 
pathways. The adaptor-dependent signalling cascades lead to the activation of 
transcription factors such as nuclear factor-κB (NF-κB) and IFN regulatory factors 
(IRFs) (Brown, Wang et al. 2011). This signalling cascade can also lead to 
activation of mitogen-activated protein kinases (MAPKs) such as p38 or c-Jun N-
terminal kinase (JNK) (Brown, Wang et al. 2011). TLRs receptor agonists have 
shown antitumor effects. For example stimulation of DCs with OK-432 (a TLR4 
agonist) increases IL-12 production and induces polarization of the T-cell response 
towards a Th1-dominant state in mice (Okamoto, Oshikawa et al. 2006). 
Furthermore TLR7 and TLR9 agonists are able to improve antitumor immunity in 
leukemia or solid tumor types and are currently in clinical trials (Harsini, Beigy et 
al. 2014). On the other hand, TLRs are also expressed on tumor cells and their 
expression have been linked to resistance of tumor cells to cytotoxic T cell and 
natural killer cell attack, resistance to apoptosis and increased invasiveness (Huang, 




Table 1: Pathogen recognition receptor classes used to identify specific 
patterns on pathogen’s surface (information derived from (Kawai and Akira 
2009) and (Oviedo-Boyso, Bravo-Patino et al. 2014)) 





Name Localisation Ligand 
TLRs   
TLR1/2  plasma membrane  triacylated lipoproteins  
TLR2/6  plasma membrane  diacylated lipoproteins  
TLR3  endosomal membrane  double-stranded RNA  
TLR4  plasma membrane  lipopolysaccharide  
TLR5  plasma membrane  flagellin  
TLR7  endosomal membrane  single-stranded RNA  
TLR8  endosomal membrane  single-stranded RNA  
TLR9  endosomal membrane  CpG DNA  
TLR10  plasma membrane  ?  
CLRs    
Dectin-1  plasma membrane  β-glucans  
DC-SIGN  plasma membrane  viruses, mycobacteria, Candida, 
Leishmania  
MBL  plasma membrane  mannose,  
N-acetylglucosamine  
RLRs    
RIG-I  cytoplasm  double-stranded RNA  








Nod1  cytoplasm  peptidoglycan (iE-DAP)  
Nod2  cytoplasm  peptidoglycan (MDP)  
NALP1  cytoplasm  MDP and anthrax toxin  
NALP3  cytoplasm  whole bacteria, bacterial RNA, purine-
like compounds, uric acid crystals, 
extracellular ATP, pore-forming toxins  
NLRC4  cytoplasm  flagellin  
NAIP5  cytoplasm  flagellin  
 
CLRs recognise sugars such as mannose or carbohydrate structures (fucose and 
glucan) and can interact with a variety of pathogens, including viruses, bacteria, 
mycobacteria, helminths and fungi (Yan, Ohno et al. 2013). Nod1 and Nod2 
recognise peptidoglycans from bacterial cell walls (McDonald, Inohara et al. 2005) 
and have been shown to activate NF-κB and MAPKs (Inohara, Koseki et al. 2000, 
Kobayashi, Chamaillard et al. 2005). The NLR members contain a caspase-
recruitment domain (CARD) and both NACHT leucine rich repeat and pyrin 
domain containing 1 (NALP1) and NALP3. These proteins form complexes with 
the adaptor apoptosis-associated speck-like protein-containing CARD (ASC) and 
caspase-1, known as inflammasomes, which convert pro IL-1β and pro IL-18 into 
active cytokines (Mariathasan and Monack 2007). The activation of NALP3 in 
tumors leads to the generation of an inflammatory response mediated by IL-1β that 
can contribute to the development and progression of many types of cancer. On the 
other hand, the activation of this pathway in DCs plays a crucial role in linking 
innate and adaptive immune response against dying tumors inducing anti-tumor 




immunity (Ghiringhelli, Apetoh et al. 2009). In addition to the recognition of 
PAMPs, TLRs (Tian, Avalos et al. 2007) and NLRs (Hornung, Bauernfeind et al. 
2008) also play a role in the recognition of danger associated molecular patterns 
(DAMPs), which can also activate immune cells and mediate transcriptional 
changes. DAMPs are patterns of host intracellular molecules that have been 
deposited in the extracellular environment from dying host cells, alerting the 
immune system about necrotic cell death. Heat-shock proteins (HSPs) were first 
discovered to activate DCs and enhance the immune response when released after 
necrotic cell death (Basu, Binder et al. 2000), although it cannot be excluded that 
microbial contamination was responsible for the effects (Bausinger, Lipsker et al. 
2002). Although various cell types can express PRRs, they are mainly present on 
DCs, macrophages and endothelial cells (Chow, Franz et al. 2015). Activation of 
NLRs and TLRs induces DC activation and maturation, characterised by increased 
expression of MHC class II molecules, T cell costimulatory molecules CD80 and 
CD86, adhesion molecules ICAM1 and CD58, and the lymph node homing CC-
chemokine receptor 7 (CCR7), all of which serve to augment DC-T cell interactions 
(Banchereau and Palucka 2005).  
 
1.2.5. DCs in the tumor microenvironment 
DCs migration to the tumor site is driven by the secretion of cytokines and other 
important biomolecules (VEGF, β-defensin, CXCL12, HGF, and IL-8), by the 
tumor and stroma cells (Murdoch, Muthana et al. 2008). There is evidence 
supporting the idea that the infiltration of DCs at the tumor site is associated with 




better clinical outcome in a variety of human cancers (Talmadge, Donkor et al. 
2007). Conversely, the tumor microenvironment can influence the infiltrating 
immune cells by potentially turning them into suppressor cells able to inhibit the 
immune response (Meirow, Kanterman et al. 2015). The molecular bases of this 
mechanism are not completely known, however the production of 
immunosuppressive chemokines by the tumor and stroma cells can induce 
suppressor cells that will facilitate the progression of tumor growth (Bianchi, 
Borgonovo et al. 2011). As a consequence, cytotoxic T cells can be impacted in 
their ability to slow advance of the tumor lesion.  
DCs infiltrating tumors have an altered phenotype with characteristics resembling 
both mature and immature DCs (Fainaru, Almog et al. 2010). Colon cancer patients 
with high infiltration of DC-LAMP (CD208) positive DCs had poor prognosis 
(Melief 2008). On the other end, the presence of CD83+ and/or CD208+ DCs are 
associated with better clinical outcome in melanoma, breast, and colorectal cancer 
(Talmadge, Donkor et al. 2007). Furthermore, immature DCs are able to promote 
tumor angiogenesis and tumor growth, while their mature counterparts do not 
(Fainaru, Almog et al. 2010). These findings demonstrate that infiltrating DCs have 
an important role at the tumor site and that their role may vary between suppressor 
or enhancer of the immune response depending on their maturation stage 
(Talmadge, Donkor et al. 2007). Many cytokines, angiogenic factors and 
chemokines that are secreted by activated immune and stromal cells at the tumor 
site, can provoke a state of chronic inflammation leading to a tumor 
microenvironment that shares many molecular features of a 'never healing wound 
(Jarnicki, Putoczki et al. 2010). Signal transducer and activator of transcription 3 




(STAT3) plays an important role in determining the outcome of the interaction 
between cancers and immune cells, both in terms of suppressing anti-tumor 
activities as well as facilitating a tumor promoting inflammatory 
microenvironment. Persistent activation of several STATs, especially STAT3 has 
been shown to promote inflammation at the tumor site and suppress the immune 
response (Yu, Pardoll et al. 2009).  These known tolerogenic mechanisms suppress 
the ability of cytotoxic T cells to kill cancer cells leading to tumor survival and 





Macrophages derive from monocytes. As monocytes move from the blood into the 
tissue they differentiate into a variety of tissue-resident macrophages. These have 
different names depending on the organ they patrol: alveolar macrophage (lung), 
osteoclasts (bone), microglial cells (central nervous system), histocytes (connective 
tissue) and kupffer cells (liver) (Martinez, Helming et al. 2009). Macrophages are 
sensitive to extracellular signals such as cytokines. Three populations of 
macrophage can arise in response to cytokine stimuli from immune cells (Mills 
2015). IFN- γ, TNF and other stimuli such as LPS can drive differentiation to 
classically activated macrophages (M1 macrophages). Furthermore Granulocyte 
macrophage colony-stimulating factor (GM-CSF) and IL-12 can induce M1 
macrophages through the JAK2/STAT5 pathway (Martinez, Helming et al. 2009). 




On the other hand wound-healing or alternatively activated macrophages (M2 
Macrophages) can be generated in response to IL-4, IL-10 or IL-13 (Roszer 2015). 
Regulatory macrophages are generated in response to various stimuli, including 
immune complexes, prostaglandins, glucocorticoids, apoptotic cells or IL-10. Each 
of these three populations has a distinct function and different physiology. For 
instance, M1 macrophages have strong microbicidal capabilities, whereas 
regulatory macrophages produce high levels of IL-10 to suppress immune 
responses (Martinez, Helming et al. 2009, Murray and Wynn 2011). Macrophages 
are equipped with a broad range of scavenger receptors that make them able to 
efficiently recognize pathogens. After interaction with microbes, they can 
subsequently internalize them and induce the secretion of inflammatory cytokines 
to initiate the immune response. For more detail regarding phagocytic surface 
receptors refer to section 1.2.4. To conclude, macrophages are responsible for 
engulfing pathogens and inactivate them. However, some pathogens are able to 
resist and can use this uptake mechanism to their advantage to continue their life 
cycle inside the macrophage’s cytoplams. In this case, macrophages serve as a host 
for various intracellular pathogens and many viruses (Hossain and Norazmi 2013). 
 
1.2.7. Macrophages in the tumor microenvironment 
Circulating monocytes and macrophages are actively recruited into tumors where 
they are able to induce tumor progression by altering the tumor microenvironment 
(Ramanathan and Jagannathan 2014). Macrophages shift their functional 
phenotypes after the interaction with various microenvironmental signals generated 




from tumor cells and surrounding stromal cells (Chanmee, Ontong et al. 2014). 
Tumor-associated macrophages (TAMs) closely resemble the M2-
polarized macrophages and are characterized by a high secretion of IL-10. On the 
other hand, IL-12 secretion by M2 macrophages is low and this phenotype 
correlates with a lower tumoricidal activity. Furthermore clinical trials have 
suggested that the presence of TAMs in the tumour microenvironment correlates 
with a poor prognosis (Zhang, Zhu et al. 2010).  
 
1.3. The T cell immune response 
 
1.3.1. T cell activation and differentiation 
Naïve T cells are activated upon encounter with cognate antigen and concomitant 
costimulation, in the presence of different cytokines. Two critical steps are 
important to achieve an optimal T cell activation (Inman, Frigola et al. 2007): 
Firstly, the T cell receptor (TCR) has to ligate with antigen presented by MHC class 
I or II molecules on APC. Secondly, costimulation signals (CD80, CD86 and CD40) 
on APC surface have to bind to their counterpart receptor CD28 on T cells. 
Moreover, T cells have to be in a microenvironment deprived of suppressive signals 
and with stimulation of cytokines such as IL-2 (Chen and Flies 2013). 
1.3.2. CD4 T cells 
CD4 T cells can differentiate into numerous subsets of cells; each subset is defined 
by specific cytokines production and by transcription factors that contribute to the 




maintenance of CD4 differentiation. After antigen recognition (in the context of 
MHC class II molecules binding to TCR), co-stimulatory signals from the antigen 
presenting cell (CD80, CD86 and CD40) and self produced IL-2 are necessary for 
the complete activation of CD4 T cells (Chen and Flies 2013). Activation of TCR 
and CD3 initiate the downstream signaling cascade, which eventually lead to naïve 
cell proliferation and differentiation into specific effector cells (Luckheeram, Zhou 
et al. 2012). The first two subsets of differentiated CD4 T cells, T helper one (Th1) 
and T helper two (Th2) were identified in 1986 (Mosmann, Cherwinski et al. 1986). 
Further studies revealed that CD4 T cell can differentiate into the Th17 and 
follicular T helper (Tfh) lineages (Luckheeram, Zhou et al. 2012). Other regulatory 
subsets have also been described recently, of which, inducible Treg, thymic-derived 
natural Treg and T helper 9 are the most well defined classes (Yuan and Malek 
2012) (Stassen, Schmitt et al. 2012). Subset-specific transcription factors are 
regulated by distinct cytokines which activate signalling pathways that are able to 
induce the specific lineage required (Yuan and Malek 2012). For example, IL-12 
signals through signal transducers and activators of transcription 1 (STAT1) and is 
important for CD4 T cells differentiation into Th1 cells. Conversely, IL-4 signals 
induces the trans-acting T-cell-specific transcription factor 3 (GATA3) which 
regulates Th2 differentiation (Luckheeram, Zhou et al. 2012). For CD4 T cells to 
become Th17 cells, IL-6 signals through STAT3 while TGF- β signals through 
Smad2 and Smad3 to induce the retinoid orphan receptors (RORs) RORgt, which 
regulate Th17 cytokine transcription (Jetten 2009). Inducible T-cell co-stimulator 
(ICOS) was reported to be essential to the differentiation of Tfh (Qi, Chen et al. 
2014). Individuals deficient in ICOS develop common variable immunodeficiency 




(CVID), with associated reductions in class-switched and memory B cells (Yong, 
Salzer et al. 2009). Another subset of CD4 T cells recently described is T helper 9 
(Th9) (Vegran, Apetoh et al. 2015).  Th9 are characterized by a high secretion of 
IL-9 and IL-21 in the tumor microenvironment that contributes to their anticancer 
functions. These cytokines trigger the activation of DCs, mast cells, natural killer 
cells, and CD8 T cells and are able to induce an antitumor reponse. To test the role 
of IL-9 in the tumour microenvironment, a study (Purwar, Schlapbach et al. 2012) 
was carried out on melanoma-bearing mice treated with an IL9-neutralizing 
antibody. Result showed that IL-9 depletion promoted melanoma growth. 
Furthermore Lu et al., suggested that immunotherapy with Th9 cells could be 
beneficial for the treatment of established tumors (Lu, Hong et al. 2012).  
1.3.3. CD8 T cells 
When naïve CD8 T cells are activated by APCs, they proliferate to large numbers 
and undergo differentiation. Activation of CD8 T cells causes changes to their 
surface marker phenotype such as the  loss of L-selectin (CD62L) and upregulation 
of CD44 (Kaech, Hemby et al. 2002). CD4 T cells are also important for the clonal 
expansion of CD8 T cell since they can provide a high concentration of IL-2 in the 
microenvironment leading to a robust expansion and further differentiation towards 
a cytotoxic phenotype (Luckheeram, Zhou et al. 2012). Activated CD8 cells will 
then migrate to sites of inflammation and infection. Differentiation transforms CD8 
T cells into effector cells that are able to kill target cells with different 
methodologies and secrete cytokines to induce inflammation and the recruitment of 
other immune cell types. CTLs are CD8 cells essential for host defences against 




malignant cells (Russell et al 2002). Activated CD4 T cells can also induce 
cytotoxicity (Quezada, Simpson et al. 2010). T cell-mediated toxicity results in lysis 
of the target cell that can be mediated by many effectors such as perforin/granzyme 
or the activation of death receptors (TRAIL pathway and FAS ligand). TRAIL, is a 
type II transmembrane protein of the TNF super-family expressed by activated T 
cells. Also known as Apo2 ligand or CD253, TRAIL has at least five receptors 
(Death Receptor (DR) 1-5) of which only two (DR4 and DR5) are capable of 
transducing an apoptotic signal in human cells (Degli-Esposti 1999, Ashkenazi 
2002). The signal transduction after activation of DR-5 comprises Fas activated 
death domain (FADD) and caspase-8-dependent pathways (Bodmer et al 2000). 
The activation of this pathway leads to mitochondrial dysfunction and cell death.  
Fas is a transmembrane receptor that belongs to the tumor necrosis factor (TNF) 
family. Stimulation of Fas receptor can be achieved by both Fas Ligand (Fas L) and 
agonistic antibodies (Cullen and Martin 2015). The stimulation of Fas on target 
cells leads to the activation of FADD causing subsequent apoptotic cell death 
(Cullen and Martin 2015). Fas and Fas L are also important in T-cell homeostasis. 
T cells after activation are initially resistant to Fas-mediated apoptosis during clonal 
expansion, but become progressively more sensitive the longer they are activated, 
ultimately resulting in activation-induced cell death (AICD) (Cullen and Martin 
2015). This process is needed to prevent an excessive immune response and 
eliminate autoreactive T-cells. 
Another important mechanism in T cell mediated cytotoxicity is mediated by 
perforins (Figure 2). Perforin proteins are stored in cytoplasmic vesicles of CTLs 
and NK cells and can produce pores in the membrane of target cells leading to 




osmotic shock. Perforin has a role in tumor killing mechanisms since it is secreted 
when effector lymphocytes encounter virus-infected or neoplastic cells (Trapani et 
al 2007). Like perforins, granzymes (Baselga et al 1996) are found in vesicles 
(granules) in CTLs and NK cells. Granzymes are secreted in a similar fashion to 
perforins and stimulate formation of pores in target cell membranes which can 
cause osmotic shock and lysis mediated by apoptotic proteins (Henkart 1985). The 
degranulation effect is thought to be initiated by receptor-mediated binding of target 
cells by NK cells or CTLs which stimulate a Ca++ dependent signal cascade that 
leads to degranulation (Topham and Hewitt 2009). It has been hypothesized that 
granzymes and perforin may work together to produce cell death: perforin could 
induce pores that are used by granzymes to penetrate target cell membrane where 
they can induce apoptosis (Lieberman et al 2003).  
CTLs are also able to secrete interferons (IFNs). IFNs are recognized as central 
regulatory mediators of the immune response. Their functions include anti-tumor 
and immuno-regulatory activities. One of the functions of IFNs is to upregulate 
major histocompatibility complex molecules, MHC I and MHC II, and increase the 
immunoproteasome activity leading to a better presentation of antigen from APCs 
to effector cells (Minn 2015). STAT1, STAT2, STAT5 and JAK are the main 
mediators of the signalling cascade. Moreover, in clinical trials on melanoma and 
renal cell carcinoma, IFN-alpha increase NK cell and T helper lymphocyte activity, 
as well as in-vitro T-cell responses and tumor infiltrating lymphocytes numbers 
(Belardelli et al 2002). 
 





Figure 2: Models regarding perforins actions 
Perforin molecules intercalates the membrane of target cell creating pores leading to osmotic shock.  
A: The initial model relied on perforin for the creation of a lytic pore that would allow lysis of target 
cells by osmotic shock.B: Activation of caspases by Granzyme B after entering the cell through 
perforin pores 
C: Activation of BID mediated apoptosis by Granzyme B after entering the cell escaping endosomes 
via perforin pores.D: The most recent model, which is still the topic of vigorous debate, is similar 
in principle to c. Granzyme B recognizes the mannose 6-phosphate receptor (MPR) and incorporates 
the idea that macromolecular complexes that contain perforin, granzymes and possibly other 
molecules (such as serglycin, SG) can be taken up into target cells without significant perforin-pore 
formation. 
Permission to publish was granted by Nature Reviews (van den Brink and Burakoff 2002). 
 
1.3.4. Naturally occurring Tregs 
Naturally occurring Tregs are mainly CD4 T cells that play a major role in 
regulating immune responses dependent on their expression of the transcription 
factor Foxp3 (Fontenot, Gavin et al. 2003). Tregs can be derived from either the 




thymus, (natural Tregs (nTregs)) or induced in the periphery (inducible Tregs 
(iTregs)) (Fontenot, Gavin et al. 2003). Tregs also contribute to maintaining 
tolerance through their production of the suppressive cytokines such as IL-10 and 
TGF-β (Sakaguchi, Wing et al. 2009). IL-10 is a crucial cytokine produced in order 
to maintain tolerance and in the absence of IL-10-producing Tregs, inflammation 
and cellular infiltration occurs in many tissues leading to the production of other 
pro-inflammatory signals (Rubtsov, Rasmussen et al. 2008). Another mechanism 
involved in Treg-mediated immunosuppression is the expression of IL-2R. It has 
been suggested that IL-2R could deprive effector T cells of IL-2 and inhibit their 
proliferation (Pandiyan, Zheng et al. 2007). The surface molecule CTLA-4 
expressed on Tregs also has inhibitory function since it can compete with CD28 for 
binding to CD80/CD86 expressed by DCs leading to the disruption of the 
immunological synapse (Tai, Van Laethem et al. 2012). In addition, Tregs prevent 
immune responses against innocuous antigens by suppressing DCs responsible for 
the sensitization process to allergens and producing suppressive cytokines 
(Joetham, Takeda et al. 2007, Curotto de Lafaille, Kutchukhidze et al. 2008). 
1.3.5. Inhibition of activation and induction of anergy 
Specific signalling pathways involved in T cell activation can be modified or 
blocked by biomolecules in the microenvironment. For example Tregs have a major 
role in this process since they can secrete suppressive cytokines such as IL-10 and 
TGF-β (Shevach and Thornton 2014). Anergy is characterized by the 
hyporesponsivness to IL-2 and defects in the T cell response to 
an allergen or antigen (Kuklina 2013). This state of inhibition can occur on T cell 




when the costimulatory signals are not present since the activation of the TCR is 
not enough to fully activate T cells. The expression of markers such as upregulated 
diacylglycerol kinases (DGKs), early growth response 2 (EGR-2), EGR-3, E3 
ubiquitin ligases and gene related to anergy in lymphocytes (GRAIL) are important 
in order to recognize an anergic T cell (Schwartz 2003, Zheng, Zha et al. 2008). 
Disproportional signaling events between highly activated calcium/NFAT versus 
diminished or defective RAS/MAPK pathways are also evidence of anergy in T 
cells (Macian, Garcia-Cozar et al. 2002, Zha, Marks et al. 2006). To avoid the 
induction of anergy in T cells, an increased expression of costimulatory molecules 
on the surface of activated DCs is essential and this enhanced expression could be 
achieved by immunomodulant or immunostimulant molecules that act on DCs (see 
chapter 1.5.2, Introduction). The inhibition of apoptosis of DCs is also a strategy 
that could be used to achieve similar results. For example, the blockade of apoptotic 
pathways that involve proteins such as BIM, PUMA or BID leads to increased DCs 
function in vivo by improving T cell activation (Chen, Huang et al. 2007, Fuertes 
Marraco, Scott et al. 2011).  
1.3.6. Memory response 
During a bacterial infection and subsequent interaction of T cells with foreign 
antigens, activated T cells robustly expand and migrate to tissue sites where they 
can exert their cytolytic (CD8) or helper (CD4) functions. After defeating the 
invading pathogens up to 95% reduction in the number of effector T cells occur 
(Perl, Gergely et al. 2002). The remaining antigen specific T cells may then 
differentiate into a long-term memory population that can be restimulated more 




effectively and rapidly than the original naïve T cells. Cytokines play an important 
role in the maintenance of the T cell memory pool. For example IL-7, is the main 
survival cytokine for CD4 memory cells since experiments showed that transferred 
CD4 cells cannot survive in its absence (Li, Huston et al. 2003). On the other hand, 
IL-15 seems to have a major role in the survival of CD8 memory T cells (Judge, 
Zhang et al. 2002). Regardless of T-cell precursor frequency, CD4 T cells do not 
match the proliferative capacity of their CD8 T-cell counterparts (Powell, Brown et 
al. 2004). However it has been shown that CD4 cells are important for the 
generation of an effective CD8 memory response (Shedlock and Shen 2003). 
Furthermore, T cell maintenance can be antigen-independent (Casey, Fraser et al. 
2012). Compared to CD8 T cells, both naïve and memory CD4 T cells are relatively 
refractory to IL-2–induced proliferation unless there is concurrent TCR engagement 
(Gesbert, Moreau et al. 2005).  
Models of viral infection allow researchers to unravel important knowledge on 
phenotypic markers and factors regulating T cell activation and memory. The 
majority of these discoveries are also applicable to human tumor immunology. Leo 
Lefrançois and colleagues recently suggested a model, named “early cell fate 
determination” model (Obar and Lefrancois 2010). In this model after initial 
activation, CD8 T cells progress into early effector stage, with cells characterized 
by a homogeneous expression of activation markers and production of Granzyme 
B and IFN-γ. As the development of an immune response goes forward, these early 
effector T cells undergo significant heterogeneity based on the signal strength 
(antigen, cytokines, and others) they receive. For example, interleukin 7 receptor 
alpha (IL-7Rα) and killer-cell lectin like receptor G1 (KLRG-1) were two markers 




found to be useful to distinguish memory T cell precursors (Omilusik, Best et al. 
2015). Furthermore, there are other models in which signal strength is not so crucial 
but other characteristics such as amount of antigen or signals from the 
microenvironments are considered to be more important (Sallusto, Geginat et al. 
2004, Stemberger, Neuenhahn et al. 2007, Harrington, Janowski et al. 2008, Turner 
and Farber 2014). A property that is shared amongst persisting memory cells is their 
ability to respond to a rechallenge of the antigen in a quicker and more efficient 
way (Migliaccio, Alves et al. 2006). We can identify two major groups of memory 
CD8 T; central memory (TCM) and effector memory (TEM) cells. Good reviews 
regarding TCM and TEM could be found here (Hamann, Baars et al. 1997, 
Bachmann, Wolint et al. 2005). TCM are CD62L+, CCR7+, and largely reside at 
lymph nodes, spleen and blood whereas TEM localize in peripheral non-lymphoid 
tissues, such as lung and liver. Studies of viral infections models strongly suggest 
that there are effector function differences between TCM and TEM. For instance, 
slow infections such as the one caused by the lymphocytic choriomeningitis virus 
(LCMV) can be controlled by the adoptive transfer of TCM, whereas Vaccinia virus 
infections (a pathogen which replicates rapidly) are not as easily controlled (Lugli, 
Dominguez et al. 2013). On the other hand, adoptive transfer of TEM can confer 
protection against both types of virus (Stemberger, Neuenhahn et al. 2007). Even if 
there is still an undergoing debate on TEM and TCM functions in vivo, it is 
recognized that TCM provide long-term protective immunity.  
 
 




1.4. The B cell Immune response 
 
1.4.1. B cell development 
 
B-lineage precursors reside in the liver during fetal life, and then in the bone 
marrow of adult mice (Allman, Ferguson et al. 1992). Human B-lineage cells are 
present in multiple tissue sites in early fetal development. However, from 
midgestation through the eighth decade of life, the bone marrow is the exclusive 
site of B lymphopoiesis (LeBien 2000).  Early B cell populations in the bone 
marrow sequentially transit a series of phenotypically distinct stages consisting of 
pro, pre, and immature B cell pools. Each of these populations can be defined by 
differential expression of surface markers consisting of CD19, B220, CD43, AA4 
and IgM (Hardy and Hayakawa 2012). These early precursors initiate expression of 
recombinase-activating genes (RAG) and undergo VDJ (variable, diversity, 
joining) rearrangement that will lead to expression of an intact Ig heavy chain, 
which pairs with a surrogate light chain to form a pre-BCR. The pre-BCR signals 
through Ig-α and Ig-β resulting in a rapid decrease in RAG protein levels and 
cessation of heavy chain rearrangement (Jung, Giallourakis et al. 2006). Cells at 
this stage also grow in size and undergo an intensive proliferative burst. The short 
half-life of immature B cells and extended life span of mature B cell compartments 
implies a tremendous selective pressure is placed on immature B cells, and show 
active negative selection in B cell development (Metzler, Kolhatkar et al. 2015). 
Those rare clones that successfully transit negative selection in the bone marrow 
are able to home via the blood to peripheral lymphoid organs such as the spleen. 




Immature B cells in the spleen are called transitional cells and are differentiated 
based on differential surface expression of CD23, IgM and CD21/35 (Guerrier, 
Youinou et al. 2012). The majority of transitional B cells in the spleen of an adult 
mouse will give rise to mature Follicular B cells, and a minor fraction will migrate 
to the marginal zone of the spleen leading to the generation of marginal zone B 
cells. Transitional B cells respond to TLR agonists and CD40 receptor cross-
linking, demonstrating these cells are capable of proliferating in response to certain 
stimuli (Allman, Ferguson et al. 1992).  
1.4.2. B cell activation and memory generation. 
Naïve B cells require multiple signals to become activated (Hua and Hou 2013). 
The first signal is delivered through the binding of the B cell receptor (IgM) to an 
antigen. Cross-linked IgM on the cell surface is then localized in clusters. This 
assembly provides intracellular signalling to the B cells mediated by the interaction 
of the BCR complex via the Igα and Igβ complex (Hua and Hou 2013). The second 
signal varies depending on the nature of the antigen encountered by the B cell. For 
T-cell dependent antigens, the second signal is delivered by T-helper cell after 
recognition of petide antigen bound to MHC class II molecules on the B cell 
surface, and the interaction between CD40 ligand (CD40L) on the T-cell surface 
and CD40 on the B cell surface (Noelle and Erickson 2005). For T-cell independent 
antigens, the second signal is mediated by interactions between the antigen itself 
and B cell surface, or by non-T-cell accessory cells (Vos, Lees et al. 2000). The 
third signal is given by the binding of TLRs, that are upregulated in naïve B cells 
upon BCR activation, as well as other co-receptors, such CD19, CD21 and CD81. 




An example of this is the T-cell independent protein LPS, which binds LPS-binding 
protein and CD14, that subsequently associates with the receptor TLR-4 on the B 
cell, leading to increased B cell activation (Hua and Hou 2013). 
During a T cell dependent response, a small proportion of activated B cells 
differentiate into short-lived low-affinity plasma cells within secondary lymphoid 
organs (Fooksman, Schwickert et al. 2010). The recruitment of activated B cells to 
the B cell follicular regions of the secondary lymphoid tissues lead to formation of 
germinal centres (GCs). GCs are micro-anatomical structures that support antigen 
specific B cell clonal expansion, positive selection based on antigen affinity and 
BCR diversification by somatic hypermutation (SHM) (McHeyzer-Williams and 
McHeyzer-Williams 2005). SHM is a process that introduces point mutations and, 
occasionally, insertions and deletions into the variable regions of the heavy chain 
immunoglobulin. This process leads to the generation of an expanded pool of B 
cells with a higher affinity for the target antigen (Chan and Brink 2012). The antigen 
specificity and affinity is often increased by several orders of magnitude during this 
process (Chan and Brink 2012). However, if the B cell does not receive required 
activation signals after SHM, it may become apoptotic (McHeyzer-Williams, 
Okitsu et al. 2012). High-affinity B cells are positively selected on the basis of 
antigen binding affinity. These cells rapidly proliferate and differentiate into either 
long-lived plasma cells or memory B cells. Plasma cells typically migrate to the 
bone marrow and spleen, and secrete high-affinity antibodies for extended periods 
of time leading to clearance of antigen (McHeyzer-Williams, Okitsu et al. 2012). 




The first exposure (the primary exposure) of a pathogen or antigen leads to the 
activation of naïve B cells that can became antigen-specific antibody producing 
plasmablasts and subsequently memory B cells (Bernasconi, Traggiai et al. 2002). 
These cells can persist for many years and are maintained in a resting state in the 
absence of sustained antigen, establishing immunological memory. Immunological 
memory allows the immune system to respond more rapidly to subsequent re-
encounter with the same antigen, with the generation of high affinity antibodies. 
Resting memory B cells are thought to have a low proliferation rate and the number 
of memory B cells is highly regulated (McHeyzer-Williams, Okitsu et al. 2012). 
 
1.4.3. B cell antitumor activity. 
The role of B cells in cancer treatment and progression is a matter of debate and has 
not received as much attention as the role of T cells. However, antitumor antibodies 
can be found in the plasma of most patients with solid tumors suggesting there may 
be an important role of B cells in tumor progression (Fremd, Schuetz et al. 2013). 
Furthermore most tumor microenvironments contain a population of infiltrating B 
cells implying an association between oncogenic events and B cell activation. The 
role of B cells at the tumor site remains largely unstudied. However, B cells can be 
beneficial by providing antibody-mediated protection (mediated by NK cells) in 
combination with chemotherapeutic regimens (Zhang, Morgan et al. 2013). In 
addition, while B cells have long been known to produce antibodies, their ability to 
act as effector cells in an immune response has only been recognized relatively 
recently (Li, Teitz-Tennenbaum et al. 2009). On the other hand, recent studies 




suggest that the activation of B cells may also be detrimental to an effective 
antitumor response (Ding, Yan et al. 2015). Apoptotic and necrotic death processes 
in cancer cells generate antigens that are often recognized by B cells. Recent data 
suggest a role of B cells in wound-healing processes at the tumor site and this 
mechanism could promote tumor growth and immunosupress T-cell responses 
(Ding, Yan et al. 2015). Therefore, methods to eliminate autoreactive B cells, or 
switch them to a B effector phenotype that amplifies Th1 T-cell responses may 
improve the clinical outcomes of T-cell-mediated immunotherapies (Linnebacher 
2013). Possible strategies include the administration of B cell depleting monoclonal 
antibodies (Kim, Fridlender et al. 2008), use of targeted B cell stimulatory agents 
such as TLR agonists (Kaczanowska, Joseph et al. 2013), and adoptive transfer of 
large numbers of ex vivo generated tumor-reactive B cells (Li, Lao et al. 2011). 
In addition to their well-known ability to differentiate into plasma cells and secrete 
antibodies, B cells also influence immunity by serving as APC. Naïve B cells are 
thought to represent an immunosuppressive type of APC because they have been 
shown to tolerize T cells that interact with them (Reichardt, Dornbach et al. 2007). 
However, under appropriate conditions that may involve CD40 ligation and 
cytokine signaling, a naïve B cell can serve as a relatively potent APC that expresses 
costimulatory molecules such as CD80, CD86, and ICOS, and activates both CD4+ 
and CD8+ T cells (Hagn, Blackwell et al. 2014). B cells exert effector functions not 
only through the production of antibodies, but also by making cytokines (Lund 
2008). There are two major types of B cells that arise through interection with Th1 
and Th2 cells and are characterized by the production of a different set of cytokines. 
B effector 1 cells secrete cytokines characteristic of Th1 immune response, 




including IFN-g, IL-12 and TNF-a. In contrast, B effector 2 cells arise through 
interactions with Th2 T cells and secrete a polarized pattern of cytokines that 
includes IL-2, IL-4, IL-6, IL-13, and TNF-a (Lund 2008). B effector populations 
may serve to differentially reinforce and amplify Th1 T cells that promote cellular 
immunity or Th2 T cells that promote humoral immunity (Wojciechowski, Harris 
et al. 2009). 
1.5. The NK cell immune response 
 
1.5.1.     NK cell function 
NK cells are large granular lymphocytes that constitute an important part of the 
innate immune system. NK cells originate from lymphoid progenitors in the bone 
marrow, where they acquire expression of NK cell specific receptors (Fathman, 
Bhattacharya et al. 2011). NK cells share with other lymphoid cells the acquisition 
of the IL-2 receptor γ-chain since their differentiation, proliferation and survival 
depend on stimulation by both IL-2 and IL- 15(Fathman, Bhattacharya et al. 2011). 
NK cells can be subdivided into two distinct subsets based on their expression of 
CD56 on the cell surface. The CD56bright NK cells comprise around 10% of 
circulating NK cells and have an immunoregulatory role through their secretion of 
proinflammatory cytokines although they have poor cytotoxic capacity (Beziat, 
Descours et al. 2010). The CD56dim NK cell subset, which is believed to be in a 
more mature state than the CD56bright NK cells, are highly granular and have 
potent cytolytic capacity (Beziat, Descours et al. 2010). 




NK cells have a role in directing the immune response by interacting with other 
immune cells. They do this either through secretion of pro-inflammatory cytokines 
such as TNFα and IFNγ (Novelli and Casanova 2004). A feature that NK cells share 
with CTLs is the capacity to exocytose granules containing perforin and granzyme 
as well as other lytic proteins (Barber, Faure et al. 2004). NK cells as well as T cells 
are able to employ an entirely different mode of cytotoxicity by engagement of 
TRAIL and Fas ligand. NK cells have been shown to be one of the main cell types 
that contribute to the ADCC effect, a key effector function in the immune response 
against infections and tumors.  
 
1.5.2.  Antibody Dependent Cellular Cytotoxicity (ADCC)  
Antibodies secreted by B lymphocytes are the main mediator of the humoral 
response. Antibodies function in four ways, via opsonisation, neutralisation, 
through activating the complement cascade and through participating in antibody-
mediated cytotoxicity (ADCC) (Davies and Metzger 1983). ADCC is an effector 
mechanism against tumor and virus-infected cells and pathogens in general. 
Specific antibodies of the IgG isotype secreted by plasmocytoid B cells are directed 
against cell surface antigens on target cells/pathogens, allowing a faster recognition 
and removal of the threat. ADCC requires three components: 1) target cells 
expressing tumor antigens on their surface; 2) IgG antibodies against the target 
antigen; and 3) effector cells expressing Fc gamma receptor (FcγR) (Clynes, 
Towers et al. 2000). The antibodies bind to the target cells having recognised the 
antigen expressed on the membrane surface. Fc receptors on immune cells 




recognize the Fc portion of antibodies bound to tumor surface antigens. The effector 
of ADCC is most commonly a NK cell (Figure 3). After the recognition and 
attachment via its Fc receptors, the NK cell can kill the target cell through release 
of granules containing perforin and granzyme B and/or activation of the Fas/Fas 
ligand apoptosis system in the target cell (Topham and Hewitt 2009). 
  
Figure 3: Mechanism of ADCC 
Specific antibodies secreted by plasma cells are able to recognize antigens expressed on the surface 
of tumor cells. NK cells can recognize antibodies bounded to target cells and release perforins or 
granzyme B after recognition.
 
1.6. Cancer Immunotherapy 
 
1.6.1.   Immunotherapy: General concepts 
Immunotherapy is a type of cancer treatment designed to boost the body's natural 
defenses to fight established tumors. Immununosuppression and dysregulation of 




the immune system in cancer patients is a composite event. Bone marrow and other 
hematopoietic organs (e.g. spleen) are targeted by tumor-derived factors leading to 
abnormal myelopoiesis and accumulation of immunosuppressive myelod cells at 
the tumor site (Sica and Bronte 2007). Dysregulation/immunosuppression is 
therefore likely to occur at two separate sites: locally (at the tumor site) where 
myeloid-derived suppressive cells (MDSC) and T regulatory cells can block target 
recognition and neutralization, and systemically, where an expanded pool of 
immature and MDSC are free to circulate and mediate suppression in lymphoid 
organs and in the blood (Lakshmi Narendra, Eshvendar Reddy et al. 2013). 
The term immunotherapy refers to any approach that seeks to mobilize and/or 
manipulate the immune system of a patient for therapeutic benefit (Steinman and 
Mellman 2004). These strategies include non-specific activation of the immune 
system with microbial components or cytokines, antigen-specific adoptive 
immunotherapy with antibodies or T cells or DCs, and antigen-specific active 
immunotherapy (cancer vaccines) (Banchereau and Palucka 2005). However, such 
in vivo or direct vaccination approaches, have not been very effective against cancer 
cells. Multiple biological factors contribute to the limited efficacy of anticancer 
vaccines, including the generally low antigenicity of cancer cells and the robust 
immunosuppressive mechanisms that are established in the course of oncogenesis 
and tumor progression (Aranda, Vacchelli et al. 2013). 
Immunotherapeutic strategies, such as cancer vaccines, can be used in order to 
direct the immune response against specific epitopes expressed by tumors. These 
types of vaccine are expected to induce both therapeutic T-cell immunity (in the 
form of tumor-specific effector T cells) and protective memory T-cell immunity (in 




the form of tumor-specific memory T cells that can control tumor relapse) (Pardoll 
1998, Gilboa 1999, Finn 2003, Li, Moon et al. 2013). Examples of anti cancer 
vaccines therapy are virus like particles (VLPs) displaying cancer antigens. These 
types of viruses can be specifically ingegnerized to express on their surface tumor 
associated antigen (Al-Barwani, Donaldson et al. 2014). The immune response 
generated will be specific for the incorporated peptide antigen and effector T cells 
will be able to interact with tumor cells, killing them. Furthermore, efficient antigen 
presentation and T-cell priming are essential components of a effective antitumor 
immunity and DCs are critical to both of these functions. Other types of 
nanoparticles such as liposomes or cubosomes are also used in cancer vaccines 
(Schwendener 2014). These nanoparticles accumulate in tumor tissues passively 
due to aberrant tumor angiogenesis that forms nonmature, leaky capillaries. These 
anomalies in tumor vascularisation can enhance the permeability to colloidal 
macromolecules or nanoparticles in comparison to normal blood vessels (Barreto, 
O'Malley et al. 2011). Liposomes are highly customizable and they are composed 
of a lipid bilayer that can be modified by the incorporation of molecules of interest. 
Furthermore, the lipid bilayer can be modified by the addition of specific 
phospholipid sensitive to pH (Zhang, Wang et al. 2015) or near-infrared light (Wu, 
Mikhailovsky et al. 2008) to promote targeted release of encapsulated molecules. 
Other nanoparticles such as cubosomes can be used as percutaneous delivery 
system and could potentially be used for the treatment of melanoma (Bei, Meng et 
al. 2010).  
1.6.2.   Immunomodulators and Immunostimulants 




“Immune-checkpoints” are key regulatory elements in the immune system that 
allow the management of the immune response and are important for the 
development of self-tolerance and to prevent autoimmunity. However, tumor cells 
consistantly benefit from this ability of the immune system in order to escape from 
its control  (Dimberu and Leonhardt 2011). Several approaches have been designed 
to prevent this inhibition of the immune response and to enhance the duration and 
activation of the T-cell mediated immunity (see table 2 for a summary of such 
strategies).  
 
Table 2: Immune checkpoint blockades therapy and adjuvant therapy 
Target Drug Reference 
TLR9 CpGs (Krieg 2006) 
CTLA-4 Ipilimumab (Eggermont, Chiarion-Sileni et 
al. 2015) 
PD-1 Nivolumab (Brahmer, Hammers et al. 2015) 
PDL-1 MSB0010718C (Lu, Lee-Gabel et al. 2014) 
 
For instance increasing the expression of co-stimulatory molecules on the surface 
of DCs (by CD40 or toll-like receptor 9 (TLR9) stimulation) (Krieg 2006, Shirota 
and Klinman 2014) is a strategy that has been used to enhance APC activation 
leading to a better cross-presentation of TAAs to T cells. Immune-checkpoint 
manipulation can be used to prolong T cell activation by inhibiting cytotoxic T-
lymphocyte antigen-4 (CTLA-4) or Programmed death-1 (PD-1) binding to 
CD80/86 or to PD1 ligand (PDL-1) respectively (Ribas, Camacho et al. 2005) 




limiting the capability of the tumour microenvironment to block the immune 
response.  Recently developed immunotherapeutic agents such as 
oligodeoxynucleotides (CpG as TLR9 agonists) and monoclonal antibodies (mAbs) 
to block CTLA-4 or PD-1 can indeed enhance the immune response in patients 
providing a more effective treatment as discussed below.  
CTLA-4 is a homolog of CD28 and acts as an inhibitory receptor for CD80/86 co-
stimulatory molecules on mature APCs. It is the main negative regulatory element 
of the T-cell mediated anti-tumour immune response since its binding to CD80/86  
downregulates T-cell activation (Kirkwood, Tarhini et al. 2008). MAbs such as 
Ipilimumab and Tremelimumab were developed to block the binding of CTLA-4 to 
CD80/86 through their higher affinities for CTLA-4 than CD80/86 and so, 
competitively inhibiting the downregulation of T-cells (Ribas, Camacho et al. 2005, 
Lussier, Johnson et al. 2015). Ipilimumab binds and blocks CTLA-4 and has shown 
striking clinical successes against metastatic melanoma, which led to its FDA 
approval in 2011 (Dimberu and Leonhardt 2011, Saraceni, Khushalani et al. 2014). 
Similar to CTLA-4 blockade, another approach to enhance the immune response 
against tumors is PD-1 blockade by the anti-PD-1 mAb. PD-1 is expressed on T-
cell surface and upon binding to PD-L1 it downregulates T-cell activation. This 
mechanism is frequently exploited by tumour cells in order to escape from the 
cytotoxic T cell activity (Dimberu and Leonhardt 2011). Phase II clinical trials for 
melanoma, renal cell carcinoma, prostate cancer, non-small-cell lung cancer or 
colorectal cancer using BMS-936558 (a newly described anti-PD-1 mAb) showed 
a similar outcome to the anti-CTLA-4 treatments with good response rates 
especially for metastatic melanoma and renal cell carcinoma (Topalian, Hodi et al. 




2012). Furthermore, there were less immune-related adverse effects compared to 
the anti-CTLA-4 treatment (Brahmer 2012).  
The most common side effect associated with checkpoint inhibitors is dermatologic 
toxicity (Lacouture, Wolchok et al. 2014) that typically does not appear until 
months after the initiation of the therapy. Side effects including rash and/or pruritus 
are treated with corticosteroid creams. Rarely, cases of Stevens-Johnson 
syndrome/toxic epidermal necrolysis have been reported and such reactions require 
hospitalization for intravenous corticosteroids (Weber, Kahler et al. 2012). 
Diarrhea is also common in patients undergoing treatment with CTLA-4 or PD-
1/PD-L1 antibodies. However, there is a much higher incidence of diarrhea in 
patients receiving CTLA-4 blocking antibodies compared to those targeting PD-
1/PD-L1 (Hodi, O'Day et al. 2010, Wolchok, Neyns et al. 2010). Hepatitis, 
and immune-related adverse events that affect the pituitary, adrenal, and thyroid 
glands were also reported to affect <10% of the patients. The treatment for these 
pathologies is various and could require hospitalization or suspension of the therapy 
as reviewed by Michael A. Postow (Postow 2015). 
Immunostimulants aim to enhance the activity of lymphocytes that are already 
involved in the anti-tumor response but are insufficient to eradicate the lesion. This 
strategy uses the patient’s own immune system in order to boost the anti-tumor 
response. The most important cytokines for cancer therapy in the late 1980s and 
early 1990s were Interleukin-2 (IL-2) and Alpha-Interferon (IFN-α). Clinical trials 
demonstrated their anti-cancer properties and they were approved by the U.S. Food 
and Drug Administration (FDA) for the treatment of cancer including renal cell 
carcinoma and metastatic melanoma (Kirkwood, Tarhini et al. 2008). Alpha-




Interferons are proteins with anti-viral properties belonging to the type-I IFN 
family. IFN-α is the most used cytokine for the treatment of more than a dozen 
types of cancer, such as hairy cell leukemia, chronic myeloid leukemia, B and T 
cell lymphomas, melanoma, renal carcinoma and Kaposi’s sarcoma (Pfeffer, 
Dinarello et al. 1998, Belardelli, Ferrantini et al. 2002, Vihinen, Tervahartiala et al. 
2015). Interleukin-2 is a glycoprotein which acts as a growth factor for both T-cell 
and NK cells and is also important for lymphocyte proliferation and immune 
regulation (Smith 1988). Unlike IFN-α, IL-2 acts indirectly on cancer cells through 
the activation of effector lymphocytes which are also called lymphokine-activated 
killer cells (Fang, Lonsdorf et al. 2008). The drawbacks of this immunostimulation 
are its high cost and its severe but reversible side effects. However, IL-2 remains 
an indispensible immunotherapeutic agent for the treatment of metastatic melanoma 
even if complete responses are rare (Fang, Lonsdorf et al. 2008, Flaherty, Othus et 
al. 2014).  
It seems that immunostimulants, on their own, are not sufficient to sustain an 
effective and selective anti-cancer immune response especially in later stage 
malignancies. However, chemical modifications to these types of molecules could 
increase their effectiveness and potentially reduce side effects increasing 
specificity. Furthermore, immunostimulants combined with chemotherapy or with 
other immunotherapies could lead to synergistic effects increasing the efficacy of 
these therapies (Dimberu and Leonhardt 2011). 
 
 




1.7. The immunomodulant and immunostimulant 
characteristics of MIS416 
 
MIS416 is a bacterial cell wall skeleton derived from Propionibacterium acnes 
comprising NOD-2 and TLR9 ligands that target cytosolic receptors expressed by 
APCs (Girvan, Knight et al. 2011). The manufacturing process generates a 
microparticulate suspension (0.5 x 2.0 micron rods) of minimal cell wall skeleton 
with bacterial DNA contained within the cage structure (Girvan, Knight et al. 2011). 
This new delivery platform exploits phagocytic uptake mechanisms to achieve 
targeted delivery to both myeloid and plasmacytoid DCs and other APCs (Girvan, 
Knight et al. 2011). This dual ligand formulation has been shown to act in a safe 
and well-defined manner, activating a broad range of key innate immune responses, 
which are central to the development of adaptive cellular and humoral immunity 
(Girvan, Knight et al. 2011). In the presence of immunogen(s), MIS416 has the 
capacity to amplify both cellular and humoral adaptive immune responses, acting 
as an effective and potent Th1 and Th2 adjuvant. Furthermore, immune response 
modifiers (IRMs) which can support the induction of adaptive Th1 immunity, offer 
the possibility for therapeutic as well as preventative vaccination.  Since most 
current cancer therapies result in immune cell depletion and associated 
immunosuppression, co-therapy with IRMs which concomitantly support 
hematopoietic restoration are likely to offer further improved therapeutic outcomes. 
In pre-clinical Lewis lung and 4T1 mammary tumor metastatic models, MIS416 
therapy alone has been shown to significantly reduce the occurrence of lung 
metastases when administered as a single i.v. bolus at various time points following 




establishment of a tumor burden (Girvan, Knight et al. 2011). Further, when used 
as a co-therapy with local tumor irradiation, there is a further reduction in the 
number of lung metastases in the Lewis lung model compared to individual 
therapies alone.  In this model, the weight loss associated with radiation toxicity is 
also ameliorated with MIS416 co-therapy, providing evidence of additional 
radioprotective effects being elicited by MIS416 therapy (patent WO2009123481 
A1, Innate therapeutics).   
The potential use of MIS416 as a therapeutic cancer vaccine adjuvant has been 
recently demonstrated in a B16-OVA tumor vaccine model (Girvan, Knight et al. 
2011).  Treatment with MIS416 in the absence of exogenous tumor antigen 
following tumor inoculation not only inhibited tumor growth, but also induced a 
significant increase in the number of OVA-specific IFN-γ secreting CD8 cells.  
These findings are important from a therapeutic standpoint, since they underscore 
the paradigm that appropriate immunostimulation in concert with endogenous 
tumor antigen can lead to autoimmunization. Furthermore, MIS416 microparticles 
have a favourable safety profile and are effective as a non-toxic Th1 adjuvant when 
either co-administered with an antigen or directly coupled to the antigen as an 
immuno-conjugate (Girvan, Knight et al. 2011). To demonstrate and further 
improve MIS416 anticancer capabilities, Girvan et al. attached TAAs to MIS416 
and were able to demonstrate that the coupling of an antigen to MIS416 improved 
the efficacy of the generated immune response compared to the control treatment 
group in which MIS416 and the antigen were not covalently bonded.  The article 
(Girvan, Knight et al. 2011) concludes saying “the ability to attach immunogens 
directly to the microparticle provides a platform for the development of effective 




subunit vaccines without compromising immunogenicity and the possibility of 
developing more dose-sparing vaccine formulations with this methodology 
warrants further evaluation.”  
In this thesis I have investigated new coupling methodologies in order to improve 
the conjugation efficiency and to further facilitate the attachment of other 
biomolecules. 
 
1.8. The model antigen SIINFEKL and the OT-1 transgenic 
mouse model 
The model antigen SIINFEKL is a Kb-restricted OVA257–264 peptide widely used in 
research (Hulseberg, Zozulya et al. 2010, Hogquist, Jameson et al. 2012). It is the 
dominant MHC-1 restricted peptide derived from the degradation of the protein 
ovalbumin. Multiple cancer cell lines have been developed in order to express 
SIINFEKL as a model tumor antigen. Cell lines such as B16-F10 melanoma (Kedl, 
Jordan et al. 2001), Lewis lung carcinoma (LLC) (Lu, Ramakrishnan et al. 2011), 
human cervical carcinoma Hela (Falk, Rotzschke et al. 1993) and thymoma EG.7-
OVA (Maitre, Brown et al. 1999) have been developed and widely used as tumor 
models for in vivo and in vitro studies. Moreover, different mouse models have been 
developed to provide useful immunological tools to study the immune response 
related to SIINFEKL. In this thesis the OT-1 mouse model (Clarke, Barnden et al. 
2000) has been used as a source of CD8 T cells specific to SIINFEKL (Miyagawa, 
Gutermuth et al. 2010). These mice contain transgenic inserts for mouse TCRa-V2 
and TCRb-V5 genes. The transgenic T cell receptor was designed to recognize 




ovalbumin residues 257-264 in the context of H2Kb and used to study the role of 
peptides in positive selection and the response of CD8 T cells to antigen (Clarke, 
Barnden et al. 2000). The OT-I transgenic line is a very powerful tool for analysing 
both thymic development and peripheral responses of CD8 T cells. For example, 
OT-1 T cells can be co-cultured with SIINFEKL pulsed DCs in order to simulate 
antigen presentation events in vitro and evaluate various parameters of T cell 
responses such as T cell proliferation, activation marker expression and cytokine 
production. T cell proliferation can be assessed by marking OT-1 T cells with a 
fluorescent dye (Carboxyfluorescein succinimidyl ester is the most often used) 
before the co-culture experiment with SIINFEKL pulsed DCs (Quah and Parish 
2010). Proliferating cells can be identified since mitosis events will dilute the dye 
inside the cytoplasm of activated T cells and this dilution can be detected by flow 
cytometry. Activation marker expression on activated OT-1 T cells such as cluster 
of differentiation 69 (CD69), can be monitored at the same time as proliferation by 
cytofluorimetric analysis with the use of specific antibodies. The media used in 
these experiments can also be analysed for cytokines production by ELISA assays 
using specific antibodies able to recognize important cytokines such as IFN-γ, IL-
10, IL-6 and TNFα. The expression of SIINFEKL by DCs can also be monitored 
with a specific antibody that can recognize SIINFEKL peptide bounded to MHC 
class II molecules on the surface of DCs (Porgador, Yewdell et al. 1997). The 
combination of these two assays provides a very useful tool to evaluate the immune 
response against a specific antigen and can be used to optimize antigen presentation 
by DCs in order to induce a better, or a prolonged T cell mediated immune response. 
 




1.9. Coupling strategies used with amino group residues 
Owing to the abundance of lysine residues in the MIS416 membrane, the favoured 
targets for coupling reactions are amino groups. Furthermore, the positive charge 
on lysine residues renders them available, since they will often be located on the 
outside surface of a native protein at physiological pH (Sokalingam, Raghunathan 
et al. 2012). Multiple classes of reactive molecules that have a specific propensity 
for amine residues have been described, however succinimidyl esters are mostly 
used for targeting -NH2 groups. N-hydroxysuccinimide (NHS) esters form stable 
amide bonds with amines at pH 7.5-8.5 (Figure 4). 
 
Figure 4: Lysine and NHS esters reaction 
Schematic of the reaction between the amino groups on Lysine with NHS esters to create protein 
conjugates. 
 
Although, these readily available amino groups ensure ease of conjugation, this can 
lead to coupling at unspecified regions of proteins. Fortunately with MIS416, 
inactivation due to the attachment of biomolecules to lysine residues is not 
considered an issue, whereas the use of NHS esters in coupling strategies involving 
proteins with catalytic or binding capabilities needs to be evaluated more closely.  
Many succinimidyl reagents and reactants have been developed to couple 
biomolecules and probes to amino groups. A broad range of compounds are 
commercially available in order to facilitate researchers interested in the addition 




of specific classes of molecules to proteins and other constructs with available 
amines. For example, modified fluorophores (Fernandes, Yi et al. 2004), peptides, 
polyethylene glycol (PEG) and biotin derivates (Ding, Zhang et al. 2011) can be 
purchased with a reactive succinimidyl ester attached for an efficient coupling 
reaction in dimethyl sulfoxide (DMSO) or dimethylformamide (DMF) (Figure 5).  
 
 
                             
Figure 5: Examples of compounds modified with the addition of a NHS ester. 
A: NHS-Fluorescein  
B: NHS-biotin  
C: NHS-peptide  
Footnote:  these compounds can be purchased from Pierce Biotechnology, Inc., or JPT 
peptide Technologies 
 
Unfortunately many succinimidyl esters of this type are not soluble in water. To 
overcome this problem, the incorporation of a sulfonic acid group as its sodium salt 
enhances the solubility in aqueous solutions such as sodium bicarbonate buffer 
(Figure 6). 
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Figure 6: Sulfo-NHS-biotin structure 
 
 
Another category of compounds widely used for coupling to amino residues has 
two reactive groups for crosslinking: an NHS ester to react with amines and another 
reactive group (e.g. alkyne, azide, alkene, thiol, sulfonylazides) to be used for 
subsequent synthesis steps. For instance, bioorthogonal sulfonylazides and terminal 
alkynes can react under the catalysis of Cu(I) to form stable N-acylsulfonamides in 
acqueous solutions (Cassidy, Raushel et al. 2006). Other examples of “click 
chemistry” use (Cu)-free cycloaddition reactions since Cu can potentially interfere 
with fluorophores, quenching them. This type of “click chemistry” reaction has 
been used to couple antibodies to amino-modified quantum dots (QD) (Kotagiri, Li 
et al. 2014). On the other hand, thiol-ene reactions occur upon irradiation of a thiol 
and an alkene with UV light at wavelengths between 365 and 405 nm (close to 
visible) to form a stable thioether bond (Chen, Triola et al. 2011) and can be used 
for coupling strategies (Figure 7A). The azide group has also been used in linkers 
for the development of peptides microarrays using solid-phase organic synthesis 











Figure 7: Examples of thiol-ene and azide reactions 
A: Array synthesis strategy using thiol-ene reaction. 
B: Array synthesis strategy using the azide reactive group for SPOS. 
 
Other types of crosslinkers such as sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC) (Figure 8A) are able 
to link amino groups to sulfhydryl residues. Sulfo-SMCC is water-soluble, non-
cleavable and membrane impermeable. An analog (Sulfo-GMBS) (Figure 8B) has 








                  
 
 
Figure 8: Heterobifunctional linkers 
A: Sulfo-SMCC structure. 
B: Sulfo-GMBS structure. 
 
Another important factor in the choice of the appropriate crosslinker for coupling 
strategies is the presence of cleavable groups that could allow a fast release of the 
attached cargo inside the cytoplasm of target cells. In this research project we 
evaluated whether the presence of a disulfide bond (SS) in the linker would improve 
the delivery capability of MIS416 to APCs exploiting the different concentration of 
glutathione between the cytoplasm and the extracellular environment. However 
other release strategies could be used to achieve the same effect. For instance 
enzymatic cleavable linkers or photo-cleaveable linkers are just two example of a 
multitude of strategies used recently by other research groups to improve the release 
capabilities of delivery systems (Leriche, Chisholm et al. 2012). To conclude, 
MIS416 could be modified by exploiting the amino groups on its surface in order 
to attach bimolecular cargoes that can be released inside the cytoplasm of target 








1.10. Aims of the study 
The overall aim of this PhD project is to design a new approach and exploit a novel 
means to deliver siRNAs and peptides into APCs in vivo. So far very few research 
studies have been aimed at enhancing DC function using delivery vectors able to 
co-deliver of siRNAs, adjuvants and TAA derived peptides in order to modulate DC 
function in vivo. In a recent study by Pallab Pradahn et al., (Pradhan, Qin et al. 
2014), an anti IL-10 siRNA was co-delivered with the adjuvant CpGs (a TLR9 
ligand) and a pDNA-antigen (encoding the idiotype protein of A20 B cell 
lymphoma) using a PLGA-PEI (poly(lactic-co-glycolic acid) and 
polyethylenimine) derived microparticle. The results showed that a microparticle 
composed of anti-IL10 siRNAs, adjuvant and pDNA antigen was able to inhibit the 
production of IL-10 in DCs and provided some protection in an A20 B-Lymphoma 
xenograft model. The microparticle vaccine adjuvant (MIS416) produced by our 
research partner, Innate Immunotherapeutics Limited, will be used as a platform for 
the delivery of biomolecules inside the plasma membrane of APCs in this study. 
This approach is hypothesized to have advantages over non-MIS416-mediated 
siRNA and peptides delivery: a very effective uptake by DCs and Monocytes: 
MIS416 particles are designed to be taken up by DCs and deliver antigens without 
other specific targeting strategies. Furthermore MIS416 microparticle have been 
proven to synergize with chemotherapy and radiotherapy providing a delay in 
growth of tumor models (US20110165250 A1 patent). 
Therefore the aim of this research is to conjugate chemically modified siRNAs and 
peptides to these microparticles with a newly developed conjugation strategy, and 
to test the efficacy of this novel vaccine adjuvant using both in vitro and in vivo 




assays. This conjugation strategy was designed in order to couple multiple 
biotinylated molecules to MIS416 to enhance the scope of MIS416 as an antigen 
delivery platform (Girvan, Knight et al. 2011). A further aim is to investigate wheter 
MIS416/SIINFEKL conjugates (MIS416+peptide antigen) are able to induce a T 
cell-mediated specific response against the peptide antigen SIINFEKL.  
 
The aims of this PhD project are: 
1) To couple fluorescent probes and peptide constructs to MIS416 
particles. 
2) To determine the ability of MIS416-siRNA conjugates to 
downregulate target mRNA levels in DCs. 
3)  To assess the ability of MIS416/SIINFEKL conjugates to 
enhance the T cell-mediated immune responses against the antigen 
SIINFEKL compared to the use of the peptide antigen alone. 
 
The results below are divided into three sections corresponding to the three 
objectives of this PhD project. 








Materials and Methods 
  




2. Materials and Methods: 
2.1. Animal Ethics 
 
Aged-matched female C57BL/6 mice were used in all in vivo experiments. Animals 
were sourced from the HTRU, University of Otago. All experiments were 
conducted strictly within the ethics approval granted by the Animal Ethics 
Committee, University of Otago, Dunedin, New Zealand Ethics ET10/13 and 
AEC17/14. 
Mice used: C57BL/6, OT-1 
2.2. List of Suppliers 
 
Invitrogen (Life technologies), Auckland, NZ:  Alexa Fluor 488, Streptavidin, 
Lipofectamine, Opti-MEM media, Superscript Vilo cDNA synthesis kit, 
ProLong ® Gold with DAPI, IR-live/dead, IMDM medium, sulfo-NHS-SS-biotin, 
sulfo-NHS-biotin, M 2-mercaptoethanol Ambion RNA extraction kit, Bolt Mes 
SDS running buffer, Bolt 4-12% Bis-tris Plus acrylamide gels, CFSE, TMB 
(Tetramethylbenzidine) substrate 
Sigma-Aldrich, Auckland, NZ: DMF, Fluorescein amine, Fluorescein 
isothiocyanate, Ethylenediamine, Cystamine dihydrochloride, 
Diisopropylethylamine, TCEP, L-glutathione reduced, PFA 
Innate Immunotherapeutics Limited, Auckland, NZ: MIS416 
Biolegend, London, UK: Streptavidin-PE 




Nanocs, New york, USA: biotin-PEG-FITC 
JPT Peptide Technologies, Berlin, Germany: Biotin-SS-SIINFEKL-FAM, Biotin-
ttds-SIINFEKL-FAM 
Moregate, Bulimba, Australia: Fetal bovine serum 
Prospec, Ness-Ziona, Israel: GMCSF, IFN-γ 
Miltenyi Biotec Inc., Auckland, NZ: CD8 magnetic beads, MACS buffer   
Genepharma, Suzhou, China: SiRNA pools for Bim and Stat3 
Integrated DNA Technologies, Leauven, Belgium: M-BIM siRNA, Primers for Q-
RT-PCR experiments, Biotin-SS-STAT3/BIM modified siRNAs 
Roche, Auckland, NZ: LightCycler  480 SYBR Green Master, Complete protease 
inhibitor 
BD Bioscience, Auckland, NZ: IL-6, IL10, VPD450 proliferative dye 
Mimotopes, Clayton. Australia: SIINFEKL 257-264 (53698-005) 
GeneWorks, Hindmarsh, Australia: CpG 
Resolving images, Preston, Australia: Ovalbumin 










Anti-beta Actin (ab8227, ABCAM) 
Stat3 (79D7, Cell Signaling Technology) 
BIM (H-5 374358, Santa Cruz) 
Anti Rabbit HRP (A0545, Sigma)  
CD11C-APC (N418, Biolegend) 
H-2Kb-PE/Cy7 bound to SIINFEKL antibody (25D1.16, Biolegend) 
CD45R/B220 (A3-6B2, Biolegend), 
F4/80 (BM8, Biolegend), 
LY6g (RB6-8C5, Biolegend) 
CD3 (17A2, Biolegend) 
CD8 (53-6.7, Cell Lab- Beckman Coulter, Inc.), 
CD69 (H1.2F3, Cell Lab) 
CD40 (3.23, Biolegend) 
CD80 (1610, Biolegend) 
CD86 (GL1, Cell Lab) 
MHC class II (N1MR-4, Cell Lab) 
BD Pharmingen: biotinylated antibodies for ELISA (IL-6, IL-10, IFN-γ, TNF-α)  
 
2.3. Preparation of MIS416 conjugates 
2.3.1. Preparation of biotinylated fluorophores 
 
This paragraph describes the series of reactions leading to the preparation of 
compound 9 and 14 (biotin-Fluorescein Isothiocyanate (FITC) and biotin-SS-FITC 




respectively). The order of the reactions follows the same order used at the 
beginning of chapter 3 (paragraph 3.1.1). 
1)Figure 9: Alexa Fluor 488 (Invitrogen)(4) (8.16 mg) and sulfo-NHS-SS-biotin (1-
(2-aminoethyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thiourea, Thermo Fisher scientific)(13)(4.70 mg) were reacted in DMF 
(Sigma)(1 mL) and the mixture was stirred overnight with the addition of 
diisopropylethylamine (N-ethyl-N-isopropylpropan-2-amine, Sigma)(11l, 8.20 
mg) dropwise during the first hour of the reaction. The mixture was purified by 
Thin-layer chromatography (TLC) using a mixture of chloroform, methanol and 
water (5, 3, 0.5 equivalents respectively) as eluent. A yellow band (Rf = 0.4) was 
scraped from the TLC plate and the compound was removed from the silica by 
washing with methanol. 200 g of compound 3 was isolated (17% reaction 
efficiency).  
2)Figure 10: Fluorescein amine (5-amino-3',6'-dihydroxy-3Hspiro[isobenzofuran-
1,9'-xanthen]-3-one, Sigma)(4) (4 mg, 0.012 mmol ) and Sulfo-NHS-biotin (sodium 
2,5-dioxo-1-((5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoyl)oxy)pyrrolidine-3-sulfonate)(1) were reacted in sodium bicarbonate 
buffer (50mM, pH 8.2, 0.5 mL) and the mixture was stirred for 1.5 h. The mixture 
was columned on a C18 SPE column eluted with water/methanol mixtures (95%, 5 
mL). Three fractions were obtained and mass spectrometry showed that none of 
these contained the target molecule. 
 




3)Figure 11: Fluorescein isothiocyanate (6) (50 mg, 0.12 mmol) in methanol (2 mL) 
was added dropwise to ethylenediamine (7) (13 L, 0.19 mmol) in methanol (3 mL) 
and the mixture was stirred for 1.5 h. The solvent was removed and methanol (10 
mL) was added to the residue. The precipitate was isolated by centrifugation to give 
1-(2-aminoethyl)-3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-
5-yl)thiourea (8) (47 mg, 78%) as red solid.  
 
 
4)Figure 12: A solution of 8 (7.8 mg, 17 mol) and sulfo-NHS-biotin (1) (5 mg, 12 
mol) were reacted in sodium bicarbonate buffer ((50mM, pH 8.2, 1 mL) and 
stirred for 4 h. The mixture was columned on a C18 SPE column eluted with 
water/methanol mixtures (95%, 5 mL), (90%, 5 mL) and (80%, 5 mL). The samples 
containing colour were freeze dried to give conjugate 9 (biotin-FITC)(5 mg, 41%) 
as a red solid.  
 
5)Figure 13A: Cystamine dihydrochloride (2,2'-disulfanediyldiethanamine 
dihydrochloride, Sigma)(10) (180 mg, 0.795 mmol) was dissolved in methanol (5 
mL) and water (2 mL) containing triethylamine (40 L). FITC (51 mg, 0.128 
mmol)(6) in methanol (5 mL) containing triethylamine (50 L) was added and the 
mixture stirred overnight. A mixture of acetonitrile and methanol (1:10, 10 mL) 
was added and the precipitate collected by centrifugation. The precipitate was 
washed with a mixture of acetonitrile and methanol (1:10, 10 mL x 2) and the 
precipitate collected by filtration to give the product 11 (1-(2-((2-





1,9'-xanthen]-5-yl)thiourea, 60 mg, 25%).  
6)Figure 13B:Compound 11 (10 mg, 0.02 mmol) and sulfo-NHS-biotin (1)(5.30 mg 
,0.012 mmol) were reacted in in sodium bicarbonate buffer (50mM, pH 8.2, 1 mL) 
and stirred for 4 h. The mixture was columned on a C18 solid phase extraction 
(SPE) column eluted with water/acetonitrile mixtures (95%, 5 mL), (90%, 5 mL) 
and (80%, 5 mL).  
7)Figure 14: Compound 8 (8.9 mg, 0.02 mmol) and sulfo-NHS-SS-biotin (4.9 mg, 
0.008 mmol)(13) and were reacted in in sodium bicarbonate buffer (50 mM, pH 8.2, 
1 mL) and stirred overnight. The mixture was columned on a C18 SPE column 
eluted with chloroform methanol mixtures (95%, 5 mL), (90%, 5 mL) and (80%, 5 
mL).  
Mass spectrometry analysis for all the products was performed using Bruker 
MicrOTOFQ with attached Dionex Ultimate 3000 HPLC system. The analysis 
performed was ESI-TOF (negative ion). For HPLC data and mass spectra see 
Appendix Figure 45-51 
For a list of compounds use in the synthesis and their application see Appendix 
table 2. 
 
2.3.2. Biotinylation of MIS416  
MIS416 (10 mg) was centrifuged (5000 x g, 5 min) in NaHCO3 buffer (50 mM, pH 
= 8.35, 1.5 mL). Sulfo-NHS-biotin (Life Technologies) (1.2 mg) was dissolved in 




NaHCO3 buffer (50 mM, pH 8.35, 1 mL) and added to the washed pellet. The 
mixture was agitated overnight at room temperature (r.t.). The supernatant was 
removed after centrifugation (5000 x g, 5 min) and the pellet washed with PBS 
buffer (1.5 mL) three times (5000 x g, 5 min). The conjugation of biotin to MIS416 
was assessed using streptavidin-phycoerythrin (streptavidin-PE) (Biolegend) as a 
solution in PBS (0.2 mg mL-1). A standard curve of fluorescence versus 
streptavidin-PE concentration is shown in Appendix, Figure 56.  The biotinylated 
microparticle (1 mg) was suspended in PBS (200 L). An aliquot of the 
streptavidin-PE stock solution (20 L, 4 g) was added and the mixture agitated for 
3 hours. After centrifugation and washing with PBS (5000 x g, 5 min) the pellet 
was re-suspended in PBS (200 L). An aliquot (20 L) was placed in one well of a 
96 well plate and PBS (80 L) was added. The fluorescence in the wells (excitation 
500nm, emission 570nm) was measured using a synergy 2 plate reader (BioTek) 
(excitation 488 nm, emission 520 nm) (Appendix, Figure 57).   
 
2.3.3. Preparation of MIS416-biotin–streptavidin–biotin-PEG-FITC 
conjugates 
Streptavidin (Invitrogen) was reconstituted in PBS at a concentration of 2.5 mg mL-
1 and was used in conjugation reactions with MIS416-biotin particles and biotin-
PEG-FITC (Nanocs, MW 3400g mol-1). A stock solution of biotin-PEG-FITC in 
PBS (50 mg mL-1) was prepared from which a working solution in PBS (5 mg mL-
1) was made. Streptavidin (50 L, 0.125 mg, 2.37 nmoles) was added to different 
amounts of biotin-PEG-FITC in an Eppendorf tube in order to saturate 0.5, 1, 2 and 




4 of the four biotin binding sites of the streptavidin. The different mixtures were 
agitated for 4 hours at room temperature.MIS416-biotin (0.4 mg in 200 L in 
sodium bicarbonate buffer pH 8.3) was added to the four different mixtures and 
agitated overnight at room temperature. After centrifugation and washing with PBS 
(5000 x g, 5 min) the pellets were re-suspended in PBS (200 L). An aliquot (20 
L) of each sample was then added to PBS (80 L) and the fluorescence was 
measured (excitation 488nm, emission 520nm). The experiment was repeated three 
times with the same batch of MIS416-biotin. As a control, MIS416-biotin (0.4 mg) 
in sodium bicarbonate buffer (200 L, pH 8.3) was added to the biotin-PEG-FITC 
from the working solution (4, 8, 16 and 32 g) (used in the previous reactions, but 
without the addition of streptavidin) to determine the non-specific attachment of 
biotin-PEG-FITC to MIS416-biotin and set background fluorescence. 
2.3.4. Preparation of MIS416-biotin-streptavidin-biotin-FITC and 
MIS416-biotin-streptavidin-biotin-SS-FITC conjugates  
Streptavidin (Invitrogen) was reconstituted in PBS at a concentration of 2.5 mg mL-
1 and was used in conjugation reactions with MIS416-biotin particles and biotin-
FITC (9) or biotin-SS-FITC (14). A stock solution of biotin-FITC and biotin-SS-
FITC in PBS (20 mg mL-1) was prepared from which a working solution in PBS (5 
mg mL-1) was made. Streptavidin (50 L, 0.125 mg, 2.37 nmoles) was added to 
different amounts of biotin-FITC or biotin-SS-FITC (See Table 6) in an Eppendorf 
tube in order to saturate between 0.2 and 4 of the four biotin binding sites of the 
streptavidin. The different mixtures were agitated for 4 hours at room temperature. 
MIS416-biotin (0.4 mg in 200 L in sodium bicarbonate buffer pH 8.3) was added 




to the four different mixtures and agitated overnight at room temperature. After 
centrifugation and washing with PBS (5000 x g, 5 min) the pellets were re-
suspended in PBS (200 L). An aliquot (20 L) of each sample was then added 
PBS (80 L) and the fluorescence was measured (excitation 488nm, emission 
520nm). As a control, MIS416-biotin (0.4 mg) in sodium bicarbonate buffer (200 
L, pH 8.3) was added to the biotin-FITC from the working solution (10, 20, 40, 
80, 160 g) (used in the previous reactions, but without the addition of streptavidin) 
to determine the non-specific attachment of biotin-FITC to MIS416-biotin and set 
background fluorescence. 
2.3.5. Preparation of MIS416-biotin-streptavidin-biotin-SS-
SIINFEKL-FAM (Conjugate A) and MIS416-biotin-streptavidin-
biotin-ttds-SIINFEKL-FAM (Conjugate B) conjugates 
Biotin-SS-SIINFEKL-Fluorescein amidite (FAM) (JPT Peptide Technologies MW: 
1839.15 g/mol) was reconstituted in in DMSO (1 g L-1). Aliquots of this (16 L, 
16 g, 8.64 nmol) were added to streptavidin (100 L 0.250 mg, 4.74 nmol) in an 
Eppendorf to saturate two of the biotin binding sites of the streptavidin. The mixture 
was agitated for 4 hours at room temperature. MIS416-biotin (0.2 mg in 100L in 
PBS) was added and the mixture was agitated overnight at room temperature. After 
centrifugation (5000 x g, 5 min) the pellet was collected and washed with PBS 
buffer (1.5 mL) three times. The pellet (conjugate A) was resuspended in PBS (200 
L) and stored at 4 °C.  




Conjugate B is a construct in which the disulfide linker has been substituted with 
N-(3-(2-[2-(3-amino-propoxy)-ethoxy]-ethoxy)-propyl)-succinamic acid (ttds). 
The same procedure, as above, was used to prepare the MIS416-biotin-streptavidin-
biotin-ttds-SIINFEKL-FAM conjugate (conjugate B) using Biotin-ttds-SIINFEKL-
FAM (JPT Peptide Technologies MW: 2279 g/mol). Standard curves of 
fluorescence versus concentration of biotin-SS-SIINFEKL-FAM and biotin-ttds-
SIINFEKL-FAM were used to evaluate the conjugation efficiency of the previous 
reactions (Appendix, Figure 58). Aliquots (20 L) of the resuspended conjugates A 
and B were each added to PBS (80 L) and the fluorescence was measured 
(excitation 488nm, emission 520nm). The results were then compared to the 
calibration curves to estimate the amount of FAM-SIINFEKL bonded to MIS416 
(Appendix, Table 1).  
 
2.3.6. Preparation of MIS416-PE conjugate. 
A fluorescent version of MIS416 with phycoerythrin (MIS416-biotin-strepatidin-
PE) was prepared adding streptavidin-PE (20 g) as a solution in PBS (0.2 mg mL-
1) to previously biotinylated MIS416 (100 g in 100 L of PBS). The mixture was 
agitated for 4 hours at room temperature. After centrifugation (5000 x g, 5 min) the 
pellet was collected and washed with PBS buffer (1.5 mL) three times. The pellet 
was resuspended in PBS (200 L) and stored at 4 °C.  
 
2.3.7. Preparation of A1 and B1 conjugates. 




Conjugates A and B were modified with streptavidin-APC (Biolegend). Conjugates 
A and B (100 g) in PBS (100 L) were added to streptavidin-APC (20 L 4 g) 
to produce conjugates A1 and B1. The mixtures were agitated for 4 hours at room 
temperature. After centrifugation (5000 x g, 5 min) the pellet was collected and 
washed with PBS buffer (1.5 mL) three times. The pellet was then resuspended in 
PBS (100 L) and stored at 4 °C.  
 
2.4. Cell culture  
 
2.4.1. Bone marrow derived dendritic cell (BMDCs) preparation.  
Bone marrow was harvested from the femurs and tibias of C57BL/6 mice and red 
blood cells (RBCs) were lysed with 2 mL of ammonium chloride buffer (4.15 g 
NH4Cl, 0.5 g KHCO3, 0.0186 g EDTA, 500 mL milli-Q water, pH 7.4) for 3 min at 
37°C. Bone marrow cells were then plated at 3x106 cells/well in a 6-well plate with 
5 mL of complete media (IMDM medium (Invitrogen) supplemented with 5% fetal 
bovine serum (Moregate), and 5 × 10−5 M 2-mercaptoethanol (Gibco, life 
technologies)) and cultured for 6 days in the presence of 20 ng mL-1 recombinant 
GM-CSF (Prospec) in humidified incubators with 5% CO2 at 37°C. Every 3 days, 
half of the cell culture media of the BMDCs cultures was replaced with fresh media 
containing additives. BMDCs were used at day 6 or day 7 when more than 80% of 
the cells were CD11c+. 
 




2.4.2. Preparation of OT-1 T cell from donor mice 
Spleens from OT-1 transgenic mice were collected and cells were separated and 
filtered through a 100m filter into a falcon tube (50 mL) containing 10 mL of PBS. 
RBC were lysed with 5 mL of ammonium chloride buffer (4.15 g NH4Cl, 0.5 g 
KHCO3, 0.0186 g EDTA, 500 mL milli-Q water, pH 7.4) for 3 min at 37 °C. Cells 
were then washed (300 x g, 5 min), in PBS (20 mL) and counted before adding 
MACS buffer (1X DPBS, 0.5% BSA, 2 mM EDTA, Filter sterilized) and CD8 
magnetic beads (Miltenyi Biotec Inc.) (90L of buffer plus 10L of beads per 107 
cells). Cells were incubated on ice for 30min and washed (300 x g, 5 min) with 1.5 
mL of MACS buffer per 107 cells. Cells were resuspended in 500L of MACS 
buffer per 108 cells and run on AutoMACS Pro Separator (Miltenyi Biotec) using 
the positive selection program according to the manufacturer's instructions. The 
positive fraction was collected and cells were washed twice in PBS (20 mL) (300 x 
g, 5 min). The percentage of positive CD8 OT-1 T cells after separation was >95% 
(data not shown).  
 
2.5. RNA and protein expression analysis 
 
2.5.1. siRNA transfection protocol with RNAiMAX 
2x105 BMDCs at day 6 were plated in 1 mL of specific media (described in the cell 
culture section 2.4.1) in a 24 well plate and transfected with a final concentration 




of siRNA of 10 or 50nM using Lipofectamine RNAiMAX reagent (Invitrogen) 
according to the manufacturer's instructions. Briefly RNAiMAX (3L) was added 
to Opti-MEM media (Invitrogen) (50 L). siRNAs (1L of a 10M stock solution, 
3pmol) were also added to Opti-MEM media (50 L). The two eppendorf tubes 
containing the siRNA and RNAiMAX diluted in Opti-MEM media were combined 
at RT for 5min and 50L of the final solution was incubated in each well for 48h 
or 72h to obtain a final concentration of siRNA in the well of 10 or 50nM. SiRNA 
pools for BIM and STAT3 were purchased from Genepharma (Table 3). Each 
siRNA pool consisted of 3 different siRNA sequences designed to knockdown BIM 
or STAT3 RNA levels while M-BIM (Chae, Choi et al. 2005) siRNA (methylated) 
was purchased from IDT (Integrated DNA Technologies).  
Table 3: 
siRNA name 5’- 3’ sequence (m stands for methylated base) 
STAT3-1962 GGGUCUGGCUAGACAAUAUTT 
STAT3- 1701 CAUCAAUCCUGUGGUAUAATT 






2.5.2. siRNA transfection protocol for MIS416 conjugates 





5x105 BMDCs at day 6 with 2 mL of complete IMDM media (described in the cell 
culture section) were plated on a 12-well plate. MIS416-SS-STAT3/BIM (3µg), 
MIS416 (3µg), and MIS416-SS-controlSiRNA (3µg) were added in separate wells 
while one well with untreated cells was used as a control. MIS416 conjugates were 
incubated for 48 or 72h. 
 
2.5.3. RNA extraction protocol. 
RNA was extracted 48 or 72 hours after siRNA transfection using an Ambion RNA 
extraction kit (Life Technologies) according to the manufacturer's instructions. 
Briefly, cells and media from wells were collected in 15 mL Falcon tubes and PBS 
(10 mL) was added to wash cells. After centrifugation (2000 x g, 2 min), lysis buffer 
(300 µl) from the RNA extraction kit was added to the pellet and an equal volume 
of EtOH 70% was added. RNA was purified using the specific Eppendorf tube 
included in the Ambion RNA extraction kit in order to retain nucleic acids. After 
washes with buffers provided in the kit (2000 x g, 2 min), RNA was eluted in 
RNAse-free water (20µl).  
 
2.5.4. RNA quantification 
RNA was quantified using a NanoDrop ND 1000 spectrophotometer. Briefly 1 µL 
of the 20 µL total for each sample was quantified. The absorbance of a diluted RNA 
sample was measured at 260 and 280 nm. The nucleic acid concentration was 




calculated using the Beer-Lambert law (Trumbo, Schultz et al. 2013), which 
predicts a linear change in absorbance with concentration. 
 
2.5.5. cDNA preparation protocol 
This procedure was used to convert RNA extracted previously into cDNA that 
could be amplified in Q-RT-PCR experiments. cDNA preparations were performed 
with Superscript Vilo cDNA synthesis kit (Invitrogen) according to the 
manufacturer's instructions. Briefly, 200ng of RNA from each sample was added to 
a mixture composed of 5xVilo reaction mix, 10X SuperScript Enzyme Mix and 
DEPC-treated water according to the protocol. Samples were then incubated for 
10min at 25°C. The reaction step was performed for 1h at 60°C followed by 5min 
at 85°C to inactivate the enzyme. Samples were collected and stored at -20°C.  
 
2.5.6. Q-RT-PCR protocol 
Q-RT-PCR analysis of cDNA samples was performed on a LightCycler 480 
(Roche) using LightCycler 480 SYBR Green Master (Roche) according to the 
manufacturer's instructions. The program used for the LightCycler480: start (1 
cycle, 2 min 95°C), amplification (40 cycles, 30 seconds 95°C, 1 min 60°C), 
dissociation (95°C continous). Bim, Stat3, B2m, ß-actin, Ywhaz, Rpl32, Minor and 
IL10r1 cDNA levels were quantified using Gapdh as reference gene. Primer’s 
sequences are listed on Table 4. The relative quantification was carried out using 
Biogazelle’s qbase+ software. 





Primer Sequence Reference 
BIM forward CGACAGTCTCAGGAGGAACC (Staton, Lazarevic et 
al. 2011) 
BIM reverse CATTTGCAAACACCCTCCTT  (Staton, Lazarevic et 
al. 2011) 
STAT3 forward GGATCGCTGAGGTACAACCC 
 
(Kim, Kim et al. 2013) 
STAT3 reverse GTCAGGGGTCTCGACTGTCT 
 
(Kim, Kim et al. 2013) 
B2M forward ATTCACCCCCACTGAGACTG  (Boon, Tomfohr et al. 
2008) 
B2M reverse TGCTATTTCTTTCTGCGTGC (Boon, Tomfohr et al. 
2008) 
β-actin forward CTACAATGAGCTGCGTGTGG (Sun, Han et al. 2008) 
β-actin reverse GGTCTCATGGATACCACAGG (Sun, Han et al. 2008) 
YWHAZ forward ACTTGACATTGTGGACATCGG
ATAC 








(Jeffs, Glover et al. 
2009) 
RPL32 reverse GGCTTTGCGGTTCTTGGA (Jeffs, Glover et al. 
2009) 




Minor forward AGCAGCTTAAAGGACCACCA (Wang, Jiang et al. 
2009) 
Minor reverse GGGTGTCAAGGAAGAGCTTG (Wang, Jiang et al. 
2009) 




(Denning, Campbell et 
al. 2000) 
 
2.5.7. Reference gene evaluation for Q-RT-PCR experiments 
Q-RT-PCR experiments were carried out to evaluate the optimal reference gene to 
be used in Q-RT-PCR experiments. B2m, Ywhaz, Rpl32 and Gapdh were selected 
as possible candidates. The average expression stability values between different 
reference targets were calculated using the GeNorm algorithm implemented in 
Biogazelle’s qbase+ software (Wang, Li et al. 2015). 
 
2.5.8. Protein extraction protocol 
Proteins were extracted using RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
sodium chloride, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% NP-40, 1% 
Sodium deoxycholic acid, 0.1% sodium dodecylsulfate (SDS)) with the addition of 
complete protease inhibitor (cOmplete mini, Roche),  phenylmethylsulfonyl 
fluoride (PMFS) 1mM and Na Orthovanadate 1mM. 




2.5.9. Western blot protocol 
Western blots were performed on Bolt 4-12% Bis-tris Plus acrylamide gels using 
Bolt Mes SDS running buffer. Electrophoresis was carried out for 40min at 165V. 
Proteins were transferred using an iBlot® Gel Transfer Device according to the 
manufacturer's instructions. 
Nitrocellulose membranes were blocked with 5% skim milk in PBST (PBS, 0.1% 
TRITON) for 1 hour. Anti-beta Actin antibody diluted 1:10000 (ab8227, ABCAM) 
and Stat3 (79D7) rabbit mAb diluted 1:2000 (Cell Signaling Technology) or Bim 
(H-5 374358, Santa Cruz) rabbit mAB diluted 1:2500 were used to evaluate protein 
loading and to quantify Stat3/Bim expression levels respectively. Primary 
antibodies were detected with anti rabbit HRP diluted 1:20000 (A0545, Sigma) and 
ECL analysis was performed using Super Signal West Pico reagents according to 
the manufacturer's instructions. Briefly, after the secondary antibody incubation 
step, membranes were washed 3 times in PBST (PBS + 0,1% Tween) for 5min and 
a solution containing both Luminol and Peroxide (ratio 1:1) was added for 5min. 
Exposure time may vary between different films and it usually was between 20 
seconds and 10min. Kodak Biomax Xar Films were developed using a 
Protec Ecomax X-Ray Film Processor. 
 
2.5.10. Protein level quantification 
Developed films from western blots were analysed using ImageJ software to 
quantify band density. The ratio between Bim or STAT3 and Gapdh band density 
was used to define a relative density. A value of 1 has been arbitrarily attributed to 




untreated cells and has been used to compare relative density values of cells treated 
with MIS416 conjugates. 
 
2.6. Disulphide bond release study: TCEP and Glutathione 
treatment  
 
2.6.1. Protocol with TCEP 
Aliquots of conjugates A and B (50 g in 50L of PBS) were treated with TCEP 
(SIGMA, 50mM, pH 7, 200 L) for 30 min at 37 °C. The supernatant was removed 
after centrifugation (5000 x g, 5 min) of the mixture and the pellets washed with 
PBS buffer (1.5 mL) three times. Pellets were resuspended in PBS (100 L). An 
aliquot (50 L in 50L of PBS) of the two conjugates was treated with PBS (200 
L) instead of TCEP and processed in the same way as a control to evaluate the 
background loss of fluorescence caused by three washes.  
 
2.6.2. Protocol with glutathione 
Aliquots of conjugates A and B (50 g in 50L of PBS) were treated with 
glutathione (L-glutathione reduced, Sigma Aldrich, 10mM, pH 7.2, 200 L) for 30, 
60 and 120 min at 37 °C. The supernatant was collected after centrifugation (5000 
x g, 5 min) of the mixture and the pellets washed with PBS buffer (1.5 mL) three 




times. Pellets were resuspended in PBS (100 L). An aliquot (50 L in 50L of 
PBS) of the two conjugates was treated with PBS (200 L) instead of glutathione 
and processed in the same way as a control to evaluate the background loss of 
fluorescence caused by three washes.  
2.6.3. Fluorescence measurements  
Aliquots of the supernatants (100L) or pellets (20L) were placed in a 96 well 
plate and the fluorescence was measured using a synergy 2 plate reader (BioTek) 
(excitation 488 nm, emission 520 nm).  
 
2.7. Microscopy experiments 
2.7.1. Cell preparation 
2x106 BMDCs were plated in a 6 well plate with 4 coverslips (13 mm diameter) in 
each well with 3 mL of complete media. DCs were allowed to adhere to the 
coverslips over night. The next day single coverslips with DCs were placed in a 24 
well plate with complete media (250 L). 
 
2.7.2. Incubation protocol with MIS416-PE conjugate and staining 
BMDCs on coverslips were treated with MIS416-PE conjugate (3μg) for 1, 4 or 
24h. After incubation coverslips were gently washed in PBS and treated with 
paraformaldehyde 4% (PFA) in PBS (300 L) for 20 min to fix the cells. CD11c-




APC antibody (clone N418, Biolegend) was used to identify BMDCs cell surface. 
The antibody was incubated at 1 g/106 cells in 100 L of PBS for 30 min at 4°C. 
 
2.7.3. Incubation protocol with conjugates A and B conjugate 
BMDCs on coverslips were pulsed with modified conjugates A1 or B1 (10 g each) 
for 20 min. After incubation cells were gently washed in PBS and new media (2 
mL) was added. One coverslip treated with each preparation was fixed in 4% PFA 
in PBS (300 L) while another two samples for each preparation were fixed after 
20 and 40 min to allow DCs enough time to process MIS416 conjugates.  
 
2.7.4. Microscopy analysis  
Coverslips were mounted using ProLong ® Gold with DAPI (Invitrogen). Images 
were taken using a Zeiss LSM 710 confocal microscope using 340nm, 488nm and 
630nm lasers for DAPI, FAM and APC respectively. Brightfield images were used 
to identify the morphology of cells. 
A quantification procedure was used to determine the percentage of DCs releasing 
FAM-SIINFEKL in the cytoplasm, and was carried out by analysing the 
photomicrographic images. In each image (the total number of images for each 
condition: A=4, B=4, C=6, D=4, E=6, F=6) the cells were scored as being either 
DCs releasing FAM-SIINFEKL (green and/or red fluorescent signal in the cell), or 
DCs that were not releasing FAM-SIINFEKL (yellow fluorescent signal in the cell). 




This data is derived from three different experiments. The percentage of DCs 
releasing FAM-SIINFEKL for each condition was then calculated as follows: 
number of releasing cells/(number of releasing cells + number of non releasing 
cells) x 100. The results were analyzed with a One Way Anova test corrected for 
multiple comparisons (Bonferroni) using GraphPad Prism version 6. 
 
2.8. Immunology experiments 
 
2.8.1. Evaluation of the expression of SIINFEKL on BMDCs surface 
1x106 BMDCs at day 5 were plated in a 24 well plate with 1 mL of complete media 
in each well and pulsed with PBS (50 L), conjugates A or B (5 g), MIS416 (5 
g), SIINFEKL (0.2 ng, Resolving Images), a combination of MIS416 and 
SIINFEKL, biotin-ttds-SIINFEKL-FAM (0.5 ng) or biotin-SS-SIINFEKL-FAM 
(0.5 ng). Cells were harvested using cold PBS after 4, 12, 24 or 48 hours and stained 
with infrared near IR-live/dead (Invitrogen, 0.05 L plus 100 l of PBS for 15 min 
at 4°C). Cells were washed in FACS buffer (300 x g, 5 min) and stained with 
CD11c-APC (clone N418, Biolegend) and H-2Kb-PE/Cy7 bound to SIINFEKL 
antibody (clone 25D1.16, Biolegend) (1 g/106 cells of each antibody in 100 L of  
PBS for 15min at 4°C). Samples were analysed using a Gallios flowcytometer 
(Beckman Coulter). In silico analysis was performed using FlowJo software 
(version 10, TreeStar, Inc.). Cells were gated for singlets (FSC-H vs FSC-A) and 
DCs (SSC-A vs FSC-A). The DCs gate was further analyzed for the uptake of IR-




live/dead negative and the expression of CD11c, taking only the live healthy DCs 
population. Results show the % of live DCs expressing SIINFEKL bound to MHC 
class I. 
 
2.8.2. Uptake experiments on splenocytes  
Splenocytes were collected from C57BL/6 mouse spleens. Cells were washed in 
PBS (300 x g, 5 min) and RBC were lysed with ammonium chloride buffer (4.15 g 
NH4Cl, 0.5 g KHCO3, 0.0186 g EDTA, 500 mL milli-Q water, pH 7.4) for 3 min at 
37°C. MIS416-PE (5ug) was incubated for 1, 4 or 24 hours with 2x106 splenocytes 
at 37°C in 2 mL of media. The same protocol was used at 4°C to evaluate the 
attachment of MIS416-PE to the cell surface (negative control). After the uptake, 
splenocytes were washed (300 x g, 5 min) and stained with CD45R/B220 (clone 
A3-6B2, Biolegend), CD11c (clone N418, Biolegend), F4/80 (clone BM8, 
Biolegend), LY6g (RB6-8C5, Biolegend) and CD3 (clone 17A2, Biolegend) (1 
g/106 cells of each antibody in 100 L of PBS for 15min at 4°C).  
FACS analysis: Cells positive for different markers, including CD45R (Bcells), 
CD11c (DCs), F4/80 (Macrophages), Ly6g (Neutrophils), CD3 (Tcells) were 
subsequently gated on PE to assess specific uptake of the microparticle formulation 
(MIS416-PE). 
 
2.8.3. Proliferation assay  




BMDCs at day 5 were plated (5x105) in 12 well plates (l mL of complete media 
each well) and incubated with SIINFEKL (0.5 g), MIS416 alone (0.5 g) or with 
the addition of SIINFEKL, conjugates A (0.5 g) and B (0.5 g) and biotin-
SIINFEKL-FAM (1 g). After 24h of incubation cells were collected, washed in 
PBS (300 x g, 5 min) and plated (5x104) in 24 well plates (0.5 mL of complete 
media each well) and OT-1 T cells (5x105 in 0.5 mL of media) were added. OT-1 
T cells were prepared as described before (2.5.2 materials and methods), and were 
pre-stained with VPD450 proliferative dye (BD Bioscience) according to materials 
and methods. Briefly OT-1 T cells were resuspended (1x106/mL) in PBS and 
VPD450 was added to a final concentration of 1mM. OT-1 cells were incubated at 
37°C for 10 min and washed 3 times in PBS (300 x g, 5 min) before adding them 
to the DCs culture. After 48 or 72h of incubation cells were harvested and stained 
with infrared near IR-live/dead (Invitrogen, 0.05 L plus 100 l of PBS for 15 min 
at 4°C). After a wash in PBS, cells were stained in FACS buffer with CD8 (clone 
53-6.7, Cell Lab- Beckman Coulter, Inc.) and CD69 (clone H1.2F3, Cell Lab)(1 
g/106 cells of each antibody in 100 L of  FACS buffer for 15min at 4°C). Samples 
were analysed using a Gallios flowcytometer (Beckman Coulter, Inc.). In silico 
analysis was performed using FlowJo software (version 9, TreeStar, Inc.). Cells 
were gated for singlets (FSC-H vs FSC-A), live/dead and CD8. The CD8+ gate was 
further analysed using the proliferation software tool in FlowJo version 9 in order 
to calculate the percentage of proliferating CD8+ OT-1 T cells in each sample.  
 
2.8.4. Upregulation of activation markers on DCs  




BMDCs at day 6 were plated in 6 well plates (1x106, 2 mL of complete media in 
each well) and pulsed with MIS416 (1, 5, 10 g), LPS (1 g), conjugates A and B 
(1 g), (sulfo-nhs-biotin (1 g) or streptavidin (1 g) for 24 or 48 hours. After 
incubation, cells were harvested using cold PBS and stained with infrared near IR-
live/dead (Invitrogen, 0.05 L plus 100 l of PBS for 15 min at 4°C). Cells were 
then divided into 4 FACS tubes (0.2x105 cells/tube) and stained separately with 
CD11c-APC antibody (clone N418, Biolegend) and CD40 (clone 3.23, Biolegend) 
or CD80 (clone 1610, Biolegend) or CD86 (clone GL1, Cell Lab) or MHC class II 
(clone N1MR-4, Cell Lab) (1 g/106 cells of each antibody in 100 L of FACS 
buffer for 15min at 4°C). All marker antibodies were tagged with PE. 
FACS analysis: Samples were analysed using a Gallios flowcytometer (Beckman 
Coulter, Inc.). Cells were gated for live/dead and DCs (CD11c+). The DCs gate was 
further analysed for expression of activation markers. Results show mean 
fluorescence intensity (MFI), the percentage of cells that are positive for the specific 
activation marker in the case of CD40.  
 
2.8.5. In vivo CD8 T cell cytotoxic assay  
Splenocytes from naïve C57BL/6 mice were collected and RBC were lysed in 
ammonium chloride buffer (4.15 g NH4Cl, 0.5 g KHCO3, 0.0186 g EDTA, 500 mL 
milli-Q water, pH 7.4) for 5 min at 37°C. Cells were resuspended in complete IMDM 
(5% FCS) 5x106 cells/mL and pulsed with SIINFEKL peptide (1 μg/mL) or left 
unpulsed (control) for 3 hr at 37°C/5% CO2.  Cells were washed in PBS 3 times (300 




x g, 5 min) to remove unbound peptide and FCS, and resuspended in PBS at 2 x 107 
cells/mL for labelling with CFSE or VPD450 proliferative dyes. Briefly VPD450 or 
CFSE were added to a final concentration of 1mM and 2μM respectively. Cells were 
incubated at 37°C for 10 min and washed 3 times in phosphate buffer saline (PBS) 
(300 x g, 5 min) before injecting them to recipient mice via i.v. route. 
Pilot study: Mice were vaccinated by subcutaneous injection of different 
concentrations of MIS416/SIINFEKL conjugate (100, 250, 500 μg of MIS416 
conjugate, SIINFEKL concentration 1.57 μg for 100 μg of MIS416), MIS416 alone 
(100 μg), PBS (100 μL), or CpG (GeneWorks) plus Ovalbumin (Resolving images) 
(10 μL of OVA + 50μp of CpG). 
Second experiment: Mice were vaccinated by subcutaneous injection of Conjugates 
A or B (100 μg), MIS416 (100 μg) plus SIINFEKL (2 μg), MIS416 alone (100 μg), 
PBS (100 μL), CpG plus SIINFEKL (2 μg) or CpG plus Ovalbumin (10 μL of OVA 
+ 50μp of CpG).  
To test their in vivo cytotoxicity, female SPF C57bl/6 6 week old mice were 
vaccinated 1 week before the injection of pulsed and unpulsed splenocytes. All 
recipient mice received a total number of 1 x 107 pulsed and unpulsed donor 
splenocytes 1 week after vaccination. Recipient mice were sacrificed at 48 hr after 
cell transfer and splenocytes collected were analysed by flow cytometry. 
FACS analysis: Samples were analysed using Gallios flowcytometer (Beckman 
Coulter, Inc.). In silico analysis was performed using FlowJo software (version 10, 
TreeStar, Inc.). Cells were gated for singlets (FSC-H vs FSC-A), and IR-live/dead 




negative. Cells positive for CFSE and VPD450 were gated to evaluate the % of 
specific lysis. 
Percentage lysis of target cells was calculated using the formula:  
Ratio vaccinated = % Control/ % peptide-pulsed, Ratio PBS = % Control/ % PBS-
pulsed  
% specific lysis = 100 – (100* (Ratio vaccinated /Ratio PBS)) 
 
2.8.6. Cytokine ELISA assay  
The level of cytokine in the culture supernatants was measured using a standard 
sandwich ELISA assay. Briefly, 96-well flat-bottom ELISA plates were coated with 
50 μL of corresponding purified antibodies (IL-6, IL10, TNF-α (Biolegend), IFN-γ 
(Prospec) (2 μg mL-1, BD Pharmingen), diluted in coating buffer over night  at 4 
°C, then washed 6 times in washing buffer (PBS + 0.05% Tween 20).  The plates 
were blocked with 200 μL blocking buffer (PBS + 1% BSA) for 2 hr at 37 °C, then 
washed 6 times in washing buffer.  Recombinant cytokine standards (concentration 
of standards from 20 pg mL-1 to 20 ng mL-1, IL-6, IL10, TNF-α, IFN-γ) and culture 
supernatants were diluted in blocking buffer and 50 μL/well was added to each 
duplicate well and then incubated for 2 hr at 37° C, followed by 6 washes.  
Biotinylated antibodies against these interleukins (BD Pharmingen) were diluted in 
blocking buffer (1 μg mL-1), and 100 μL/well was added, then incubated for 1 hr at 
37 °C and then washed 6 times.  Streptavidin-HRP (Biolegend) was diluted 1/3000 
in blocking buffer, and 100 μL was added to each well then incubated at room 




temperature (RT) for 30 min, followed by 8 washes. TMB substrate (Life 
Technologies) was added (100 μL/well), and incubated at RT for color 
development.  1N H2SO4 was added (100 μL/well) to stop the reaction.  The 
absorbance was then read by ELISA plate reader (Biotek synergy 2) at 450 nm. 
2.8.7. Statistical Analyses 
All statistical analyses were performed using GraphPad Prism software version 
6. Student’s T test was used to analyse un-grouped column graphs while two-
way ANOVA multiple comparison (Bonferroni) was used to analyze grouped 
column graphs.  
Error bars represent the standard error of the mean (SEM). Results that are not 
significant are marked with ns while significant results are marked with * 
depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005).




























3. Proof of principle of the conjugation and release strategies 
 
3.1. Development of a conjugation strategy for the coupling of 
biotinylated molecules to MIS416 
 
In vivo gene silencing using small interfering RNA (siRNA) has many challenges. 
First of all, siRNAs have to reach the desired cell target avoiding degradation by 
ribonucleases in the blood stream. Furthermore, the physiochemical properties of 
siRNAs (hydrophilicity and net negative charge) do not facilitate permeation of 
target cells. The enhancement of siRNAs as therapeutic agents requires a delivery 
system designed to accomodate their physiochemical properties. One of the 
strategies used to deliver siRNAs in vivo relies on the use of nano or microparticles 
that are able to protect the nucleic acid and at the same time target a specific cell 
population allowing the entrance of siRNAs into target cells (Lee, Yoon et al. 2013). 
For the purposes of this project, the aim of which is to deliver siRNAs and peptides 
to DCs, I hypothesize that MIS416 is a suitable candidate as a delivery agent for 
siRNAs since these microparticles have been used previously by Innate 
Immunotherapeutics (Girvan, Knight et al. 2011) to deliver a model protein antigen 
(Ovalbumin) to DCs and other antigen presenting cells. I also hypothesize that the 
use of MIS416 as delivery agent for siRNAs would allow rapid entry into the 
cytoplasm of DCs where siRNAs are able to block the translation and/or induce 
degradation of target mRNAs. However, the coupling of siRNAs to MIS416 is not 




straightforward because double-stranded short RNAs are inherently unstable and 
are not easy to manipulate without resulting in degradation. Moreover MIS416 is a 
relatively uncharacterized bacterial microparticle, which makes its use in 
conjugation strategies a challenge. In order to achieve this goal, the development of 
an appropriate conjugation strategy is required. Furthermore, siRNAs are expensive 
and we can only afford to purchase them in small amounts, whereas MIS416 is 
available in gram quantities and this has to be taken into consideration for the 
development of a new conjugation strategy. However, if a successful conjugation 
strategy is developed the MIS416-siRNA conjugates would then be able to be used 
to target specific genes expressed by DCs to evaluate the downregulation potency 
of such conjugates and their cell-targeting capabilities. 
To develop a strategy for the conjugation of siRNAs to MIS416 several conjugation 
experiments between MIS416 and other molecules (fluorophores and peptides) 
were designed to investigate whether a conjugation strategy involving MIS416 was 
feasible and whether the coupling of small quantities of material (such as siRNAs) 
to MIS416 was indeed possible. The conjugation experiments undertaken are 
illustrated in the overall plan below (Table 5). Furthermore experiments were also 
carried out to evaluate if the incorporation of a disulfide bond between MIS416 and 
the attached molecular cargo would facilitate the release of the coupled molecule 
from MIS416 once inside the cell. I  hypothesize that the use of a disulfide could 
provide an endosome escape strategy for siRNAs in order to minimize lysosomal 
degradation.  
Table 5: Plan for the conjugation experiments  





Table 5: Plan for the conjugation experiments 
The first part of this chapter includes experiments performed to synthesize compound 9 and 14 
(biotin-FITC and biotin-SS-FITC respectively).The second part includes experiments carried out to 
optimize the coupling of biotinylated fluorescein derivatives to MIS416 using streptavidin as a 
bridge between MIS416-biotin and a biotinylated molecular cargo (fluorophores, peptides). The last 




part comprises experiments carried out to evaluate if a disulfide bond included in the linker between 
biotin and the attached cargo would facilitate the release of the coupled biomolecule from MIS416. 
 
 
3.1.1. Synthesis of biotinylated fluorescent probes 
Initially research focused on the preparation of biotinylated fluorophores. These 
fluorophores were used to provide a proof of principle for the conjugation strategy 
based on a streptavidin bridge between biotinylated MIS416 (MIS416-biotin) and 
biotinylated fluorophores. This step was necessary to optimize the conjugation 
protocol for the coupling of biotinylated molecules to MIS416 as a preliminary step 
for the coupling of siRNAs and peptides in the future. The newly developed 
compounds (Biotin-FITC and Biotin-SS-FITC, 9 and 14 respectively) were used to 
quantify the amount of material that could be coupled to MIS416-biotin and were 
compared to a commercially available biotinylated fluorophore (biotin-PEG-FITC). 
This comparison was important to verify whether the newly developed fluorophores 
were purified correctly and were able to perform with similar characteristics to 
fluorophores that were purchased. Furthermore, it was necessary to synthesize a 
biotinylated fluorophore possessing a disulphide bridge between the biotin and the 
fluorophore for further release studies. 
 
 
3.1.1.1. Synthesis with Alexa Fluor 488 





The first fluorescent molecule used for coupling experiments was biotinylated 
Alexa Fluor 488 (3). Alexa Fluor 488 (2) has aromatic amine groups that could 
potentially couple with succinimidyl activated biotin ester (1). Succinimidyl esters 
are species that react with amino groups to form amido bonds (See introduction 1.9 
for further details) 
 
Figure 9: Alexa Fluor 488 reaction with sulfo-NHS-biotin 
Sulfo-NHS-biotin (1) reaction with Alexa fluor 488 (2) to create Alexa fluor 488-biotin conjugate 
(3). 
 
The reaction of 1 and 2 (Figure 9) was monitored by thin layer chromatography 
(TLC) and a small amount of product 3 (less than 5 µg) was isolated by preparative 
TLC. High-performance liquid chromatography (HPLC) results showed a product 




that contained both AlexaFluor 488 and biotin (Appendix, Figure 45). However, 
the small amount of material that was isolated was insufficient for use in further 
coupling reactions. 
3.1.1.2. Reaction of Fluoresceinamine with sulfo-NHS-biotin  
After the experiments with Alexa Fluor 488, the focus switched on a more readily 
accessible fluorescent molecule, fluoresceinamine (4). Unfortunately, attempted 
coupling of this with sulfo-NHS-biotin (1) to provide probe 5 proved unsuccessful 
(Figure 10). 
 
Figure 10: Fluoresceinamine reaction with sulfo-NHS-biotin (failed) 
Fluoresceinamine (4) reaction with sulfo-NHS-biotin (1) to create fluoresceinamine-biotin 
conjugate (5). 
 
The product expected (5) could not be detected in the MALDI-TOF deprotonated 
molecular ion [(M-H)-] spectra (Appendix, Figure 46). It was hypothesized that the 




aromatic amine was not reactive enough or was too sterically hindered to efficiently 
bind to the sulfo-NHS-biotin. A brief literature research found this hypothesis to be 
true (Belov, Bossi et al. 2009).  
 
3.1.1.3. Modification of fluorescein isothiocyanate (FITC)   
 To overcome the previous issue, a new approach was devised. Ethylene diamine 
(7) was reacted with FITC (6) to give compound 8 as an orange powder. This 
fluorescein derivative has been prepared using the method developed by Chongxiao 
Tan (Tan, Gajovic-Eichelmann et al. 2010) (Figure 11). 
 
Figure 11: FITC reaction with ethylene diamine 
FITC (6) reaction with ethylene diamine (7) to create (8) conjugate. 
 
A protonated molecular ion in the mass spectrum confirmed the formation of this 
product (Appendix, Figure 47).  
 
3.1.1.4. Synthesis of compound 9 (biotin-FITC) 




It was proposed that the primary amine of 8 would be more reactive than the one in 
fluoresceinamine. To prove this hypothesis a new reaction with sulfo-NHS-biotin 
was designed. Reaction of (8) with sulfo-NHS-biotin gave biotinylated FITC adduct 
(9) in 41% yield (Figure 12). 
 
Figure 12: Modified FITC reaction with sulfo-NHS-biotin 
Modified FITC (8) reaction with sulfo-NHS-biotin (1) to create biotin-FITC (9). 
 
The product (9) was purified by reverse phase chromatography on a solid phase 
extraction (SPE) column. The negative ion ESI-TOF mass spectrum showed a 
deprotonated molecular ion [(M-H)-] at m/z = 674.1778 consistent with its 
molecular formula (C33H32N5O7S2) which has a calculated m/z = 674.1749 
(Appendix, Figure 48)  
3.1.1.5. First attempt to synthesize biotin-SS-FITC 




Given the success of the previous reaction a similar modification of FITC 
incorporating a disulfide in the spacing arm was required for the synthesis of biotin-
SS-FITC. FITC (6) was reacted with cystamine (10) to give the disulfide containing 
fluorescein thiocarbonate (11) (Figure 13A). The mass spectrum supported the 
formation of the product with a deprotonated molecular ion [(M-H)-] of m/z = 
540.0814 consistent with its molecular structure (C25H22N3O5S3) which as a 
calculated m/z = 540.0727 (Appendix, Figure 49) 
 
 
Figure 13: Attempt of synthesis of product 12 (Failed) 
A: FITC (6) reaction with cystamine (10) to create fluorescein thiocarbonate (11). 
B: Fluorescein thiocarbonate (11) reaction with sulfo-NHS-biotin (1) to create compound 12. 
B 
A 





Unexpectedly, the reaction of 11 with biotin derivative 1 (sulfo-NHS-biotin) to give 
probe 12 failed (Figure 13B). (Appendix, Figure 50). Analysis of the crude reaction 
material showed it to be a complex mixture of products indicating that the target 
molecule might be unstable.  
3.1.1.6. Synthesis of compound 14 (biotin-SS-FITC) with the use 
of sulfo-NHS-SS-biotin 
To overcome the problem in the last reaction, another approach was considered in 
which conjugate 8 was reacted with sulfo-NHS-SS-biotin (13) to create the biotin-
SS-FITC conjugate (14) (Figure 14). 
 
Figure 14: Modified FITC reaction with sulfo-NHS-SS-biotin 
Compound 8 reaction with sulfo-NHS-SS-biotin (13) to create a biotin-SS-FITC (14). 
 




The product (14) was purified by reverse phase chromatography on a SPE column. 
The Mass spectrometry showed a deprotonated molecular ion [(M-H)-] with m/z = 
837.1934 consistent with its molecular structure (C38H41N6O8S4) which has a 
calculated m/z = 837.1874 (Appendix, Figure 51) 
The success of this last reaction allowed the preparation of compound 14 (biotin-
SS-FITC). Both probes (9 and 14) were used in conjugation experiments with 
MIS416 (paragraph 1.4, Figure 11). 
 
3.2. Biotinylation of MIS416 
 
The next step in the conjugation strategy was the preparation of biotinylated 
MIS416 (MIS416-biotin) to be used for further reactions. In order to create such 
conjugates, sulfo-NHS-biotin was reacted with MIS416 exploiting the amine 
residues on the lysines on the surface of the microparticle. After purification steps 
(Material and Methods 1.1), streptavidin-phycoerythrin (streptavidin-PE) was 
added to MIS416-biotin to ascertain whether the coupling reaction was successful. 
After the reaction, the fluorescence of the pellet was measured by 
spectrophotometry (excitation 488nm, emission 570nm). Results showed that 
streptavidin-PE is able to bind to the biotin groups on MIS416-biotin efficiently 
while the same reaction with unmodified MIS416 showed no significant difference 
in fluorescence to that of untreated MIS416 (Figure 15). Also visual inspection of 
the pellets from these experiments showed that the MIS416-biotin-streptavidin-PE 
conjugates were pink in colour as expected while the reaction between MIS416 and 
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Figure 15: Coupling of MIS416-biotin with Streptavidin-PE 
Fluorescence output (excitation 488nm, emission 570nm) of MIS416-biotin and MIS416 pellets 
after the reaction with streptavidin-PE. MIS416 without the addition of streptavidin was used as a 
negative control. Error bars represent the standard error of the mean (SEM). Results that are not 
significant are marked with ns while significant results are marked with * depending on the P values 
(* P < 0.05, ** P < 0.005, *** P < 0.0005). This experiment was repeated three times. 
 
 
3.3. Proof of principle of the conjugation strategy: coupling of 
biotinylated molecules to MIS416. 
 




The reaction steps necessary to couple biotin-PEG-FITC and the newly developed 
biotinylated fluorescent probes 9 and 14 to MIS416-biotin are depicted in Figure 
16. 
 
Figure 16: Conjugation strategy to couple biotinylated fluorophores to MIS416 
Schematic of the conjugation strategy used to couple biotynilated molecules to MIS416. 
Briefly, MIS416 is reacted with sulfo-NHS-biotin to obtain MIS416-biotin. In a second reaction, the 
biotinylated fluorophore of interest is reacted with streptavidin using 2 moles of the biotinylated 
fluorophore for each mole of streptavidin. The last conjugation step involves the mixing of two 
reaction products to obtain the final result in which the biotinylated fluorophore is coupled to 
MIS416-biotin via streptavidin bridge. 
 
This strategy relies on streptavidin acting as a bridge between MIS416-biotin and a 
biotinylated FITC molecule. Since conjugates 9 and 14 were not ready at the time 
of these experiments, a biotinylated pegylated fluorescein derivative (biotin-PEG-
FITC) was used to measure coupling efficiency. A series of experiments with 
varying molar ratio of biotin-PEG-FITC to streptavidin (Figure 17) (Table 2 
Material and methods, section 2.4.2) was performed.  





Figure 17: Molar ratio used in the coupling reactions 




The resulting complexes (streptavidin-biotin-PEG-FITC) were mixed with 
MIS416-biotin. As negative controls and also to measure the background 
fluorescence through unspecific binding interactions, the same amounts of biotin-
PEG-FITC were mixed with MIS416-biotin without the addition of streptavidin. 
Results in Figure 18 show that when two biotin binding sites on streptavidin were 
occupied with biotin-PEG-FITC prior to the coupling with MIS416-biotin (Column 
3, Figure 18) the conjugate formed had the highest fluorescence/mass output, 
indicating high conjugation efficiency. When all four binding site on streptavidin 




were filled with biotin-PEG-FITC, the fluorescence of the conjugate’s pellet 
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Figure 18: Coupling of biotin-PEG-FITC to MIS416-biotin 
Fluorescence output (excitation 488nm, emission 520nm) of different MIS-biotin-Streptavidin-
biotin-PEG-FITC conjugates prepared in order to saturate different biotin binding sites on 
streptavidin. Negative controls (black bars) represent the unspecific binding of biotin-PEG-FITC to 
MIS-biotin. Error bars represent SEM. Results that are not significant are marked with ns while 
significant results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 
0.0005). This experiment was repeated three times. 
 
3.4. Conjugation experiments with newly synthesized biotin-
FITC (9) and biotin-SS-FITC (14).  
 
Following the experiments carried out as a proof of principle for the conjugation 
strategy with biotin-PEG-FITC, further experiments were carried out with the 
synthesized fluorescent probes (biotin-FITC and biotin-SS-FITC). These two 




compounds were designed to investigate if the insertion of a disulfide bond in the 
linker would allow the release of the attached cargo from MIS416-biotin-
streptavidin-probe conjugates under reducing conditions. To further validate the 
initial coupling results shown in Figure 18, similar conjugation experiments with 
the newly designed fluorescent probes were carried out and the conjugation 
efficiency to MIS416-biotin was compared between the different biotinylated 
probes. Five different molar ratios of streptavidin to the biotinylated fluorescent 
probes were used as showed in Table 6. The theoretical number of biotin binding 
sites occupied by the biotinylated probes was calculated as the ratio of the amounts 
(μmol) of biotin used compared to the amount of streptavidin. 
Results in Figure 19 show that there are no significative differences in the 
fluorescence emission of conjugate’s pellets after the reaction of MIS416-biotin 
with the three different biotinylated fluorophores. However it should be taken into 
consideration that different molar ratios were used for the three fluorescent probes. 
Furthermore, the fluorescein moieties in conjugates prepared from 9 and 14 are 
physically nearer to streptavidin leading to a possible quenching effect. However, 
in the case of biotin-PEG-FITC this group is separated from streptavidin and the 
microparticle by a long PEG chain (PEG 2000). 
 







Theoretical number of biotin binding site blocked on 
each streptavidin for: 








Compound 9 Compound 14 Biotin-PEG-FITC 
1 5 10 0.25 0.31 0.37 
2 10 20 0.50 0.62 0.75 
3 20 40 1.01 1.25 1.5 
4 40 80 2.02 2.51 3.01 




Figure 19: Coupling of 9 and 14 to MIS416-biotin  
Fluorescence output (excitation 488nm, emission 520nm) of different MIS416 conjugates with 
compound 9 (biotin-FITC), 14 (biotin-SS-FITC) and biotin-PEG-FITC prepared in order to saturate 
different biotin binding sites on streptavidin. The five columns for each treatment group represent 
the different molar ratios of streptavidin/biotin in Table 2 Negative controls (black bars) represent 
the unspecific binding of biotin-PEG-FITC to MIS416-biotin. Error bars represent SEM. Results 
that are not significant are marked with ns while significant results are marked with * depending on 
the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). This experiments was repeated three times. 
 






3.5. Preparation of MIS416 conjugates with SIINFEKL. 
 
The experiments detailed above demonstrated that the conjugation strategy based 
on streptavidin as a bridge between MIS416-biotin and biotinylated probes was 
successful. New sets of MIS416 conjugates were then prepared with the addition of 
SIINFEKL for further experiments. Biotin-SS-SIINFEKL- fluorescein amidite 
(FAM) and biotin-ttds-SIINFEKL-FAM were purchased from JPT Peptide 
Technologies and conjugated to MIS416-biotin as detailed in the Material and 
Methods section 1.4. These two new conjugates were called conjugate A 
(possessing a disulfide (SS) group) and B (no SS). The conjugation efficiency of 
the reactions between MIS416-biotin and fluorescent probes was approximately 
20% as showed by results in Figure 20. This was based upon the quantification of 
the total fluorescence output of the pellets compared to that of the starting 
biotinylated fluorescent SIINFEKL. 
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Figure 20: Conjugation efficiency of conjugates A and B 
Evaluation of the conjugation efficiency of Biotin-SS-SIINFEKL-FAM and biotin-ttds-SIINFEKL-
FAM to MIS416-biotin to form conjugates A and B. The fluorescence of pellets was measured 
(excitation 488nm, emission 520nm) and the percentage of conjugation efficiency was calculated 
dividing the total amount of fluorescence at the beginning of the reactions with the fluorescence 
output from pellets after the reactions. Error bars represent SEM. Results that are not significant are 
marked with ns while significant results are marked with * depending on the P values (* P < 0.05, 
** P < 0.005, *** P < 0.0005). This experiments was repeated three times. 
 
 
No significant differences in the coupling efficiency were found between the two 
probes. The amount of probe coupled was ~3 µg for each 100µg of MIS416-biotin 
used (Table 7). Three different coupling reactions were carried out for each of the 
two probes. 
 











Total mass of 
SIINFEKL-




coupled to 10 g 
of MIS416 (nmol) 




200 g 6.3 g 0.171 nmol 




200 g 5.7 g 0.158 nmol 
 
3.6. Release study: the use of a disulfide as an endosome escape 
strategy 
 
3.6.1. Release of the conjugated fluorophore from MIS416 after 
degradation of the disulfide bond linkage: In vitro study  
The incorporation of a disulfide bond into our conjugation strategy has been used 
to facilitate the release of the attached cargo into the cytoplasm of target cells (Lin 




and Engbersen 2009). To show the feasibility of this approach we attached 
biotinylated fluorophores to MIS416 via a streptavidin bridge. Two MIS416 
conjugates were prepared: one that included a disulfide bond between the 
microparticle and the attached fluorophore (conjugate A) and a control conjugate 
without the disulfide bond (conjugate B). The release of the fluorophore in a 
reducing environment (TCEP 50 mM, pH 7, 30 min) was monitored for each of 
conjugate A and B (Figure 21A).  The results show that when the disulfide bond is 
included in the linker (conjugate A), release of the fluorophore occurs after the 
treatment of the conjugate with TCEP, as compared to conjugate B which lacks the 
disulfide bond. A further assay using glutathione as the reducing agent was 
designed in order to complement the previous experiments and to better simulate 
the reducing environment of the cytoplasm. Conjugates A and B were treated with 
PBS or glutathione and the fluorescence of both pellets and supernatants were 
measured. The release of the attached fluorophore from conjugate A occurs rapidly 
in a reductive environment. Results show that after 30 min of treatment the 
fluorescence of the pellet of conjugate A (SS) is halved Figure 21 (B, C). The 
reduction in fluorescence of the pellet at later timepoints follows a logarithmic 
trend. The release of the fluorescent probe from MIS416 remains incomplete after 
2 hours. This could be due to non-specific attachment of the biotinylated 
fluorophore to MIS416 and the relatively low concentration of gluthatione used in 
Figure 21 B and C. Regarding Figure 21 A, the release was incomplete because 
TCEP was added for only 30 min. 
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Figure 21: Disulfide bond degradation study under reductive conditions 
A: Fluorescence release assay. Conjugates A and B (30 μg) were treated with PBS (100 μL) or   
TCEP (100 μL) for 30 min at RT. After washes, the pellet was resuspended in PBS (100 μL) and 








B and C: Fluorescence release assay. Conjugates A and B (30 ug ) were treated with PBS (100 μL) 
or  glutathione (100 μL) for 30,60 or 120 min at RT as represented by each bar. After centrifugation, 
pellets (B) and supernatants (C) were collected and the fluorescence was measured (Abs 488, Em 
520) 
This experiments was repeated three times. 
Error bars represent SEM. Results that are not significant are marked with ns while significant results 
are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). 
 
3.6.2. Degradation of the disulfide bond linkage allows the release of 
the conjugated fluorophore from MIS416.   
Following the release experiments in vitro using TCEP and glutathione as reducing 
agents (Figure 21), microscopy experiments were carried out to visualize the release 
of the attached fluorophore/peptide in the cytoplasm of BMDCs. We hypothesised 
that glutathione would reduce the disulfide bond present in conjugate A allowing 
the release of FAM in the cytoplasm while conjugate B would have a slower release 
caused only by lysosomal processing. To test this hypothesis, a modification of 
conjugates A and B is required to identify MIS416 and the attached molecular cargo 
separately. An additional fluorophore (streptavidin-Allophycocyanin (APC)) was 
coupled to MIS416 to identify its structure while FAM will be used to identify the 
released cargo. Treatment of A and B with streptavidin-APC resulted in the 
formation of two new conjugates A1 and B1 respectively where this fluorophore 
was bound to residual biotin molecules on the surface of MIS416 (Figure 22A, 
Material and Methods 1.6). The fluorescence of FAM (excitation (ex) 488nm, 
emission (em) 521nm) and APC (ex 650nm, em 660nm) in the conjugates A1 and 
B1 made the resulting conjugates fluorescing yellow in microscopy experiments. 
Cleavage of the disulfide bond would release SIINFEKL-FAM (green) which 




would diffuse in the cytoplasm away from MIS416 particles identified by the 
fluorophore APC (red) (Figure 22B). These modified conjugates A1 and B1 were 
added to BMDCs for 20 min allowing uptake and internalization of MIS416 
conjugates (T0 Figure 22B). A wash was carried out to remove extracellular 
MIS416 conjugates and fresh media was added. BMDCs were allowed to process 
the conjugates for 20 and 40 min. The results show the release of SIINFEKL-FAM 
from conjugate A1 between 20 and 40 min after uptake identified by diffuse green 
fluorescence in the cytoplasm of target cells. However conjugate B1 does not show 
any sign of release in any of the time point tested. However at later timepoints (2 
and 4 hours) release of the fluorophore from conjugate B1 is evident (data not 
shown). These results confirm that the inclusion of a disulfide group in the linker 













Figure 22: Visualization of release of attached molecular cargo from MIS416 
A: Representation of conjugate A1. B and S represent Biotin biotin and streptavidin respectively. 
B: Confocal analysis of BMDCs treated with modified MIS416 conjugate A1 (MIS416-biotin-
streptavidin-biotin-SS-SIINFEKL-FAM) and B1 (MIS416-biotin-streptavidin-biotin-ttds-
SIINFEK-FAM). The top three quadrants (A, B, C) represents BMDCs treated with conjugate A1 
while lower quadrants (D, E, F) represent BMDCs treated with conjugate B1. Picture A and D 
represents the timepoint when cell have been washed to remove the excess of MIS416 conjugates 
from the medium after 20 min of uptake. B and E represent time points after 20min from the washes 
while C and F represent time points after 40min. Red staining represents streptavidin-APC coupled 
to MIS416. Green staining represents released SIINFEKL-FAM and Blue represent nuclear staining 
B 
C 




with DAPI. Arrows represent release of the fluorescent probe (green color) from MIS416 in the 
cytoplasm of treated DCs. 
C: Graph of the quantification of the results obtained from confocal microscopy. Cells in the images 
were scored if they contained at least 1 internalized microparticle (see Materials and Methods section 
2.8.4). The total number of cells counted for each condition was as follow: A=24, B=34, C=66, 
D=23, E=78, F=56. Error bars represent SEM. 
 
In conclusion the fluorescent probes and biotinylated peptides were successfully 
coupled to MIS416-biotin proving that the conjugation strategy based on a 
streptavidin bridge was working. Furthermore the newly developed MIS416 
conjugates of SIINFEKL (conjugates A and B) were ready to be used for further 
immunological experiments. The release study under reducing conditions as 
visualized by microscopy showed that conjugate A allowed a more rapid release of 
the peptide cargo in the cytoplasm of the target cells, consistent with previous 
results (Goldenbogen, Brodersen et al. 2011, Yang, Chen et al. 2014) using TCEP 
and glutathione as reducing agents. 
 
3.7. Discussion  
The initial focus of this chapter was directed towards the preparation of biotinylated 
fluorescent probes which were necessary to provide a proof of principle for the 
conjugation strategy based on a streptavidin bridge between a biotinylated version 
of MIS416 (MIS416-biotin) and biotinylated molecules (Figure 23).  





Figure 23: Conjugation Strategy 
The conjugation strategy used to link MIS416 to biotinylated peptides and fluorophores. MIS416 
was modified with the addition of biotin (B). Biomolecular cargoes (X) were previously biotinylated 
and then coupled to MIS416-biotin using streptavidin (S) as a bridge. The addition of a disulfide 
bond in the linking group (L) would facilitate the release of the attached cargoes inside the cytoplasm 





Conjugate (siRNA or peptide) X 
Linkers structure Conjugates Name of the 
preparation 
Disulfide (SS)  SIINFEKL-FAM A 
No Disulfide  SIINFEKL-FAM B 
 




Initially Alexa Fluor 488 (2) was conjugated to biotin using an activated biotin ester 
(sulfo-NHS-biotin, 1). The reaction was successful but low yielding and, given the 
small amount of product recovered and the high price of Alexa Fluor 488, attention 
moved to more readily available fluorophores derived from fluorescein. After some 
initial problems since fluoresceinamine (4) was not reactive towards NHS groups 
(Results, Figure 10), a modified fluorescein isothiocyanante (FITC, 6) was reacted 
with ethylene diamine to give the reactive derivative 8 (Tan, Gajovic-Eichelmann 
et al. 2010) that was supposed to be more reactive towards NHS groups. 
Coumpound 8 was used successfully to prepare the biotinylated fluorescent probe 
9 (Results, Figure 12).  
The inclusion of a disulfide group into one of the probes was necessary to determine 
if intracellular glutathione would facilitate the release of attached fluorescent probe 
molecule. Fluorescein isothiocyanate FITC (6) was reacted with cystamine (10) in 
order to create a modified fluorescein (12) bonded via a disulfide containing chain 
to a reactive amine. Although the mass spectral data of 12 confirmed that this 
product had formed, its reaction with sulfo-NHS-biotin proved unsuccesful. The 
reason for this result was unclear. It is possible that product 12 was unstable as no 
starting materials were recovered from the reaction. A new approach was then 
developed where a water soluble succinimidyl ester of biotin possessing a disulfide 
(sulfo-NHS-SS-biotin, 13) was purchased and successfully coupled to ethylene 
diamine modified fluorescein (8) giving compound 14.  
A commercially available biotinylated fluorescein derivative (biotin-PEG-FITC) 
and the newly developed fluorescent probes (compound 9 and 14) were used to 
quantify the amount of material that could be coupled to MIS416-biotin using a 




streptavidin bridge. After preliminary experiments, it was found from coupling 
reactions that two molar equivalents of biotin-PEG-FITC to one of streptavidin 
(Results, Figures 18) led to the highest coupling efficiency. Further coupling 
experiments with compound 9 and 14 (Results, Figure 19) confirmed the previous 
conjugation results. Although variability of the mean fluorescence was observed in 
these experiments, they all showed that the ideal ratio of the biotinylated molecules 
to streptavidin was 2:1. The variablity could possibly be due to quenching 
interactions with streptavidin especially for compounds 9 and 14 where the 
fluorophore is in close proximity to the protein. This quenching effect is due to the 
interaction of the fluorophore with biotin-binding pockets on streptavidin 
containing tryptophan residues (Marme, Knemeyer et al. 2003). The quenching 
could be avoided by the addition of a spacer between the biotin and the fluorophore 
such as PEG (Gruber, Marek et al. 1997). Every conjugate in this study (a parte 
from MIS416-SS-FITC and MIS416-FITC used in Figure 19) was prepared with 
PEG or another carbon-based spacer in order to avoid this issue. These series of 
coupling experiments proved that the strategy using streptavidin as a bridge 
between biotinylated fluorescent probes and MIS416-biotin was effective and could 
be a useful method to couple any biotinylated compound to MIS416.  
Commerial companies such as JPT Peptide Technologies can synthesise 
biotinylated molecules to order. Examples include biotinylated fluorescent probes, 
peptides and oligonucleotides. With this in mind it was envisaged that MIS416 
could be exploited with the addition of a broad range of molecules such as siRNAs 
and peptide antigens. Furthermore, since the conjugation can be achieved in 
aqueous solutions such as PBS buffer, the risk of denaturation by solvents such as 




DMSO or DMF can be avoided. Other advantages of this strategy are that the 
conjugation can be achieved in a relatively short time (a day) and the purification 
by centrifugation gives pellets of MIS416 conjugates where the unbound molecules 
can be removed by washing. One disadvantage of this coupling strategy is that the 
reaction of the biotinylated molecules with streptavidin is not easily controlled. The 
optimal reaction of two biotinylated species to one of streptavidin would give a 
range of conjugates that follow a Gaussian distribution where the predominant 
product is where two of the four binding sites are occupied. Consequently, some 
streptavidin molecules are bound to four biotinylated molecules and will not be 
available for the coupling to MIS416-biotin leading to a partial waste of the 
reactants. This was predicted as previous studies showed that streptavidin binds 
biotin molecules in a non-cooperative way (Jones and Kurzban 1995, Gonzalez, 
Bagatolli et al. 1997) (Figure 24).  
 
Figure 24: Streptavidin interaction with biotin 
Illustration of two models for streptavidin interaction. Cooperative (A) and non-cooperative (B) 
binding of biotin to streptavidin. 
 




Two conjugates, A and B, were prepared by the the addition of biotinylated-
SIINFEKL-FAM derivatives to MIS416 bridged by streptavidin using the 
optimized conjugation conditions (Materials and Methods 2.4.4). The difference 
bewteen the two conjugates was that A contained a disulfide group in the linker. 
After the preparation of these new conjugates, it was found that the coupling 
efficiency was relatively low (~20%) based upon their mean fluorescence. The 
quantification methodology was based upon previous experiments producing 
biotin-PEG-FITC conjugates. Other groups have used streptavidin as a bridge for 
conjugation of antibodies, protein, nanoparticles (quantum dots) and 
oligonucleotides (Kurihara and Pardridge 1999, Chodosh and Buratowski 2001, 
Chu, Twu et al. 2006, Mao, Yuan et al. 2011) . However, none of these groups have 
reported any data regarding the conjugation efficiency with multiple biotinylated 
probes to streptavidin so the results could not be compared. 
 
The addition of a disulfide bond was included to ascertain whether cleavable linkers 
increased the release of coupled cargo to target cells. For these series of experiments 
the newly developed MIS416/SIINFEKL conjugates (A and B) were treated with 
the reductive agents, TCEP and glutathione.  The mean fluorescence of the 
supernatant from these experiments showed that there was a release of the 
fluorescent peptide from conjugate A. On the other hand the supernatant from 
conjugate B, on treatment with either of the reductive agents showed no difference 
in fluorescence compared to the untreated control. These results were supported by 
microscopy studies on BMDCs that showed release of the attached fluorescent 
cargo from conjugate A inside the cytoplasm of target cells after 1 hour post 




internalization. The same experiment with conjugate B showed no release of the 
attached fluorophore at the same time point (Results, Figure 22). However since the 
two fluorophores used to identify the released cargo and MIS416 structure (FAM 
and APC respectively) are normally distributed between MIS416 conjugates, the 
balance of the two fluorophore is not always in a 1:1 ratio leading to a few particles 
in which one of the two fluorophores is predominant. This particular problem was 
predicted. Nevertheless the microscopic analysis clearly shows differences at later 
timepoints even if a few particles do not have an optimal streptavidin-APC/FAM 
balance. 
 
In conclusion the first objective of this PhD project was achieved since multiple 
biotinylated molecules were coupled to MIS416-biotin and newly developed 
MIS416 conjugates of SIINFEKL were ready to be used for further experiments. 
This step was important for the further coupling of siRNAs to MIS416. 
Furthermore, conjugate A contains a disulfide group that allows a more rapid 
release of peptide in the cytoplasm of the target cells and provides an endosomal 
escape strategy for siRNAs coupled to MIS416.



















Results: Evaluation of the downregulation capabilities of 
MIS416/SiRNAs conjugates in DCs





4. Evaluation of the downregulation capabilities of 
MIS416/SiRNAs conjugates 
4.1. Coupling of siRNAs to MIS416 
 
The delivery of siRNAs into cells in vivo is an important obstacle that needs to be 
overcome and this research work tries to address this issue. MIS416 microparticles 
are investigated here as a new platform for the delivery of siRNAs with the final 
goal of delivering therapeutic siRNAs in vivo. I hypothesized that MIS416 could be 
used to successfully deliver siRNAs to the cytoplasm of DCs, and experiments will 
be carried out in this chapter to investigate if MIS416/siRNA conjugates have 
potential for in vivo use. MIS416/siRNA conjugates will be developed in this 
chapter using a streptavidin bridge conjugation strategy to link a biotinylated 
siRNA to a biotinylated version of MIS416 (MIS416-biotin). This coupling 
methodology was described in the previous chapter and has been used to effectively 
couple fluorophores and peptides to MIS416. I also hypothesize that these newly 
developed MIS416/siRNAconjugates will be able to negatively regulate the 
expression of target proteins. Western blot and Q-RT-PCR techniques will be used 
to measure the degree of downregulation at both protein and mRNA level. Two 
MIS416/siRNA conjugates targeting two important regulators of the survival and 
homeostasis of DCs (Bim and Stat3 respectively) will be investigated.  
BIM is a member of the BCL-2 family and is usually associated with microtubules. 
The protein encoded by this gene (BCL2L11) contains a Bcl-2 homology domain 3 
(BH3) which is responsible for pro-apoptotic functions (Chen, Huang et al. 2007, 





Fuertes Marraco, Scott et al. 2011). Upon activation of cell death, BH3-only 
proteins are induced and/or activated transcriptionally and/or post-translationally. 
Since BIM has a high affinity for the anti-apoptotic Bcl-2 protein, its binding 
liberates both BAX and BAK inducing apoptosis (Tait and Green 2010). BH-3 only 
proteins also determine the fate of lymphocytes during haematopoiesis. In fact Bim-
/- mice have an excess of DCs, macrophages, granulocytes, B cells and T cells 
(Bouillet, Metcalf et al. 1999). Granulocytes derived from these mice are also 
highly resistant to apoptosis induced by cytokine deprivation (Bouillet, Metcalf et 
al. 1999). Furthermore, DCs derived from Bim-/- mice are protected from 
spontaneous apoptosis in vitro and are able to increase immunogenicity in vivo. On 
the other hand, the prolonged downregulation in the Bim-/- mouse model leads to 
autoimmunity and production of autoreactive antibodies. Taken together, these 
studies demonstrate that BIM is a key apoptotic regulator in a variety of tissues and 
that manipulation of its expression could potentially enhance the immune response 
by increasing DCs survival. 
STAT3, is a transcription factor member of the STAT family. IL-5 , IL-6 , IL-10, 
hepatocytes growth factor (HGF), epidermal growth factor (EGF) and other factors 
are able to induce the phosphorylation of STAT3 with consequent migration to the 
nucleus where it can bind specific DNA sequences and promote gene expression. 
Nuclear factor-κB (NF-κB) is one of the main proteins modulated by STAT3 and 
has been linked to the expression of numerous oncogenic and inflammatory genes 
(Yu, Kortylewski et al. 2007). Research on STAT3-/- immune cells (Kortylewski, 
Kujawski et al. 2005) has highlighted the importance of STAT3 in DCs. DCs from 
STAT3-/- mice have enhanced expression of MHC II, CD80 and CD86 and their 





cross presentation capabilities are increased. Furthermore, DCs derived from 
STAT3-/- mice are able to improve the activation of antigen specific CD4 T cells ex 
vivo. On the other hand, the expression of STAT3 by DCs in the tumor 
microenvironment inhibits their ability to initiate the adaptive immune response, 
leading to a more suppressive phenotype (Wang, Niu et al. 2004). These findings 
suggest that STAT3 is a promising molecular target to enhance DCs function and 
to improve the immune response against tumors.  
To conclude, the overall aim of this chapter is to prepare MIS416/siRNA conjugates 
and to test their ability to downregulate specific genes (Bim and Stat3) in treated 
BMDCs. 
4.2. Reference gene evaluation for Q-RT-PCR experiments. 
 
A series of Q-RT-PCR experiments were carried out to identify an optimal 
reference gene for further Q-RT-PCR experiment. The effect of MIS416, LPS and 
a control siRNA treatment on different reference genes (B2m, ß-actin, Ywhaz, 
Rpl32 and Gapdh, see Figure 52 appendix for primers binding schematics) was 
quantified by measuring the mRNA levels of these genes after treatment. Cells 
treated in these experiments were BMDCs since these cells were used for most of 
the experiments in this thesis. Results showed that the treatments did not alter the 
mRNA expression levels of reference genes significantly, except for Rpl32 
(MIS416 treatment) (Figure 25A). The average expression stability (M) between 
different reference gene targets was calculated and the results in Figure 25B show 
that Gapdh was found to be the optimal reference gene.  
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Figure 25: Average expression stability for reference genes 
A: DCs were treated with a scrambled siRNA sequence (transfected with RNAiMAX), MIS416 or 
LPS overnight. Q-RT-PCR was performed and results were normalized to the expression of different 
genes in untreated samples (value set to 1) to compare results. Error bars represent SEM. These 
experiments were repeated twice. 
B: Average expression stability values (M) of candidate reference genes by geNorm analysis. DCs 
were treated with MIS416 and with PBS and RNA was extracted. Q-RT-PCR was performed on 
A 
B 





cDNA generated from total RNA extracted from the cells. The highest M values characterize genes 
with the least stable expression, indicative of a less optimal reference gene 
 
4.3. Evaluation of an siRNA pool from Genepharma for the 
knockdown of Bim 
 
I hypothesized that attachment of biotinylated siRNAs to MIS416 may be achieved 
using the coupling methodology developed in chapter 3 (Figure 23). However, 
siRNAs prior to conjugation would require modifications (the addition of a 
fluorophore for quantification purposes, a disulfide for release of the attached 
siRNA from MIS416 and biotinylation). The choice of the target gene is also an 
important consideration. BIM is a member of the BCL-2 family and is a key 
apoptotic regulator in a variety of tissues. BIM is activated upon apoptotic 
stimulation (Ren, Tu et al. 2010) and thereby mediates apoptosis. DCs derived from 
Bim-/- mice are protected from spontaneous apoptosis in vitro and have 
correspondingly increased immunogenicity in vivo (Chen, Huang et al. 2007). I 
hypothesized that identifying BIM as a primary target for siRNA therapy would 
ultimately enhance DCs survival leading to an increase in T cell activity as a result 
of the treated DCs activating greater numbers of T cells for a prolonged period of 
time. In this series of experiments I aimed to identify the ideal candidate siRNA 
sequence to be used for coupling experiments with MIS416. A pool of 4 siRNAs 
targeting the mRNA BIM were puchased (428, 494, 540, M-BIM, see Figure 53 
appendix for siRNA binding schematics). Sequences 428, 494 and 540 were 
standard RNA duplexes from a specific BIM siRNA pool developed by 
Genepharma, while the M-BIM duplex had 4 methylated bases and derives from a 





sequence previously used (Chae, Choi et al. 2005). M-BIM siRNA was designed to 
resist ribonucleases degradation. However,  methylated bases could affect the 
activity of the siRNA in an unknown way (Chen, Weinmann et al. 2008). After 
optimization of the transfection procotol, experiments were carried out using two 
different concentrations of siRNAs (10 and 50nM). Results were normalized to 
untreated cells, since RNAiMAX treatment with a scrambled siRNA showed no 
significant difference compared to untreated cells (Figure 54, Appendix). Q-RT-
PCR experiments on BMDCs (Figure 26) showed that all siRNAs were able to 
knockdown BIM mRNA to an extent. siRNA sequence 428 showed a level of 
downregulation of 85% (10nM) and 80% (50nM) and performed better than the 
other siRNA sequences. However there was no significant difference between 
siRNA 428 and 494 at 50nM. siRNA sequence 428 performed better at 10nM while 
there was no significant difference with sequence 494 at 50nM 
To conclude, siRNA 428 (Genepharma) was able to achieve significant 
downregulation of BIM mRNA in BMDCs and was shown to be the best candidate 
for synthesis of biotin-SS-siRNA to be used for subsequent conjugation to MIS416-
biotin. The methylated siRNA (M-BIM) was not able to downregulate Bim RNA 
levels any greater than siRNA 428. However M-BIM performed similarly to siRNA 
494 and 540 at 10nM and therefore it seems that the methylated bases in M-BIM 
did not interfere with its ability to downregulate Bim mRNA levels.  
 



































































Figure 26: Relative quantification of Bim expression levels following treatment 
with siRNAs targeting Bim. 
BMDCs were transfected for 48h with siRNA 428, 494, 540 using RNAi Max as transfection 
reagent. Q-RT-PCR was performed on cDNA generated from total RNA extracted from cells. Gapdh 
was used as the reference gene for relative quantification of Bim expression. siRNA treatments were 
compared to untreated cells. Relative Bim quantification on untreated cells was set to 1 in all the 
experiments and results were normalized to this. Error bars represent SEM. Results that were not 
significant are marked with ns while significant results are marked with * depending on the P values 
(* P < 0.05, ** P < 0.005, *** P < 0.0005). These experiments were repeated three times. 
 
4.4. Preparation of MIS416 conjugates with siRNAs targeting 
the protein Bim. 
 
Following the Q-RT-PCR results showing that siRNA sequence 428 was the best 
candidate for the preparation of biotinylated siRNA constructs, I then designed an 
siRNA using this sequence that could be coupled to MIS416. This siRNA was 
purchased with the addition of a biotin, FAM (a fluorophore to quantify the amount 
of siRNA coupled to MIS416) and a disulfide between the biotin and siRNA (to 
facilitate the release of the siRNA from MIS416 after internalization by the target 





cells). Furthermore, a similar siRNA construct was purchased with a control 
sequence to be used as a negative control. These new MIS416 conjugates were 
called MIS416-SS-Bim and MIS416-SS-controlsiRNA, and were prepared 
following the same protocol used to attach SIINFEKL to MIS416 as detailed in 
materials and methods, section 2.4.4. Instead of coupling biotin-SS-SIINFEKL-
FAM (rationale detailed in section 1.5 of chapter 3), biotin-SS-siRNA-FAM was 
coupled to MIS416 using the same optimized conjugation protocol (schematic is 
shown Figure 27A). After the coupling reactions, the resulting conjugates were 
analyzed using spectrophotometry to quantify the amount of fluorophore (FAM) 
coupled to MIS416 to evaluate the conjugation efficiency. The results were 
compared with previous fluorescence measurements performed with 
MIS416/SIINFEKL conjugates (Figure 27B) and indicated that the conjugation 
efficiency was ~20% with no significant differences between the different 
conjugates. Similar results were obtained previously for the conjugation of 
















Figure 27: Preparation of MIS416-SS-Bim and evaluation of the conjugation 
efficiency 
A: Schematic representing the reaction procedure to prepare MIS416-SS-BIM and its extended 
molecular structure. 
B: Comparison of the conjugation efficiency of conjugation A, B, MIS416-SS-BIM and MIS416-
SS-Control sequence. The conjugation efficiency was calculated using the amount of FAM coupled 
to MIS416 divided by the total amount of FAM used for the conjugation reaction (for raw and raw 
data see appendix, Figure 55). The amount of FAM at the start of the reaction was known while the 
amount of FAM coupled after the conjugation reaction was calculated comparing the fluorescence 
of the pellets with the fluorescence of FAM at different known concentrations. Standard curves were 
used for this comparison (see material and methods section 1.4) 
B 





Error bars represent SEM. Results that were not significant are marked with ns while significant 
results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). 
These experiments were repeated three times. 
 
 
4.5. Quantification of protein levels after treatment with 
MIS416/siRNAs conjugates 
 
Successful conjugation experiments led to the preparation of two MIS416/siRNA 
conjugates. The first conjugate (MIS416-SS-Bim) was developed to target the 
mRNA for Bim while the second conjugate (MIS416-SS-controlsiRNA) did not 
target any specific mRNA and was used as a negative control. I hypothesized that 
treatment of DCs with MIS416-SS-Bim conjugate would lead to downregulation of 
Bim protein levels. This effect would be achieved by the incorporation of the 
attached siRNA into the RISC complex in cells after internalization of MIS416-SS-
Bim by DCs. Following degradation of Bim mRNA by the siRNA/RISC complex, 
Bim protein levels should drop significantly. To verify this, a series of Western blot 
studies were designed. DCs were treated with MIS416, MIS416-SS-controlsiRNA 
and MIS416-SS-BIM for 48h. BIM protein levels were quantified following 
Western blotting, by enhanced chemiluminescence (ECL) analysis and normalized 
with ß-Actin expression levels. The results showed that MIS416-SS-BIM was able 
to downregulate Bim protein levels by 70% after two days of incubation with DCs 
(Figure 28). In contrast, MIS416-SS-controlsiRNA did not significantly affect Bim 
protein levels.  






          
 
Figure 28: Western blot quantification of Bim protein levels  
DCs were treated for 48h with MIS416, MIS416-SS-ControlsiRNA and MIS416-SS-BIM. Proteins 
were extracted from treated cells and analyzed by ECL Western Blot, using ß-Actin as the reference 
gene for normalization. 
A:Relative Bim protein levels were calculated by dividing Bim expression levels by ß-Actin 
expression levels previously quantified using ImageJ software. Bim expression levels after treatment 
with MIS416-SS-controlsiRNA were set to 1 for normalization.Error bars represent SEM. Results 
that were not significant are marked with ns while significant results are marked with * depending 
on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). These experiments were repeated four 
times. 
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B: Example of quantification of Bim and ß-Actin level of expression following Western blot 
analysis. Numbers represent quantification of the band intensity using ImageJ software. Expression 
of Bim and ß-Actin in untreated cells was set to 1 in each experiment to be able to compare multiple 
experiments 
 
4.6. Quantification of Bim RNA levels after treatment with 
MIS416 siRNAs conjugates. 
 
Since siRNAs exert their function by downregulating mRNA levels of the target 
protein, this mechanism should be responsible for the Bim protein downregulation 
that was observed in the previous Western blot experiments (Figure 28). To verify 
this interpretation, a series of Q-RT-PCR experiments were carried out to 
investigate if Bim mRNA levels were downregulated after treatment with MIS416-
SS-BIM conjugate. The results showed that there was no significant difference 
between DCs treated with MIS416, MIS416-SS-controlsiRNA and MIS416-SS-
Bim at 48 and 72 hours (Figure 29A). Bim mRNA levels were downregulated after 
treatment with MIS416 alone, and any effect due to MIS416-SS-Bim siRNA was 
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Figure 29: Q-RT-PCR quantification of Bim mRNA levels 
A: DCs were treated for 48 or 72h with MIS416, MIS416-SS-controlsiRNA and MIS416-SS-BIM. 
Q-RT-PCR was performed on cDNA generated from total RNA extracted from treated cells. 
Downregulation of Bim mRNA levels was observed at both timepoints in all the treated samples. 
Error bars represent SEM. Results that were not significant are marked with ns while significant 
results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005).  
This experiment was repeated three times 
B: Example of amplification curves representing Bim mRNA expression levels in treated or 
untreated samples. Cycle threshold (CT) values used to quantify Bim mRNA expression levels in 
A 
B 





Figure 29A were derived from these curves using LightCycler480 software. An example of CT value 
is showed in the figure (marked as CT). Lower CT values represent samples in which there were 
more copies of Bim mRNA meaning that Bim mRNA was more highly expressed in those samples. 
 
4.7. Evaluation of alternative mRNA sequences of possible new 
siRNA targets  
 
The previous experiments showed that MIS416 alone was able to cause the 
downregulation of Bim mRNA levels in treated DCs (Figure 29). This result did not 
allow the verification of the previous hypothesis in which MIS416-SS-BIM 
conjugate would have affected Bim mRNA levels leading to the downregulation of 
Bim protein levels. The effect of MIS416-SS-BIM on Bim mRNA levels was 
however similar to the effect of MIS416 alone or MIS416-SS-controlsiRNA. This 
negative result was unexpected since if MIS416-SS-Bim is able to significantly 
downregulate Bim protein levels (Figure 28), this specific downregulation must be 
caused by the siRNA coupled to MIS416 and not by MIS416 alone, since the 
treatment of DCs with MIS416 alone did not alter Bim protein levels. The most 
likely interpretation of these data is that the effect of the siRNA coupled to MIS416 
was masked by the effect of MIS416 alone in the downregulation of Bim mRNA 
levels. Further investigations with MIS416/siRNA conjugates therefore would 
require a new and more suitable mRNA target, different from BIM. Ideally the 
treatment with MIS416 should not alter or only slightly upregulate the mRNA 
levels of the new target gene. In this ideal case, the effect of the siRNA coupled to 
MIS416 would be easier to evaluate since MIS416 alone would not downregulate 
target mRNA levels. Different candidates were taken into consideration after a 





literature review. These candidates, if downregulated by MIS416/siRNA 
conjugates, would enhance DCs function in different ways. Similar to Bim, 
mitogen-inducible nuclear orphan receptor (Minor) is involved in the regulation of 
apoptosis (Wang, Jiang et al. 2009). DCs treated with siRNAs targeting Minor were 
more resistant than untreated DCs to apoptosis (Wang, Jiang et al. 2009). Minor 
was also chosen as a possible candidate since other proteins involved in the 
regulation of apoptosis of DCs (BAK, BAX, BAD, BID and PUMA) compensate 
for each other and the downregulation of only one of them would not strongly alter 
DCs survival (Zinkel, Gross et al. 2006, Adams and Cory 2007). Another way to 
increase DCs function involves the blockade of inhibitory pathways that could lead 
DCs towards a suppressive phenotype. IL-10 receptor 1 blockade, for example, 
increased intratumoral DCs expression of IL-12 during chemotherapy in vivo 
(Ruffell, Chang-Strachan et al. 2014). The reduction in the number of receptors for 
this suppressive cytokine in DCs could be advantageous especially in the context 
of tumor microenvironment, which may contain high levels of IL-10 (Landskron, 
De la Fuente et al. 2014). IL-10 also promotes the downregulation of activation 
markers and MHC class molecules in DCs (Kim, Kang et al. 2011). Such effects 
need to be avoided in order to cause strong activation of  DCs in order to activate T 
cells (Schwarz, Banning-Eichenseer et al. 2013). Another different approach that is 
used to enhance DCs function is inhibition of signal transducer and activator of 
transcription 3 (STAT-3) which is an important regulator of DCs homeostasis. 
STAT3 downregulation in DCs is associated with many benefits, such as the 
augmented secretion of Interferon- γ, IL-12 and TNF- α and inhibition of IL-10 
(Sanseverino, Purificato et al. 2014). The inhibition of STAT3 in DCs can also 





make them more resistant to suppressive effects derived from cancer cells such as 
IL-10, IL-6 and VEGF (Iwata-Kajihara, Sumimoto et al. 2011). 
To investigate wheter Minor, IL10r1 and Stat3 mRNA levels were affected by the 
treatment of DCs with MIS416, various Q-RT-PCR experiments were carried out. 
Primer sequences for Minor, IL10r1 and STAT3 were identified after a literature 
research and primers were designed (Table 4, 2.6.6 Materials and Methods). Primer 
binding regions are highlighted in Figure 52 (Appendix). These experiments were 
also used to confirm the previous results in which Bim mRNA levels were 
downregulated by MIS416 treatment (Figure 29). DCs were treated for 24, 48, 72 
and 96 hours with MIS416 and the mRNA levels of the candidate genes and Bim 
were quantified using Gapdh as a reference gene for relative quantification. 
Untreated cells were used as controls and to set the background level of expression 
of the target genes tested.  
The results in Figure 30 showed that treatment of DCs with MIS416 alone led to 
enhanced STAT3 mRNA expression at 24 and 48h in treated cells compared to 
untreated cells. Downregulation of Bim mRNA levels by MIS416 was also 
observed at all timepoints, confirming the previous results (Figure 29). MIS416 
treatment downregulated Minor mRNA levels at later time points and the same 
trend was noticeable for IL-10r1 even at earlier time points. 
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Figure 30: Q-RT-PCR results of mRNA levels of IL10r1, Stat3, Bim and Minor 
DCs were treated with MIS416 for 24h, 48h, 72h or 96 hours and the mRNA levels of the different 
target genes (IL10r1, Stat3, Bim and Minor) were compared with the one of an untreated sample at 
the same time point. The relative level of expression for all the candidates gene was set to 1 for the 
untreated sample. Relative quantification was achieved using Gapdh as a reference gene. Error bars 
represent SEM. Results that are not significant are marked with ns while significant results are 
marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005).  This 
experiment has been repeated 3 times. 
 
4.8. Validation of the siRNA pool for the knockdown of STAT3 
mRNA levels 
STAT3 was identified as the ideal target for siRNA treatment in DCs due to the 
slight upregulation of its mRNA levels after the treatment of DCs with MIS416. No 
change or upregulation of STAT3 mRNA levels after MIS416 treatment was 
important in the choice of the candidate gene because this would lead to an easier 





evaluation of the possible downregulation effect caused by MIS416/siRNA. A pool 
of 3 different siRNAs (1962, 1701, 1107, see Figure 53 appendix for binding 
schematics) was investigated in DCs using RNAiMAX as the transfection reagent, 
as had been done previously (Figure 26). A control siRNA was not used in these 
experiments, since I aimed to identify the best performing siRNA of the three 
different sequences used. Furthermore, I did not aim to quantify an absolute 
downregulation of Stat3 mRNA levels in these experiments but only to show the 
relative differences between the three siRNAs. The results showed that siRNA 1962 
was able to downregulate Stat3 mRNA levels by 80% at 10nM and 85% at 50nM. 
However there was no significant difference with siRNA sequences 1701 or 1107 
at 50nM (Figure 31). The 10nM dose of siRNA was identified as the best 
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Figure 31: Validation of the siRNA pool for the knockdown of STAT3 mRNA 
levels 





DCs were treated with 10nM or 50nM of siRNAs (1962, 1701, 1107) using RNAi Max as the 
transfection reagent. Q-RT-PCR was performed on cDNA created from total RNA extracted from 
cells following 48h of treatment. Gapdh was used as the reference gene for relative quantification 
of STAT3 expression. SiRNA treatments were compared with untreated cells. Relative STAT3 
quantification on untreated cell was set to 1 in all experiments. Error bars represent SEM. Results 
that were not significant are marked with ns while significant results are marked with * depending 
on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). These experiments were repeated three 
times. 
 
4.9. Preparation of MIS416 conjugates with siRNAs targeting 
the protein STAT3. 
 
Following the Q-RT-PCR results suggesting that siRNA sequence 1962 was the 
optimal candidate for future studies, a new MIS416 conjugate was prepared 
utilizing a biotinylated siRNA targeting the Stat3 mRNA (using sequence 1962). 
This new MIS416/STAT3 conjugate (called MIS-SS-STAT3) was used to evaluate 
wheter the siRNA coupled to MIS416 was able to downregulate Stat3 mRNA and 
protein levels. The MIS416-SS-STAT3 conjugate was prepared following the same 
protocol used to couple siRNAs or SIINFEKL peptide to MIS416 (see the 
conjugation procedure detailed in material and methods, section 1.4). The only 
change made to the conjugation protocol was the siRNA sequence used (see Figure 
19A for the conjugation protocol schematic). The coupled siRNA was modified by 
the addition of FAM, biotin and a disulfide in the same way as the previous siRNA 
targeting BIM. The conjugation efficiency of the reaction was calculated by 
measuring the fluorescence output of the pellet following conjugation using 
spectrophotometry, and compared with the conjugation efficiency of the other 
conjugates prepared (MIS416-SS-BIM and MIS416-SS-controlsiRNA). The results 
showed that the conjugation efficiency was ~22% with no significant differences 





observed between the different samples (Figure 32). Raw fluorescence output data 
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Figure 32: Comparison of the conjugation efficiency of MIS416-SS-STAT3 with 
the previous preparations 
The fluorescence of pellets of MIS416-SS-STAT3 conjugates was measured (excitation 488nm, 
emission 520nm) and compared with the previously prepared conjugates (MIS416-SS-BIM, 
MIS416-SS-controlsiRNA). The conjugation efficiency was calculated by dividing the total amount 
of fluorescence at the beginning of the reactions with the fluorescence output from pellets after the 
reactions. A reaction without streptavidin was prepared to evaluate the amount of biotin-SS-STAT3 
coupled to MIS416 in an unspecific manner. Error bars represent SEM. Results that were not 
significant are marked with ns while significant results are marked with * depending on the P values 
(* P < 0.05, ** P < 0.005, *** P < 0.0005). This experiments was repeated three times. 
 





4.10. Quantification of STAT3 mRNA levels after treatment 
with MIS416 siRNA conjugates. 
 
After conjugation, the MIS416-SS-STAT3 conjugate was tested on DCs. I 
investigated whether MIS416-SS-STAT3 was able to downregulate Stat3 mRNA 
levels compared to MIS416 alone or MIS416-SS-control siRNA. BMDCs were 
treated with MIS416-SS-STAT3 and MIS416-SS-control siRNA conjugates and 
RNA was extracted after 48 or 72 hours of treatment. Q-RT-PCR analysis was 
performed and the results showed that there were significant differences in the 
downregulation of Stat3 mRNA levels between DCs treated with MIS416-SS-
Control siRNA and MIS416-SS-STAT3 at 48 (P=0.046) and 72 hours (P=0.024) 
(Figure 33). These data suggest that MIS416-SS-STAT3 was able to reduce to the 
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Figure 33: Q-RT-PCR quantification of STAT3 mRNA levels 





DCs were treated for 48 or 72h with MIS416, MIS416-SS-controlsiRNA and MIS416-SS-STAT3. 
Q-RT-PCR was performed on cDNA generated from by total RNA extracted from treated cells. 
Downregulation of STAT3 mRNA levels occurs at both timepoints in all samples treated with 
MIS416-SS-STAT3 compared to controls. The relative level of expression of STAT3 was set to 1 
for the untreated sample. The relative quantification was carried out using Biogazelle’s qbase+ 
software. Error bars represent SEM. Results that were not significant are marked with ns while 
significant results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 
0.0005).  This experiment was repeated three times. 
 
4.11. Quantification of STAT3 protein levels after treatment 
with MIS416 siRNAs conjugates. 
 
Western blot studies were performed to evaluate STAT3 protein levels after 
treatment of BMDCs with MIS416, MIS416-biotin-streptavidin-SS-STAT3-FAM 
(MIS416-SS-STAT3) and MIS416-biotin-streptavidin-SS-controlsiRNA-FAM 
(MIS416-SS-controlsiRNA). STAT3 protein levels were quantified using β-actin 
for gel loading normalization. The results showed that there were significant 
differences between DCs treated with MIS416-SS-controlsiRNA and MIS416-SS-
STAT3 at 48 (P = 0.049) and at 72h (P=0.021) (Figure 34). Furthermore 
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downregulation of about 45% and 60% of STAT3 protein levels was achieved at 
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Figure 34: Western blot quantification of STAT3 protein levels  
DCs were treated for 48 or 72h with MIS416, MIS416-SS-ControlsiRNA and MIS416-SS-STAT3. 
Protein were extracted from treated cells and analyzed by ECL Western Blot using ß-Actin as 
reference gene for normalization. 
A: representation of 3 different experiments. Relative STAT3 protein levels were calculated by 
dividing STAT3 expression levels by ß-Actin expression levels previously quantified using ImageJ 
software. Error bars represent SEM. Results that are not significant are marked with ns while 
significant results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 
0.0005). These experiments were repeated three times. 
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B: example of quantification of STAT3 and ß-Actin level of expression. Numbers represent 
quantification of the band intensity using ImageJ software. Untreated cells expression STAT3 and 
ß-Actin expression level were set to 1 in each experiment to be able to compare multiple experiments 
 
To conclude, STAT3 was chosen as a suitable protein target to determine wheter a 
MIS416-SS-STAT3 siRNA conjugate was able to downregulate both Stat3 mRNA 
and protein levels. QT-RT-PCR experiments with this new conjugate suggested that 
MIS416-SS-STAT3 was able to downregulate Stat3 RNA levels compared to 
MIS416-SS-controlsiRNA. The protein level of STAT3 was also downregulated 
after 48 and 72h of treatment with MIS416-SS-STAT3 compared to MIS416-SS-
controlsiRNA. These experiments have therefore addressed the main question 
being asked in this chapter of whether MIS416 can deliver functional siRNAs to 
DCs to downregulate the expression of genes of interest. 
 
4.12. Discussion  
RNAi technology can be used to regulate gene expression in target cells, and the 
idea of coupling siRNAs to MIS416 to further increase the ability of these 
microparticles to enhance the immune response is appealing. The choice of a 
potential siRNA target required some thought since it had to be specifically 
designed to affect the main population of cells targeted by the delivery system (in 
the case of MIS416 , APCs) and at the same time have a strong effect over a short 
time period.  The rationale for initially choosing Bim was as follows. Circulating T 
cells, that are not able to kill tumor cells due to an immunosuppressive tumor 
microenvironment, are still able to kill circulating DCs that express the specific 





antigens that can be recognized by the T cells. This effect could reduce the capacity 
of APCs to induce an immune response against pre-existent tumors (Chen and 
Wang 2010). This idea is also supported by the fact that autologous DCs transplants 
fail to induce an antitumor activity in the majority of patients treated in clinical 
trials (Castera, Hatzfeld-Charbonnier et al. 2009, Kim, Kang et al. 2009, Anguille, 
Smits et al. 2014). To improve the immune response and increase the resistance of 
activated DCs to CD8 killing, the downregulation of the Bim protein was thought 
to be a good initial target of interest for siRNA therapy associated with MIS416 
delivery because: Bim has been shown to play a crucial role in the regulation of 
homeostasis and apoptosis in DCs and lymphocytes (Bouillet, Metcalf et al. 1999). 
This BH3-only protein has also been linked to autoimmunity and its dysregulation 
leads to an increase resistance to apoptosis in DCs (Chen, Triola et al. 2011). DCs 
derived from Bim-/- mice also have increased survival compared to their wild type 
counterparts after transfer into recipient mice. These findings support the idea that 
a temporary knock down of Bim in activated DCs expressing an associated tumor 
antigen could lead to a strong immune response improved by the synergistic effect 
of the adjuvant properties of MIS416. MIS416 was conjugated to an siRNA 
targeting Bim after previously evaluating of the effectivness of the siRNA sequence 
to knockdown Bim using standard transfection procedures on DCs. Both Bim 
protein levels (Figure 28) and mRNA levels (Figure 29) were downregulated in 
cells treated with MIS416-SS-Bim compared to untreated cells. However the 
treatment with MIS416 alone was able to downregulate Bim mRNA levels masking 
the effect of the siRNA in MIS416-SS-Bim conjugate, and resulting in no 
significant difference between the two treatments. This results was contradictory to 





previous experiments carried out by other groups in which TLR ligands given to 
DCs were able to upregulate Bim protein levels (Chen, Huang et al. 2007). Since 
MIS416 contains TLR ligands such as CpGs, it was hypothesized that treatment 
with MIS416 would upregulate Bim mRNA levels but the experimental evidence 
(Figure 29) suggested the contrary. MIS416 also contains NOD-2 ligands and other 
important immunostimulatory molecules that may have affected Bim mRNA levels 
acting on unknown protein targets. Furthermore these results were unsatisfactory 
since the downregulation of Bim mRNA levels caused by MIS416 alone, strongly 
interfered with the analysis of the downregulation caused by MIS416-SS-Bim 
conjugate. This negative result was also confirmed by further Q-RT-PCR 
experiments (Figure 30). However, different reference genes were used in the two 
analyses (Westernblot: ß-actin Q-RT-PCR: Gapdh), which means that the results 
are not fully comparable. The effect of MIS416 on ß-actin mRNA level in DCs is 
minimal as showed in Figure 19 A and this difference would most likely not 
interfere with the analysis of final results. Gapdh was preferred as the reference 
gene for Q-RT-PCR since MIS416 treatment showed almost no effect on Gapdh 
mRNA expression and Gapdh exhibited better average expression stability values 
compared to ß-actin (Figure 19 B). Furthermore, naked siRNAs were not used in 
DC transfections as a negative control since it has been previously been shown that 
naked siRNAs have no effect unless they are transfected using specific carriers to 
avoid lysosomal degradation (Lingor, Michel et al. 2004), or they are at a very high 
concentration (>100nM) leading to cytotoxicity (Overhoff, Wunsche et al. 2004). 
To be able to evaluate the mRNA downregulation caused by a siRNA coupled to 
MIS416, a new more suitable mRNA target was necessary. Ideally the treatment 





with MIS416 should not downregulate the mRNA levels of the new target gene. 
This would allow an easier evaluation of the specific mRNA downregulation caused 
by the siRNA coupled to MIS416. The MIS416 effect on the mRNA levels of three 
candidate genes (Minor, IL10r1 and Stat3) was evaluated (Figure 30). These genes 
were selected as potential targets for siRNA therapy on DCs after a literature review 
(for rationale on the choice of target genes, see Chapter 4, paragraph 4.7). The 
results showed that both IL-10R1 and Minor mRNA levels were negatively affected 
by the treatment with MIS416. As a consequence, Stat3 was chosen as the preferred 
candidate genes since its expression levels were upregulated after the treatment with 
MIS416. The upregulation of Stat3 in DCs after uptake of MIS416 was most likely 
caused by the auto/paracrine production of IL-6 and IL-10 (Rebe, Vegran et al. 
2013). This effect is thought to have limited the ability of DCs to produce higher 
levels of IL-12 and TNF- α under TLR stimulation (Iwata-Kajihara, Sumimoto et 
al. 2011) possibly limiting the potential effect of MIS416. This experiment also 
showed that the treatment with MIS416 can impact the expression many of 
important genes in DCs. Immune response related genes such as IL-10R1 and the 
apoptosis regulator Minor were downregulated after the treatment with MIS416 
leading to activation of DCs towards a non-immunosuppressive phenotype 
favoured by the dimished potential responsiveness to IL-10 in the tumor 
microenvironment by DCs. Since MIS416 is seen as a threat and recognized as a 
pathogen, the expression of a wide range of genes is modified in response to 
MIS416 uptake. A more in-depht study regarding the effect of MIS416 on DCs 
gene expression should be considered. For example a microarray based approach 





could produce insightful data that could be used to further exploit MIS416 as a 
delivery system to DCs. 
A new MIS416/siRNA conjugate was prepared (MIS416-SS-STAT3) and tested on 
DCs. Stat3 RNA levels were significantly downregulated after treatment of DCs 
with the new conjugate for 48 and 72h compared to controls (Figure 33). Both 
MIS416 and MIS416-SS-controlsiRNA were able to upregulate Stat3 mRNA 
levels. The effect of MIS416 alone on Stat3 mRNA levels after 48h of treatment 
was similar to previous results (1.5x upregulation, Figure 30), however at 72h the 
results between the two experiments were different (1.3x upregulation in Figure 30 
compared to 2.8x in Figure 33). Further experiments on Stat3 protein levels (Figure 
34) showed that MIS416-SS-STAT3 was able to downregulate Stat3 protein levels 
significantly compared to MIS416-SS-controlsiRNA at both time points tested (48 
and 72h). A difference was noticed in Stat3 mRNA and protein levels after MIS416 
treatment compared to untreated cells. Stat3 mRNA levels were upregulated after 
MIS416 treatment (Figure 33) but protein levels remain unchanged (Figure 34).  
In conclusion the second objective of this PhD project was mostly achieved. The 
preparation of MIS416/siRNAs conjugates was successful and new conjugates were 
able to downregulate target protein levels. The results in this chapter suggested that 
MIS416 could be used as delivery platform for siRNAs, however in vivo 
experiments would be necessary to prove the efficacy of the new MIS416/siRNA 
conjugates in a therapeutic setting.
















Results: Evaluation of the immunomodulation capabilities 

















5. Evaluation of the immunomodulation capabilities of 




In this PhD project, the MIS416 platform was used as a delivery system for siRNAs 
and peptides. In the first two results chapters I focused attention on the optimization 
of the conjugation strategy to couple fluorescent probes to MIS416 (chapter 3) and 
coupling experiments with siRNAs and potential effects of the newly developed 
MIS416/siRNAs conjugates on protein and mRNA levels of Bim and Stat3 (chapter 
4). In the third and final results chapter the experiments carried out were mainly 
designed to evaluate the effects that MIS416 has on APCs and how the 
MIS416/SIINFEKL conjugates can improve T cell responses. I hypothesize that 
MIS416/SIINFEKL conjugates would be quickly internalized by APCs such as 
DCs and macrophages. Furthermore, MIS416/SIINFEKL conjugates would induce 
activation of the APCs mediated by TLR9 and NOD2 receptors. The activation of 
DCs would then lead to a specific T cell response against the model antigen 
SIINFEKL. Activated DCs would also secrete cytokines that would facilitate 
proliferation of antigen specific T cells in vitro. To verify the first hypothesis 
regarding the targeting of MIS416, uptake experiments with a fluorescent version 
of MIS416 (MIS416-PE) were designed. The activation state of MIS416 pulsed 
DCs was evaluated by measuring the expression of costimulatory molecules on the 
DCs surface. Furthermore, the ability of MIS416/SIINFEKL conjugate to deliver 
the antigen to DCs was also evaluated by measuring SIINFEKL/MHC class I 





complexes on the surface of DCs. Moreover, the ability of OT-1 T cells (CD8+ T 
cells engineered to recognized SIINFEKL peptide expressed onto MHC class I 
molecules) to proliferate after antigen recognition was tested in co-culture 
experiments with DCs pulsed with different combinations of SIINFEKL and 
MIS416. During these co-culture experiments, the activation state of OT-1 T cells 
was evaluated by measuring the expression of CD69. Cytokines secreted by DCs 
and OT-1 T cells were also measured in order to evaluate if MIS416 was having an 
effect on the production of IL-6, IL10, TNF-α and IFN-γ.  These cytokines were 
chosen since they play a major role in tumor control and in the regulation of the 
immune cells involved in the adaptive response against cancer cells. For example, 
IL-6 production by DCs is important for the generation of CD8+ memory cells 
(Daudelin, Mathieu et al. 2013). Furthermore, IL-6 induces the differentiation of B 
cells into plasma cells able to produce immunoglobulins (Tanaka and Kishimoto 
2014). On the other hand, IFN-γ and TNF-α produced by Th1 cells have been linked 
to both anti-tumor immunity and cancer progression (Zaidi and Merlino 2011). 
TNF-α has different roles in the tumor microenvironment since it can induce 
angiogenesis and tumor proliferation and it can also induce apoptosis in tumor cells 
(Wang and Lin 2008). However, I hypothesize that DCs treated with MIS416 would 
produce high levels of TNF-α since its production has been linked to an anti-
microbial immune response (Merlin, Gumenscheimer et al. 2001). The ability of 
MIS416/SIINFEKL conjugate-pulsed DCs to activate OT-1 T cells will be 
evaluated both in vitro and in vivo. These experiments will be also carried out to 
understand if conjugates A and B were able to initiate a specific immune response 
against the peptide antigen SIINFEKL. This is an important step towards the 





demonstration of MIS416/SIINFEKL conjugates to induce a specific immune 
response able to eradicate tumor cells. 
  
5.1. Visualization of MIS416-PE conjugate uptake by BMDCs. 
 
The aim of these preliminary microscopy experiments was to visualize the uptake 
of MIS416 into BMDCs. A fluorescent version of MIS416 with phycoerythrin 
(MIS416-biotin-strepatidin-PE) was added to cultures of BMDCs for 1, 4 or 24h 
and images were acquired. Nuclei were stained with DAPI while CD11C-APC 
antibody was used to identify BMDCs. Results showed that MIS416 was readily 
internalized by BMDCs after 1 hour (Figure 35A) and the amount of MIS416-PE 
accumulated in the cytoplasm was increased in later timepoints. At 24h almost 




Figure 35: Internalization of MIS416-PE (MIS416-biotin-streptavidin-PE) by 
BMDCs. 
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DCs (2x105on coverslips in 250 μL of media) were treated with MIS416-PE (3μg) for 1, 4 and 24h. 
After incubation, cells were washed in PBS and stained with PFA 4%. Staining used: green, red and 
blue for CD11C-APC, MIS416-PE and DAPI (nuclei) respectively. CD11C-APC was incubated at 
1 g/106 cells in 100 L of PBS for 30 min at 4°C. Images were taken using a Zeiss LSM 710 
confocal microscope Figure A, B and C represents time points at 1, 4 and 24h respectively. This 
experiment was repeated 3 times. 
BMDCs on coverslips were treated with MIS416-PE conjugate (3μg) for 1, 4 or 
24h. After incubation coverslips were gently washed in PBS and treated with 
paraformaldehyde 4% (PFA) in PBS (300 L) for 20 min to fix the cells. CD11C-
APC antibody (clone N418, Biolegend) was used to identify BMDCs cell surface. 
The antibody was incubated at 1 g/106 cells in 100 L of PBS for 30 min at 4°C. 
 
5.2. Uptake experiments with MIS416-PE on splenocytes 
 
MIS416 has been described as a microparticulate platform able to deliver attached 
cargo to APCs (Girvan, Knight et al. 2011). To further assess the targeting 
capabilities of MIS416, the uptake efficiency of various cell populations in the 
spleen was analysed using flow cytometry. In this series of experiments splenocytes 
were pulsed with MIS416-PE conjugate for 1, 4 or 24 hours and the capability of 
macrophages, DCs, T cells, neutrophils and B cells to acquire MIS was assessed. 
Different cell populations (Macrophages, DCs, T cells, Neutrophils and B cells) 
were identified with specific antibodies (F480, CD11c, CD3, LY6, B220) 
respectively. A 4°C control was used to evaluate non-specific binding of MIS416-
PE to cell surfaces. 
Results showed that all the populations tested apart from T cells (negative control) 
were able to internalize MIS416-PE. 80% of the macrophages after 24h of uptake 





were positive for MIS416-PE while only around 40% of neutrophils, B cells and 
DCs were positive. There were no major differences between the timepoint at 1 and 
4h showing that uptake of the microparticle occurred rapidly in vitro. However at 
the 24h timepoint, the uptake by macrophages increased by about 20% compared 
to the previous timepoint. This was dependent on MIS416-PE concentration. The 
different concentrations of MIS416-PE tested (1, 5, 25μg) were directly correlated 
to the extent of uptake showing that higher concentrations were able to induce a 
higher internalization of MIS416-PE. Uptake experiments at 4 °C showed that 
around 10% of the PE positivity at 37°C was due to MIS416-PE binding to the 
surface of target cells instead of specific uptake and that macrophages were more 
prone to this effect since they showed the higher PE positivity at 4 °C in all the 
timepoints tested. 
To conclude all APCs tested were able to take up MIS416-PE microparticles to an 
extent while T cells (negative control) could not. 
 













Figure 36: Uptake experiment on splenocytes 
Splenocytes (2x106 in 2 mL of media) were pulsed with MIS416-PE (5ug) for 1, 4 or 24h. After 
incubation, cells were collected and with different antibodies (LY6, B220, CD11c , F480, CD3, 1 
g/106 cells of each antibody in 100 L of  PBS) to identify different cell populations (Neutrophils, 
B cells, DCs, Macrophages and T cells) respectively. Figures represent a comparison between the 
unspecific binding at 4°C and uptake at 37 °C. The gating strategy is explained in Figure 59 
(Appendix).Error bars represent SEM. Results that are not significant are marked with ns while 
significant results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 
0.0005). This experiment was repeated three times 
 
5.3. Evaluation of the ability of MIS416 to upregulate specific 









Assessment of activation markers on BMDCs was undertaken to determine whether 
MIS416 was able to induce activation of this APC. As a second aim, the series of 
experiments was designed to evaluate if the biomolecules used in the conjugation 
strategy (Streptavidin and Biotin) were able to activate DCs. BMDCs were pulsed 
with various concentrations of MIS416 or LPS for 24 or 48h. Cells treated with 
biotin or streptavidin were used as negative controls while LPS was used as a 
positive control. Results showed upregulation of MHC class II, CD80, CD86 and 
CD40 after treatment of DCs with MIS416 (Figure 37A and B). The degree of 
upregulation varied for each activation marker tested. However the degree of 
activation was directly correlated with the concentration of MIS416 used in these 
experiments. Furthermore BMDCs treated with biotin and streptavidin showed no 
sign of activation (Figure 38). These preliminary results suggested that MIS416 was 
able to activate DCs. This process is essential to allow the DCs to migrate to the 
lymph nodes and subsequently activate T cells. The expression of activation 
markers was also evaluated after BMDCs interaction with conjugation A and B for 
24h to further prove that chemical modifications to MIS416 have no effect on DC 
activation. Results in Figure 39 showed that there were no major differences in the 


























































DCs (1x106 in 2 mL of media) were treated with LPS (1 g) and MIS416 (1, 5, 10 g). Cells were 
collected and stained in live/dead assays (0.05 L plus 100 L of PBS for each sample) and with 
different antibodies to detect activation markers (CD86, CD40, CD80, MHC class II) and DCs 
(CD11c). The concentration used for antibodies was 1 g/106 cells of each antibody in 100 L of 
FACS buffer for 15min at 4°C. 
A: Evaluation of CD86 expression on BMDCs. In the top part of the figure BMDCs were gated on 
dimension, Live/Dead and CD11c+ to identify DCs. In the lower part the histogram represent CD86-
PE expression after the gating strategy. 
B: Evaluation of the expression of MHC class II (1), CD80 (2) and CD86 (4) on BMDCs. Y axis 
represents the Mean Fluorescence Intensity (MFI). Figure 37B-3 represents the % of positive cells 
for CD40 instead of MFI. 
Results in Figure B are derived from flowcytometry plots in which the gating strategy is explained 
on Figure A. Error bars represent SEM. Results that are not significant are marked with ns while 
significant results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 




Figure 38: Example of gating strategy for the evaluation CD86 expression on BMDCs 
pulsed with Biotin or Streptavidin. 
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A: Forward scatter and Side scatter gating.B: gate on live/Dead to identify alive cells (negative 
population). C: Gate on CD11c+ to identify DCs. D: the histogram represents CD86-PE expression 
after the previous gating strategy. This experiment was repeated three times. 
 
 
Figure 39: Evaluation of activation marker expression on DCs after treatment 
with conjugation A and B 
DCs (1x106 in 2 mL of media) were treated with MIS416, LPS (1 g), and conjugates A and B (1 
g each). Cells were collected and stained in live/dead assays and with different antibodies to detect 
activation markers (CD 86, CD40, CD80, MHC class II) and DCs (CD11c). The concentration used 
for antibodies was 1 g/106 cells of each antibody in 100 L of FACS buffer for 15min at 4°C. 
A: Evaluation of CD86 expression on BMDCs pulsed with Conjugates A or B. Y axis represents the 
MFI  
B: Evaluation of CD40, CD80 and MHC class II expression on BMDCs pulsed with Conjugates A 
or B. Y axis represents the MFI. This experiment was repeated three times 
 
5.4. Evaluation of the expression of SIINFEKL by DCs after 
stimulation with MIS416-SIINFEKL conjugates. 
The internalization and processing of MIS416 by DCs promotes the activation and 
increases expression of costimulatory molecules such as CD40, CD80 and CD86 
on DCs (Figure 37B). I hypothesized that this adjuvant effect would synergize with 
the enhanced expression of MHC class molecules on the surface of DCs allowing 
better presentation of the antigen together with increased costimulatory signal to T 
cells. To test this hypothesis, an in vitro assay was developed in order to test if 
A B 





BMDCs were able to process MIS416/SIINFEKL conjugates efficiently and 
subsequently express the model tumor antigen SIINFEKL into MHC class I 
molecules. BMDCs were pulsed with MIS416/SIINFEKL conjugates A and B and 
SIINFEKL expression on MHC class I molecules was measured by flowcytometry. 
Results showed that approximatly 20% of DCs cells pulsed with SIINFEKL alone 
were able to express the peptide antigen at 12 hours. However this effect slowly 
faded over the next 40 hours (Figure 40). Conversely, DCs pulsed with the same 
amount of SIINFEKL conjugated to MIS416 (conjugates A and B) were able to 
express the peptide antigen at higher levels at earlier time points (4 and 12 hours) 
compared to SIINFEKL alone.  Expression levels further increased at 24 and 48 
hours. No significant differences were found between conjugate A and B at 
different timepoints tested. DCs treated with PBS and MIS416 were used to set the 
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Figure 40: Percentage of DCs positive for SIINFEKL/MHC staining:  
DCs (1x106 cells in 1 mL of media) were treated for 4,12,24 and 48h with PBS (50 L), conjugates 
A or B (5 g), MIS416 (5 g), SIINFEKL (0.2 ng) a combination of MIS416 and SIINFEKL (5 g 





and 0.2 ng respectively), biotin-ttds-SIINFEKL-FAM (0.5 ng) and biotin-SS-SIINFEKL-FAM (0.5 
ng). Cells were collected and stained with live/dead, CD11c and and antibody to detect 
SIINFEKL/MHC class I complexes. This experiment was repeated three times 
 
5.5. Evaluation of OT-1 T cell proliferation and CD69 
expression. 
SIINFEKL was chosen as a model tumour antigen in this research because T cells 
derived from transgenic mice with a T cell repertoire specific for SIINFEKL (OT-
1 T cells) are a useful immunological tool  to evaluate the immune response to our 
chosen vaccine. I hypothesized that OT-1 T cells in co-culture with DCs pulsed 
with MIS416/SIINFEKL conjugates would be able to proliferate in response to the 
recognition of SIINFEKL/MHC complexes on the surface of DCs. Furthermore the 
expression of CD69 (a T cell activation marker) was evaluated. BMDCs were 
pulsed with conjugates A and B or a combination of MIS416 and SIINFEKL for 
24h. Biotin-SIINFEKL-FAM (the biotinylated version of SIINFEKL used to 
prepare conjugate B) and SIINFEKL were used as positive controls while MIS416 
and untreated cells were used as negative controls. Activated BMDCs after 
treatment with various conjugates were co-cultured for 3 days with OT-1 T cells 
and CD69 expression was assessed. Results showed that BMDCs pulsed with 
SIINFEKL alone or conjugated with MIS416 were able to induce proliferation of 
OT-1 T cells (Figure 41A). Five peaks representing different rounds of mitosis were 
identified. Overall results in Figure 41B showed that there was a significant 
difference in OT-1 T cell proliferation induced by BMDCs treated with conjugates 
A or B. Furthermore, CD69 expression was enhanced in T cells that were activated 





by DCs pulsed with conjugate A compared to conjugate B (Figure 42). Moreover, 
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Figure 41: Evaluation of OT-1 T cell proliferation 
BMDCs (5x105, in 1 mL of media) were pulsed with SIINFEKL (0.5 g), MIS416 alone (0.5 g) or 
with the addition of SIINFEKL, conjugate A (0.5 g) and B (0.5 g) and biotin-SIINFEKL-FAM 
A 
B 





(1 g). Untreated cells were used as negative control. After 24 hours, OT-1 (5x105) cells were co-
cultured with previously pulsed DCs (5x104) for 72h. OT-1 T cells were pre-stained with VPD450 
proliferative dye. Cells were stained with live/dead assays (0.05 L plus 100 l of PBS for 15 min 
at 4°C)CD8 and CD69(1 g/106 cells of each antibody in 100 L of  FACS buffer for 15min at 4°C). 
A: Example of gate strategy: A: Forward scatter and Side scatter gating to identify lymphocytes. B: 
gate on live/Dead to identify alive cells (negative population). C: Gate on CD8+ to identify OT-1 T 
cells D: the histogram represents VPD450 proliferative dye staining of OT-1 T cell. Peaks reflect 
multiple dilutions of VPD450 dye in OT-1 T cell identifying different rounds of mitosis. OT-1 T 
cells co-cultured with untreated DCs were used as negative controls to identify OT-1 T cells at a 
non-proliferative stage. 
B: Combined results of 5 OT-1 T cell proliferation assays. The percentage of proliferation for each 
sample was calculated with FlowJo (V9) flow cytometry data analysis software. Results that are not 
significant are marked with ns while significant results are marked with * depending on the P values 
(* P < 0.05, ** P < 0.005, *** P < 0.0005). This experiment was repeated three times. 
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Figure 42: Evaluation of OT-1T cell activation markers profile. 
BMDCs (5x105, in 1 mL of media) were pulsed with SIINFEKL (0.5 g), MIS416 alone (0.5 g) or 
with the addition of SIINFEKL, conjugation A (0.5 g) and B (0.5 g) and biotin-SIINFEKL-FAM 
(1 g). Untreated cells were used as negative control. After 24 hours, OT-1 (5x105) cells were co-
cultured with previously pulsed DCs (5x104) for 72h. OT-1 T cells were pre-stained with VPD450 
proliferative dye. Cells were stained with live/dead assays (0.05 L plus 100 l of PBS for 15 min 
at 4°C) CD8 and CD69(1 g/106 cells of each antibody in 100 L of  FACS buffer for 15min at 









5.6. Quantification of cytokine secretion by OT-1 T cells. 
 
Cytokine secretion is an important factor in the development of a strong anti-tumour 
response. I hypothesized that MIS416 adjuvant properties would be able to induce 
activation of DCs leading to an enhanced secretion of cytokines important for T cell 
activation. The cytokine profiles of OT-1 T cells were assessed measuring the 
amount of cytokines released in the media of co-culture experiments with pulsed 
DCs. A similar assay was previously carried out by InnateTherapeutics (Girvan, 
Knight et al. 2011), however only the supernatant of DCs following the treatment 
with MIS416 was analyzed. ELISA assays were carried out to measure the 
production of IL-6, IL10,TNF-α and IFN-γ.  Results showed production of IFN-γ 
at both 48 and 72h with a ~5 fold increase at 72h compared to 48h (Figure 43A). 
There is a significant difference between conjugate A and B at 48h, however this 
difference was not significant at 72h. Regarding TNF-α  (Figure 43B), the secretion 
of this cytokine began at 24h and slowly increased at later time points. There was a 
significant difference between SIINFEKL and MIS416+SIINFEKL and conjugate 
A at 24h, however these differences were not significant at 48 and 72h. The 
production of IL-10 (Figure 43C) followed a similar trend to TNF-α  with some 
differences. Samples in which DCs were treated with MIS416 (alone or in 
combination with SIINFEKL) tended to have a higher amount of IL-10 compared 
to treatment with SIINFEKL or biotin-SIINFEKL-FAM. Regarding IL-6 (Figure 
43D), conjugate A and B were able to induce a greater production compared to 
MIS416+SIINFEKL and SIINFEKL at 24 48 and 72h, however the difference with 
MIS416+SIINFEKL was not significant at 72h.  







Figure 43: Evaluation of OT-1T cell cytokines profile. 
Supernatants (50 μL) from co-culture experiments between DCs and OT-1 T cells of previous 
experiments (Figure 41 and 42) were analyzed to measure the production of different cytokines 
(Interferon gamma, TNF-alpha, IL-10 and IL-6). Samples were analysed using a sandwich ELISA 
assay. Standard curves were prepared for each cytokines and were used to determine the cytokines 
concentration in all the samples. Results that are not significant are marked with ns while significant 
results are marked with * depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). 











5.7. In vivo cytotoxicity induced by different MIS416 conjugates. 
 
In order to understand whether MIS416/SIINFEKL conjugates were able to induce 
an antigen-specific anti-tumour immune response, an in vivo cytotoxicity assay was 
undertaken. An initial in vivo pilot study was carried out to evaluate the optimal 
dose of MIS416/SIINFEKL conjugates to be injected subcutaneously to initiate an 
immune response against the peptide antigen SIINFEKL. Mice were vaccinated 
with different concentrations of MIS416/SIINFEKL conjugates and then injected 
intravenously (i.v.) with two different populations of fluorescently-stained target-
cells. One target-cell population was pulsed with SIINFEKL prior to injection while 
the second one was untreated. After two days mice were sacrificed and the specific 
killing of SIINFEKL pulsed splenocytes was evaluated by cytofluorimetric 
analysis. Results showed specific cytotoxic activity in mice vaccinated with the 
three doses of MIS416/SIINFEKL conjugate and positive controls (in Figure 44B). 
However there were reproducibility issues since only three mice for each group 
were used. For further experiments a lower dose of MIS416/SIINFEKL conjugate 
(100μg) was used since the percentage of specific cytotoxicity achieved in these 
samples was a ~60% and it was optimal for the detection of differences between 
different treatments that could enhance this effect. The vaccination efficacy 
between conjugate A (disulfide bond) and conjugate B (no disulfide bond) was 
compared together with negative controls (PBS and MIS416) and positive controls 
(CpG + SIINFEKL or CpG + OVA) (Figure 44C). The overall results showed a 
lower amount of specific cytotoxicity in general compared to the pilot study. This 
was noticeable especially in the positive controls that failed to achieve >90% of 





specific cytotoxicity. Conjugate B was more effective in inducing a specific 
cytotoxicity than conjugate A leading to the possible conclusion that the disulfide 
bond was not stable in vivo since the efficacy of conjugate A is similar to MIS416 
+ SIINFEKL (not conjugated). Furthermore the vaccination with conjugate B was 
able to achieve a degree of specific downregulation similar to positive controls 
(CpG+SIINFEKL or CpG+OVA). The percentage of specific cytotoxicity was 
calculated using the ratio between cells stained with VPD450 (pulsed with 
SIINFEKL) and CFSE (unpulsed) of the vaccinated groups compared to the control 
group (PBS). To conclude, this series of experiments showed that the disulfide bond 
in the linker between MIS416 could be unstable in vivo allowing a fast release of 





















Figure 44: Evaluation of specific cytotoxicity induced by vaccination with 
MIS416/SIINFEKL conjugates. 
A: Gating strategy: cells were gated for live/dead staining and doublets. Cells positive for CFSE 
were untreated while VPD450 was used to stain splenocytes pulsed with SIINFEKL. 
B: Pilot study: 3 mice were used in each group and they were vaccinated with 100,250,500 μg of 
MIS416 conjugate (SIINFEKL concentration 1.57 μg for 100 μg of MIS416), MIS416 alone (100 
μg), PBS (100 μL), or CpG plus Ovalbumin (10 μL of OVA + 50μg of CpG). After 1 week mice 
were challenged with two population of splenocytes (1 x 107  cells, pulsed with SIINFEKL or not) 
and after two days specific cytotoxicity was evaluated.  
C: 6 mice were used in each group and they were vaccinated with Conjugates A or B (100 μg), 
MIS416 (100 μg) plus SIINFEKL (2 μg), MIS416 alone (100 μg), PBS (100 μL), CpG plus 
SIINFEKL (2 μg) or CpG plus Ovalbumin (10 μL of OVA + 50μg of CpG). After 1 week mice were 
challenged with two population of splenocytes (1 x 107 cells, pulsed with SIINFEKL or not) and 
after two days specific cytotoxicity was evaluated. CpG + OVA was used as positive control while 
PBS and MIS416 were negative controls. . The difference between Conj B, CPG+SIINFEKL and 













5.8. Discussion  
 
MIS416 and MIS416/SIINFEKL conjugates were tested in different immunological 
settings to evaluate their adjuvant activity and whether MIS416/SIINFEKL could 
induce an antigen-specific T cell response. MIS416 adjuvant activity was tested on 
DCs to determine whether activation markers and the expression of markers (CD80, 
CD86, MHC class II, CD40) were enhanced after uptake. Results (Figure 40) 
showed that all activation markers were upregulated and the degree of activation 
was dose-dependent. Girvan et al., previously reported similar results (Girvan, 
Knight et al. 2011), however their experiments were carried out with different doses 
of MIS416 and on human derived DCs. Another group obtained similar results 
using a bacterial-derived microparticle that was also used to deliver the peptide 
antigen SIINFEKL (Meraz, Melendez et al. 2012).  
We wished to determine whether biotin and streptavidin had an effect on DC 
activation. Results showed that there was no effect on DCs, and that these molecules 
were suitable to use as conjugation strategies allowing MIS416 to be used in vivo. 
Streptavidin and biotin are also currently used in clinical trials in which streptavidin 
is bound to an antibody or other molecules. These studies (Breitz, Weiden et al. 
2000, Lazzeri, Pauwels et al. 2004, Shen, Forero et al. 2005, Park, Shenoi et al. 
2011) did not show cytotoxicity related to the use of streptavidin. On the other hand, 
immunization with MIS416 conjugates could lead to the generation of anti-
streptavidin antibodies. However this hypothesis has not been tested. The 
generation of anti-streptavidin or anti-MIS416 antibodies could potentially 





facilitate the uptake of MIS416 by antigen presenting cells so, in the case of 
MIS416, I speculate that this would not be a disadvantage. Previous results from 
Girvan et al., were also confirmed regarding the uptake of MIS416 from DCs. 
Furthermore, uptake experiments on splenocytes showed that all APCs tested were 
able to take up MIS416-PE microparticles efficiently. Macrophages were the main 
population targeted by MIS416-PE (~80% positivity at 24h) while only ~40% of 
DCs were positive. These results strongly suggest that MIS416 could be used to 
efficiently target infiltrating macrophages at the tumor site as suggested by a recent 
paper (Khan, Kolomeyevskaya et al. 2015). However, Khan et al., showed that 
MIS416 treatment alone in tumor bearing mice was also able to increase the amount 
of infiltrating MDSC which are likely to reduce the adjuvant effect of MIS416. Data 
from this study showed that the use of an anti-CD11b antibody, in order to deplete 
infiltrated MDSC, was beneficial if associated with MIS416-OVA vaccination 
treatment. This combined treatment regime significantly delayed tumor progression 
in a murine model of ovarian cancer compared to vaccination alone, demonstrating 
that myeloid depletion synergizes with MIS416 treatment. Taking into 
consideration these results, the coupling of STAT3-siRNA to MIS416 could alter 
tumor-infiltrating MDSC homeostasis as suggested by a recent study (Hossain, Pal 
et al. 2015). Hossain et al., showed that the immuno suppressive potential of MDSC 
in prostate cancer patients could be abrogated by treatment with CpG-STAT3 
siRNA. This result complements previous results from Khan et al., and suggests 
that the vaccination potential of MIS416/SIINFEKL conjugates could be improved 
by the co-delivery of STAT3 siRNAs. Conjugates A (disulfide) and B (no disulfide) 
were able to deliver the peptide antigen to DCs both in vitro (Figure 43) and in vivo 





(Figure 47). Interestingly, the amount of SIINFEKL presented on MHC molecules 
is slightly higher (although not significantly) on DCs treated with 
MIS416/SIINFEKL conjugates containing a disulphide bridge (conjugate A) 
compared to the conjugate without a reducible linker (conjugate B). This minor 
increase (not significant for the SIINFEKL expression on MHC I) could be 
amplified in the context of OT-1 T cell proliferation since the exponential growth 
of cells in 3 days could be influenced by an earlier increased amount of SIINFEKL 
presented by DCs. Furthermore, in vitro and in vivo results were discordant since 
no significant differences were found between conjugate A and B in vitro at the 
different timepoints tested. However, the in vivo cytotoxicity experiment showed 
that conjugate A was less effective in inducing specific cytotoxicity compared to 
conjugate B. This unexpected result could have been caused by the dissociation 
between MIS416 and SIINFEKL in vivo or by an incorrect preparation of conjugate 
A used in the in vivo experiment. Furthermore conjugate A (SS) could be unstable 
in vivo due to potential instability of the disulfide bond in vivo as suggested in this 
review (Brulisauer, Gauthier et al. 2014). However, multiple studies using 
nanoparticles possessing a disulfide bond (Qiao, Zhang et al. 2011, Chacko, 
Ventura et al. 2012, Song, Lou et al. 2014, Chan and Lin 2015) showed no signs of 
specific disruption of the disulfide bridge in vivo. Furthermore, the stability of the 
disulphide bond in vivo depends on the steric hindrance of the carbon atoms 
adjacent to the disulfide linkage (Kellogg, Garrett et al. 2011). The carbon atoms 
close to the disulphide in conjugate A are not hindered due to the carbon-based 
spacers between biotin-SS-SIINFEKL and this could lead to a faster release in 
plasma/blood (Kellogg, Garrett et al. 2011). As a consequence, further biotinylated 





probes should be designed taking in consideration the hindrance of the carbon 
atoms close to the disulphide. Furthermore, the stability of biotin/streptavidin bonds 
is high (dissociation constant (Kd) is in the order of ≈10−14 mol/L) (Holmberg, 
Blomstergren et al. 2005) and MIS416/SIINFEKL conjugates without a disulphide 
are stable in in vivo experiments. 
A literature search highlighted contrasting results regarding the mechanism of 
disulfide reduction in endosomal/lysosomal compartments. For example, Austin et 
al., showed that recycling endosomes, late endosomes, and lysosomes are not 
reducing environments for disulfides (Austin, Wen et al. 2005). However, Yang et 
al., showed with FRET imaging that the reduction of disulfide bonds occurred in 
early endosomes (Yang, Chen et al. 2006). Multiple studies (Chong, Sexton et al. 
2009, Li, Luo et al. 2013, Gaowa, Horibe et al. 2015, Yao, Tai et al. 2015) have 
highlighted the beneficial effects of delivery systems that incorporate a disulfide in 
both in vivo and in vitro experiments. However few of them specifically evaluated 
whether the inclusion of a disulfide bond in the conjugation strategy was beneficial. 
For example Yao et al., suggested that indeed the inclusion of a disulfide in the 
linker of a peptide based system for the delivery of nucleic acid was advantageous 
both in vivo and in vitro (Yao, Tai et al. 2015). However Gaowa et al., suggested 
that the inclusion of a disulfide for the delivery of a cytotoxic peptide had very small 
effect on antitumor efficacy. To conclude, possible explanations for the negative 
results of the in vivo cytotoxicity experiment are that the disulfide was unstable in 
the blood stream, or that there was an incorrect preparation of conjugate A. 
Unfortunately, the experiment could not be repeated to clarify any doubts due to 
the lack of funds and the timerequired to write a new ethical approval. This would 





have been the best way of ensuring the validity of the cytotoxicity in vivo results. 
Furthermore, the conjugate A stock prepared for the experiment had been used 
entirely and its serum stability could not be tested afterwards. 
The cytokine profiles (IL-10, IL6, TNF-α and IFN-γ) of OT-1 T cells expanded in 
vitro with proliferation assays (Figure 41) were correlated with previous in vitro 
results and showed no major differences between conjugates A and B. An 
interesting result was the partial induction of IL-10 and IL-6 in samples when DCs 
co-cultured with OT-1 T cells were treated with MIS416 alone. These results 
correlate with previous results from Girvan et al. and suggest that DCs activated by 
MIS416 tend to secrete high levels of these cytokines, which could lead to a 
stronger activation of T cells.  
The production of IL-10 by MIS416 pulsed DCs is included in the cytokine 
repertoire secreted in response to bacterial infections. Since MIS416 is composed 
by procaryotic-derived proteins and peptoglycans, IL-10 is expected to be produced 
by DCs. The local production of IL-10 after a bacterial infection serves to dampen 
inflammation and to limit potential tissue damage that could be deleterious to the 
host (Cyktor and Turner 2011). However, in the contest of cancer treatment, this 
could be detrimental since IL-10 is immunosuppressive and could reduce the 
activity of activated T cells. On the other and IL-10 is needed for T-helper cell 
functions, T-cell immune surveillance, and suppression of cancer-associated 
inflammation (Dennis, Blatner et al. 2013). To conclude, TLRs ligands could be 
considered a double-edged sword in cancer treatment since they have both 
immunosuppressive and immunostimulant properties (Basith, Manavalan et al. 
2012). 































The overall aim of this research project was to develop a delivery system for peptide 
antigens and siRNAs in order to target APCs and induce an immune response 
against tumor cells. This project has addressed whether implementation of a 
molecular release mechanism associated with an APC targeting vector (MIS416) 
would be advantageous to avoid the degradation of siRNAs and peptide antigens.  
Multiple strategies can be used to couple peptides or siRNAs to MIS416 
microparticles. The amino group residues on MIS416 surface were the favoured 
targets for coupling reactions to MIS416 due to their availability. Girvan et al., 
previously coupled OVA peptide antigens to the surface of MIS416 using Sulfo-
GMBS (a heterobifunctional cross-linker that contain a NHS ester and a maleimide 
group). This conjugation procedure allowed the coupling of 1 µg of OVA for each 
400µg of MIS416 used (Girvan, Knight et al. 2011). The new conjugation strategy 
developed in this thesis that relies on a streptavidin bridge between MIS416-biotin 
and a biotinylated peptide/siRNAs was more efficient and allowed the coupling of 
3.15 µg of biotin-SS-SIINFEKL-FAM for each 100µg of MIS416-biotin used (~12 
times more compared to the bifunctional linker Sulfo-GMBS)(Table 7, Results 
chapter 3). However the methodology used to evaluate the coupling efficiency in 
my research was not based on protein assays (Fluorescence assay instead of 
coomassie staining) since SIINFEKL was coupled instead of OVA and so the 
results were not directly comparable. The coupling of SIINFEKL instead of OVA 
can have advantages and disadvantages in the generation of a specific immune 





response. First of all, the amount of antigen loaded on MIS416 using SIINFEKL 
instead of OVA is higher and this could lead to a higher amount of activated CD8 
T cells.  However, the ability of a peptide antigen to be presented to T cells in the 
draining node depends on its affinity with MHC molecules on DCs (Slingluff 2011). 
SIINFEKL has relatively high affinity for the cell surface protein Kb (Eisen, Hou et 
al. 2012), which is part of the MHC class I complex. Furthermore, short peptides 
with low affinity for the MHC may be less immunogenic than they would be if they 
were more continuously being presented (in case of the whole protein) (Slingluff 
2011). However, this point has to be taken into consideration mainly for the delivery 
of “free” peptides rather than peptides coupled to microparticle since “free” 
peptides can bind directly the MHC pocket on DCs while the microparticle-based 
delivery system will have to be processed inside the cytoplasm leading to a 
relatively slow but prolonged presentation on MHC class I molecules on DCs. 
Furthermore, the conjugation strategy developed in this research project was 
designed to simplify the coupling of additional biotinylated molecules to MIS416, 
and so potentially allowing the coupling of multiple different biotinylated 
compounds at the same time. This would allow the potential use of MHC I and 
MHC II peptides antigens simultaneoudly leading to the improvement of the 
immune response generated by CD8 T cells with the addition of the helper function 
of CD4 T cells. 
The coupling of biotinylated fluorophores, peptides or siRNAs showed similar 
conjugation efficiencies to SIINFEKL (Figure 27, Results chapter 4) while the 
coupling of different compounds to MIS416 using bifunctional linkers could be 
difficult due to the differences in the dissociation constant of sulfo-GMBS to the 





maleimide group between different compounds. The conjugation efficacy could be 
improved moving towards a conjugation strategy that relies on a single reaction 
between MIS416 and the molecular cargo to limit possible wasting of coupling 
materials. This could be achieved by modifying the molecular cargo and MIS416 
prior to the conjugation in order to develop a “click chemistry” type reaction (see 
page 53). The biotin/streptavidin conjugation protocol was originally designed to 
easily couple biotinylated molecules to MIS416 for research purposes. However, in 
the case of in vivo experiments or clinical trials where a large amount of the 
conjugates is required, the switch towards a simplier type of coupling strategy (not 
requiring biotin and streptavidin) could be economically advantageous. 
The main disadvantage in the use of a streptavidin-based conjugation strategy is 
that only biotinylated compounds can be coupled to MIS416-biotin. To circumvent 
this issue, linkers such us sulfo-NHS-biotin can be used to add biotin moieties to 
amino groups containing molecules. Another disadvantage in using streptavidin and 
biotin as linking molecules is the possible induction of an immune response leading 
to the production of anti-biotin and anti-streptavidin antibodies. Hnatowich et al. 
and Armitage et al., reported the generation of anti-streptavidin antibodies in 50% 
of the patients treated with streptavidin-modified proteins (Armitage, Perkins et al. 
1986, Hnatowich, Virzi et al. 1987). However this would not be a major 
disadvantage with MIS416 since the microparticle itself is immunogenic and the 
generation of anti-MIS416 antibodies is standard, as it would be for any other 
bacterial-derived particle. The generation of anti-MIS416 antibodies would most 
likely facilitate the uptake of the microparticle. However, this hypothesis has not 
been tested yet. 





Regarding the delivery of siRNAs to DCs, MIS416 has advantages over other 
delivery systems since MIS416 microparticles are avidily taken up by DCs and 
other antigen presenting cells (Figure 39). These results are consistent with previous 
analysis done by Girvan et al. (2011), in which they demonstrate with microscopy 
experiments that MIS416 was phagocytosed by plasmacytoid and myeloid DCs or 
monocytes. However, siRNAs coupled to MIS416 are not protected from 
degradation by ribonucleases. In order to circumvent this issue, a modified siRNA 
against Bim (M-BIM, which included 4 methylated bases) was designed to resist 
ribonuclease degradation as has been suggested by different studies (Amarzguioui, 
Holen et al. 2003, Li, Yang et al. 2005). However, the results (Figure 29) showed 
that M-BIM was not able to silence Bim expression as strongly as other standard 
siRNAs, making the use of methylated siRNAs in this case less desirable. In in vitro 
experiments MIS416/siRNA conjugates were able to downregulate the level of 
expression of target proteins due to the insertion of a disulfide bond that allowed 
fast release of the coupled siRNAs from MIS416 after phagocytosis. This was 
necessary to prevent lysosomal-mediated degradation of the siRNA as reported by 
others (Breunig, Hozsa et al. 2008). Rapid release of attached molecules linked to 
MIS416 by a disulfide bond was confirmed by microscopy experiments (Figure 25). 
The coupled molecules were released from MIS416 20-30 min after uptake, 
following disruption of the disulfide bond in the cytoplasm of the target cells. 
Furthermore, rapid uptake of MIS416 microparticles by APCs could be sufficient 
to limit the degradation of siRNAs in the blood stream, which usually occurs 
rapidily (siRNAs in serum have a half-life that varies from minutes to hours 
(Dykxhoorn, Palliser et al. 2006, Novobrantseva, Borodovsky et al. 2012)).  





MIS416 was also used in this research project as an antigen delivery system for the 
delivery of SIINFEKL peptide. An advantage of using MIS416 compared to other 
delivery systems such as liposomes or other nanoparticles is the intrinsic adjuvant 
activity of MIS416. MIS416 uptake by DCs was accomplished by increased 
expression of costimulatory markers on the surface of DCs. These results were 
consistent with the previous results of Girvan et al. (2011). Induction of activation 
in DCs by MIS416 enhanced the expression of antigen delivered onto MHC 
molecules. This synergistic effect however did not significantly improve the ability 
of pulsed DCs to activate T cells in vitro (Figure 41 and 42). 
The mechanism of action of MIS416 microparticle is only partially known. Three 
papers on MIS416 have been published so far and only one research paper was 
published before the start of this research project. Girvan et al., showed that 
treatment with a MIS416/OVA conjugate was able to induce a Th1 based immune 
response characterized by the secretion of IgG2c antibodies. They suggest that this 
polarization toward a Th1 immune response could be due to the activation of TLR-
9 in APCs. A recent study from Khan et al., (Khan, Kolomeyevskaya et al. 2015) 
in which MIS416/OVA was used in combination with OT-1 T cell associated 
adoptive cell therapy in a murine model  of epithelial ovarian cancer (OVA 
positive), showed that MIS416/OVA  treatment was able to enhance infiltration of 
OT-1 T cells at the tumor site. However, this increased accumulation of activated 
OT-1 T cells was short-lived (3 weeks).  Interestingly, the combined treatment of 
adoptive cell therapy and MIS416/OVA was only able to delay tumor growth 
modestly when compared with OT-1 T cells transfer alone. Furthermore, 
MIS416/OVA vaccination caused accumulation of MDSC at the tumor site leading 





to inhibition of OT-1 T cell anti-tumor activity. Depletion of CD11b+ cells with a 
monoclonal antibody affecting myelod cells was able to significantly enhance the 
efficacy of the combined treatment, suggesting that disruption of immuno 
suppression at the tumor site could synergize with MIS416 activity (Khan, 
Kolomeyevskaya et al. 2015). Furthermore, I speculate that the use of MIS416-
STAT3 in combination with immune checkpoint blockade therapies (anti PD-1, 
PDL-1, CTLA-4) could be beneficial in the generation of a stronger immune 
response versus cancer cell since immune suppression blockade at the tumor site 
would synergize with the activity of STAT3-depleted DCs in the generation and 
activity of CTLs. 
The systemic effect of MIS416 treatment was evaluated in a recent study (White, 
Webster et al. 2014) in the context of experimental autoimmune encephalomyelitis 
(EAE), a model for Multiple sclerosis (MS). MIS416 is currently in clinical trial for 
the treatment of secondary progressive multiple sclerosis and showed a protective 
effect in a murine model of MS. The results showed that treatment with MIS416 
suppressed systemic antigen-specific Th17, Th1, and Th2-associated cytokines and 
led to an expansion in specific splenic subpopulations including CD4+ CD25+ 
FoxP3+ Tregs, MDSC, and red pulp macrophages. Furthermore, in the context of 
EAE, MIS416 treatment was able to suppress Th17, Th2, and Th1 responses as well 
as inducing increased serum IFN-γ, which is required for MIS416-mediated 
protection.  
Further studies involving MIS416 as an antigen/siRNA delivery system would have 
involved the evaluation of the effectiveness of such conjugates in the remission of 
established tumors in mice. These experiment were planned, however a lack of 





grant funds did not allowed the experiments to be carried out. Future studies could 
also include microarray analysis of the effect of MIS416 conjugates on DC gene 
expression. This would allow a better understanding of the molecular changes 
involved in the activation of DC and could give new insight on new potential 
mRNA targets for siRNAs treatment on DCs. 
 To conclude I was able to couple fluorophores, peptides and siRNAs to MIS416 
with the development of a new conjugation strategy, achieving objective one (see 
introduction, section 1.9). Furthermore, MIS416 was shown to be a promising 
delivery system for siRNAs in vitro since MIS416/siRNA conjugates were able to 
downregulate the level of expression of target proteins achieving objective two. 
However in vivo experiments would need to be carried out to extend the positive in 
vitro results to show whether the conjugates can silence genes in vivo. Furthermore, 
MIS416 conjugates were able to deliver peptide antigens to DCs, induce activation 
and initiate the adaptive immune response against the coupled antigen in vivo. 
However the inclusion of a disulfide bond linkage did not provide a significant 
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Figure 45: HPLC analysis of Alexa fluor 488 + Sulfo-NHS-biotin. 
Solvent used: Methanol 




























































A: Full width mass spectrum. 
B: Expansion of the spectrum in the region of interest showing the isotopic pattern. 




Figure 47: Mass spectrum of Ethylene diamine + FITC 
A: Full width mass spectrum. 
B: Expansion of the spectrum in the region of interest showing the isotopic pattern. 































































Figure 48: Mass spectrum of compound 8 + Sulfo-NHS-biotin 
A: Full width mass spectrum. 
B: Expansion of the spectrum in the region of interest showing the isotopic pattern. 





Figure 49: Mass spectrum of FITC + cystamine 











































































B: Expansion of the spectrum in the region of interest showing the isotopic pattern. 





Figure 50: Mass spectrum of Fluorescein thiocarbonate (11) with sulfo-NHS-
biotin 
A: Full width mass spectrum. 
B: Expansion of the spectrum in the region of interest showing the isotopic pattern. 














































































Figure 51: Mass spectrum of compound 8 + Sulfo-NHS-SS-biotin 
A: Full width mass spectrum. 
B: Expansion of the spectrum in the region of interest showing the isotopic pattern. 








































Figure 52: Schematics of the binding regions of primers used in this thesis. 
Coding sequences (cds) used for ß-actin, B2m,Ywhaz, Rpl32,Gapdh, IL-10R1, Minor, Stat3 and Bim 
are NM_007393.3, NM_009735.3, NM_001253805.1, NM_172086.2, NM_001289726.1, 
NM_008348.2, NM_015743.2, NM_213659.2 NM_207680.2 respectively. The cds were analysed 
using MacVector software to underline primers binding regions. Primer sequences are listed in the 









Figure 53: Schematics of the binding regions of siRNAs for Bim and Stat3. 
Cds used for Bim and Stat3 are NM_213659.2 and NM_207680.2 respectively. The cds were 
analysed using MacVector software to underline siRNAs binding regions. Primer sequences are 
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Figure 54: Relative quantification of Bim mRNA levels on BMDCs after 48h of 
treatment.  
BMDCs were transfected with RNAi Max (transfection reagent only), a control siRNA 
(transfected with RNAi Max) or were left untreated for 48 or 72h. Q-RT-PCR was 
performed on cDNA generated from total RNA extracted from cells. GAPDH was used as 
reference gene for relative quantification of BIM expression. siRNA treatments were 
compared with untreated cells. Relative BIM quantification on untreated cells was set to 1 
in all the experiments to be able to compare them. Error bars represent SEM. Results that 
were not significant are marked with ns while significant results are marked with * 
depending on the P values (* P < 0.05, ** P < 0.005, *** P < 0.0005). These experiments 







Normalized output fluorescence Normalized output fluorescence Conjugation efficiency %
data of pellets after conjugation data of mixtures before conjugation
Conjugate A 2846 Conjugate A 15938 Conjugate A 17.85669
3325 16390 20.28676
3428 15286 22.42575
Conjugate B 3354 Conjugate B 16398 Conjugate B 20.45371
3478 17003 20.45521
4179 15498 26.96477






MIS416-SS-control siRNA 3193 MIS416-SS-control siRNA 16435 MIS416-SS-control siRNA 19.42805
3098 15209 20.36952
3287 15368 21.3886




Figure 55: Normalized fluorescent output data of different conjugates prior and after 
the conjugation reaction 
The fluorescence output of the pellets was measured using synergy 2 plate reader (BioTek) 
(excitation 488 nm, emission 520 nm). For sample processing see 2.1.4 Materials and 
Methods. Raw fluorescent data were normalized using standard curves. 
 
 
Figure 56: Calibration curve of streptavidin-PE  
The fluorescence of Streptavidin-PE standards (2 fold dluition starting from 1000nM) was 
measured (excitation 500nm, emission 570nm). This standard curve was used to quantify 







Figure 57: Demonstration of coupling of NHS-biotin to MIS416.  
This graph represents the percentage of streptavidin coupled in 4 separate experiments. The 
% of coupling has been calculated dividing the total amount of fluorophore coupled to 














































Calibration curve for biotin-
SIINFEKL-FAM 
































Calibration curve for biotin-SS-
SIINFEKL-FAM 
 Figure 58: Calibration curve of biotin-SS-SIINFEKL-FAM and biotin-ttds-                   
SIINFEKL-FAM 
The fluorescence of biotin-SS-SIINFEKL-FAM and biotin-ttds-SIINFEKL-FAM 
standards (2 fold dluition starting from 1000nM) was measured (excitation 488nm, 
emission 522nm). This standard curve was used to quantify the amount of biotin-SS-



















coupled to 10 g of 
MIS416 (nmol) 




200 g 6.3 g 0.171 nmol 






















































Figure 59: Gating strategy for Figure 36 
Splenocytes were gated for dimension and for positivity to the different markers 
representing different cells populations. A: B cells, B: Macrophages, C: DCs D: 
Neutrophiles, E: T cells. Cells that have internalized MIS416-PE microparticles were 
identified as PE positive. The bottom left panel represent cells positive for MIS416-PE 
where the uptake experiment was conducted at 4°C. Right bottom panel represent a 37°C 
sample.  
Table 2: List of compounds used for the synthesis of biotinylated fluorescent probes 







1 Alexa fluor 488 Fluorophore used in preliminary conjugation studies. 
4 Fluoresceinamine Second fluorophore tested for conjugation with sulfo-
NHS-biotin. 
6 FITC Third fluorophore tested for conjugation with sulfo-
NHS-biotin. 
8 FITC (long NH2 
arm) 
Fluorophore developed to increase the reactivity towards 
sulfo-NHS-biotin. 
9 Biotin-FITC Final conjugate without disulphide. 
11 FITC (long arm 
SS-NH2) 
Fluorophore developed to synthesize biotin-SS-FITC  
13 Sulfo-NHS-SS-
biotin 
Reacted with compound 8 instead of the reaction of 11 
with sulfo-NHS-biotin (failed) 
14 Biotin-SS-FICT Final conjugate with disulphide. 
 
 
